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Abstract 
 
Solid tumours are composed of cancer cells and a variety of other cell types, forming the 
tumour microenvironment (TME). Cells within the TME promote cell survival, proliferation 
and epithelial-mesenchymal transition (EMT) of cancer cells. Among the key metastasis-
inducing cellular components of the TME are cancer-associated fibroblasts (CAFs), which 
are activated by cancer cells through release of factors such as TGFβ.   
Here we sought to delineate the role of the PKN kinases in breast cancer with a focus on 
mesenchymal-phenotype TNBC models and subsequently in CAFs. This study was 
motivated by the critical roles identified for PKN2 in mesenchymal cells during 
development, as well as in cell behaviours critically hijacked during breast cancer 
development and progression.   
TNBC cells with mesenchymal-like morphologies (SUM159 and MDAMB231) showed 
reduced survival with PKN2 and PKN3 knockdown. This corroborated with previous finding 
where loss of PKN2 reduced proliferation of mice embryonic fibroblasts (MEFs) and 
systemic PKN2 knockout resulted in impaired development of the mesenchyme in mouse 
embryo. Therefore, subsequent studies in this project investigated the role of PKN2 in 
fibroblasts and their interaction with cancer cells. 
The importance of the stroma in breast cancer has been demonstrated in several studies. 
The presence of stroma/desmoplasia in triple-negative breast cancer (TNBC) has been 
linked to bad prognosis, which is also contradicted in other studies. Our laboratory 
identified several cancer-associated roles for PKN2 in pancreatic fibroblasts, including 
activation and reciprocal signalling to cancer cells to promote proliferation and invasion. 
Data from this project indicate dependency on PKN2 for fibroblast activation. 
Subsequently, a panel of genes associated with PKN2-dependent fibroblast activation was 
selected to investigate the clinical relevance of PKN2 in breast cancer stroma. 
Furthermore, stromal deletion of PKN2 in a mouse orthotopic model resulted in tumours 
with reduced fibrotic stroma and decreased vasculature.  
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1. Introduction 
 
1.1 Breast cancer 
 
1.1.1 Background 
 
In 2015 around 300,000 cases of new cancer diagnoses were registered in the UK, of 
which breast cancer was the highest contributor (15.4%) (Statistics 2017) and was the 
most common cancer in women. Although survival rates are improving, 1000 women die 
from breast cancer per month in the UK. Breast cancer causes 1 in 6 of all cancer deaths in 
women and thus represents the leading cause of cancer-related deaths after lung cancer 
(Dewis and Gribbin 2009). 
1.1.2 Clinical & molecular classification of breast cancer 
 
Conventional methods of classification involve histopathological methods, by using 
immunohistochemistry to identify oestrogen receptor (ER), progesterone receptor (PR) 
and HER2 expression, supplemented by clinicopathological factors such as tumour grade, 
size, lymph node and distant metastases. Studies using this method have demonstrated 
the prognostic and therapeutic relevance of this form of classification (Vallejos et al. 2010) 
(Cheang et al. 2009).  
Furthermore, analysis of tumour gene expression in breast cancer has identified the 
implications of distinct molecular profiles in patients on treatment and outcome (Weigelt, 
Baehner, and Reis-Filho 2010). Perou et al classified breast cancer into five intrinsic 
subtypes (luminal A, luminal B, HER2 overexpression, basal and normal-like), based on 
gene expression, by using complementary DNA microarrays on tumour samples (Perou et 
al. 2000). Furthermore, the correlation between gene expression and clinical outcome was 
studied by Sørlie et al (Sørlie et al. 2001). Subsequently, studies using tissue microarrays 
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enabled protein expression profiling to validate the clinical relevance of classification by 
gene expression profiles (Abd El-Rehim et al. 2005). Overall, breast cancer is typically 
classified into three broad groups: luminal, HER2-enriched and triple-negative/basal 
tumours. 
1.1.2.1 Luminal breast cancer 
 
Luminal tumours express cytokeratin 8/18 and ER, components of normal mammary 
luminal epithelium. Luminal tumours can be further classified into two subtypes (luminal A 
and luminal B). Both luminal A and B express ER and/or PR. Patients with these tumours 
are responsive to hormonal therapy and have in general a good prognosis.  Luminal B 
tumours are often more aggressive, with high Ki67 staining, expressing high levels of 
proliferative genes, with significantly worse prognosis than luminal A (Sorlie et al. 2003). A 
subset of luminal tumours also express HER2. 
1.1.2.2 HER2-enriched breast cancer 
 
These tumours lack ER and PR and are often grade 3 tumours, associated with poor 
prognosis (Sørlie et al. 2001). The enhanced expression of HER2 in these tumours act as a 
predictive factor of sensitivity to HER2-targeting therapy. Two key HER2-targeting agents 
are trastuzumab (Herceptin), a monoclonal antibody and lapatinib, a tyrosine kinase 
inhibitor (Abramson and Arteaga 2011).  Furthermore, patients with this subtype of breast 
cancer have significantly higher pathological complete response due to better response to 
anthracyclines and taxanes (Brenton et al. 2005) than patients with luminal subtype.  
1.1.2.3 TN/basal breast cancer (TNBC) 
 
This subtype is the most invasive and heterogenous, characterised by absence of ER, PR 
and HER2 expression. Tumours of this subtype contribute to 10-20% of breast cancers, 
most common in younger patients, with poor outlook on survival and increased risk of 
relapse (Carey et al. 2006). 
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Gene expression profiles of this subtype of cancer share similarities with normal basal 
epithelial and breast myoepithelial cells, due to high expression of proliferative markers 
and basal markers (such as keratins 5, 6, 14, 17, EGFR) (Perou et al. 2000). TN/basal 
tumour have unique metastatic tropism of the visceral organs and rarely involves lymph 
node metastasis (Anders and Carey 2009).  
1.1.2.4 TNBC subtypes 
 
Gene expression analysis by Lehmann et al classified TN breast cancer (TNBC) into 6 
subtypes: basal-like (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), 
mesenchymal stem–like (MSL), and luminal androgen receptor (LAR) (Lehmann, Bauer, 
Chen, Sanders, Chakravarthy, Shyr, et al. 2011).  
BL1 is associated with high expression of genes involved in the cell cycle, whereas BL2 
tumours express genes involved in growth factor signalling such as EGF, IGF1R and MET 
pathway. Due to enhanced expression of proliferative markers, patients with BL1 and BL2 
tumours treated with anti-mitotic drugs such as taxanes, as a neoadjuvant therapy, 
respond better than those with other subtypes (63% pathologic complete response) 
(Bauer et al. 2010). On the other hand, IM tumours express genes involved in immune 
responses.   
Tumours of the M subtype are rich in motility-related genes, as well genes involved in 
cellular differentiation and ECM interaction pathways. This includes effectors in the Rho, 
Wnt, anaplastic lymphoma kinase (ALK) and TGFβ signalling pathways (Lehmann, Bauer, 
Chen, Sanders, Chakravarthy, Shyr, et al. 2011). MSL tumours are characterised by genes 
involving the growth signalling pathways such as EGFR, PDGF, G-protein coupled receptor 
and ERK1/2. This subtype is also known to have enhanced expression of genes related to 
angiogenesis (for example VEGFR and Tie2). Breast cancer of the LAR subtype express high 
number of androgen receptors, compared to other TNBC subtypes. These tumours express 
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genes involving hormonal regulation of androgen/estrogen metabolism and steroid 
synthesis. Compared to MSL and BL1, LAR has lower relapse-free survival (RFS). 
1.1.3 Progression of breast cancer 
 
Breast cancers confined to the mammary epithelium are known as in situ carcinoma, 
whereas tumours that have penetrated the surrounding tissues are known as invasive 
carcinoma. Tumours initiate from either the duct (ductal carcinoma) or the lobule (lobular 
carcinoma). Wellings et al first proposed the breast cancer progression model, starting 
with flat epithelial atypia (FEA), followed by atypical ductal hyperplasia (ADH) and ductal 
carcinoma in situ (DCIS) and finally invasive and metastatic ductal carcinoma (Wellings and 
Jensen 1973).  
1.1.3.1 FEA 
 
FEA involves proliferation of cells into benign lesions and changes in polarisation of 
columnar cells in the luminal epithelium (Aroner et al. 2010). This benign lesion is thought 
to precede low grade malignancy, although the link between FEA development and risk of 
progression to malignancy is not known for certain and was investigated by Said et al (Said 
et al. 2015). This study of more than 11,000 women with benign breast lesions reported a 
very low incidence of FEA (2.4%) and found no enhanced risk of progression to breast 
malignancies due to the presence of FEA. However, there is a correlation between 
presence of FEA and progression to ADH, which increases the risk of progressing to breast 
cancer. 
1.1.3.2 ADH 
 
ADH is often discovered during mammographic screenings in patients with 
microcalcification. ADH is a small focal benign lesion, formed by polygonal cells with 
hyperchromatic nuclei. ADH share some but not all characteristic features with DCIS. 
Unlike FEA, the increased risk of breast cancer in association with ADH is well established; 
17 
 
around four to five times increased risk in general, six-fold risk in pre-menopausal women 
and a ten-fold risk in those with a first-degree relative affected by breast cancer (Pinder 
and Ellis 2003). 
1.1.3.3 DCIS 
 
DCIS is a non-invasive malignant lesion, containing highly proliferative epithelial cells 
surrounded by myoepithelial cells and basement membrane within the luminal ducts 
(Pinder and Ellis 2003). Holland et al, proposed the classification of DCIS as high, low, or 
intermediate grade based on cellular features (Holland et al. 1994). Studies report an 
incidence of 50% for invasive breast cancer with the presence of microscopic DCIS at the 
same site, hence DCIS is a precursor lesion of invasive breast carcinoma (IBC).  
1.1.3.4 Invasive Carcinoma 
 
There are two arguments to explain the progression of DCIS to invasive carcinoma: 
acquired genetic changes and non-genetic changes. Evidence suggests a role for the 
tumour microenvironment (TME) as a non-genetic contributor to breast cancer 
progression.  ECM remodelling, changes in non-malignant cell types of the TME such as 
fibroblasts and myoepithelial cells and epigenetic alterations in the stroma are thought to 
mediate disease progression (Cowell et al. 2013). This theory is supported by the 
characteristic loss of containment of malignant cells in invasive ductal carcinoma by the 
basement membrane, which is maintained in DCIS with the aid of tumour suppressive 
factors secreted by the surrounding myoepithelial cells. Changes in myoepithelial cells 
occurs in DCIS, where their role of tumour suppression is reversed to induce cancer 
progression. Work by Allen et al demonstrated that this change is driven by upregulation 
of the integrin αvβ6, leading to activation of TGFβ and MMP9 signalling (Allen et al. 2014).  
Clinical studies demonstrated that 50% of patients with low-grade DCIS progress to breast 
cancer. This poses the need to identify the likelihood of developing breast cancer when 
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DCIS is detected during screening. Ma et al used samples from DCIS and matched invasive 
tumours using laser capture microdissection to compare the genetic expression profiles, 
to identify genes predictive of disease progression (Ma et al. 2003).  This study 
demonstrated enriched expression of a set of 29 genes in invasive tumours, relative to the 
matched DCIS samples. This suggests these genes to be related to disease progression, 
though their significance in predicting progression is unknown. 
1.1.4 Treatment options for breast cancer 
 
1.1.4.1 Localised early breast cancer 
 
Chemotherapy and targeted hormone therapy (depending on ER, PR and HER2 status) is 
given to patients with advanced but localised tumour prior to surgery (neoadjuvant 
therapy). Anthracycline- and taxane-based regimens are considered in the neoadjuvant 
setting.  
Surgical options include breast-conserving lumpectomy or mastectomy with or without 
reconstruction, followed by regional or whole breast post-operative radiotherapy, 
depending on number of cancer-positive axillary nodes (Board 2017). According to the 
European Organization for Research and Treatment of Cancer's trial (EORTC-10801) (van 
Dongen et al. 2000) both surgical procedures carry low risks of local recurrences. Meta-
analysis has shown the association between positive margins post-surgery with a two-fold 
increased risk of recurrence within the same site (Moran et al. 2014). Radiotherapy is 
essential in those with breast conserving surgery to eliminate residual disease and lower 
the chances of local recurrence. Adjuvant radiotherapy on the chest wall and regional 
lymph nodes is given to patients after mastectomy. 
Post-operative treatment (adjuvant) includes chemotherapy, such as tamoxifen and 
aromatase inhibitors, depending on clinicopathological factors. Commonly anthracycline-
based therapies, involving fluorouracil, epirubicin, and cyclophosphamide, are used as 
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adjuvants (Board 2017). Additional benefits were seen with the inclusion of taxanes, such 
as paclitaxel and docetaxel, to anthracycline-based regimens (De Laurentiis et al. 2008). In 
addition to systemic chemotherapy ER, PR and/or HER2 receptor expression are targets of 
endocrine therapy in hormone receptor-positive cancer. HER-2 receptor-positive patients 
can be treated with trastuzumab (Herceptin) and lapatinib, whereas ER and PR-positive 
cancers can be treated with tamoxifen. Absence of hormone receptors in TNBC therefore 
relies solely on chemotherapy.  
1.1.4.2 Metastatic breast cancer 
 
The aim of therapy at the metastatic stage is to extend and improve quality of life 
(referred to as palliative care). Patients with localised metastases can undergo surgery and 
radiotherapy. Otherwise, systemic chemotherapy and targeted or hormonal therapies are 
used. For hormone receptor-positive metastatic breast cancer, tamoxifen and aromatase 
inhibitors are mainly used in both pre- and post-menopausal women (Mauri et al. 2006).  
Furthermore, HER2-positive cancers can be targeted by HER2 directed monoclonal 
antibodies such as trastuzumab and pertuzumab (Perjeta) or by lapatinib (a tyrosine 
kinase inhibitor of HER2 receptor). Resistance to these endocrine therapies develop, 
requiring further targeted therapies such as rapamycin (mTOR inhibitor) and Palbociclib 
(CDK4/6 inhibitor).  
Chemotherapy also plays a role in managing metastatic disease, particularly in hormone 
receptor-negative cancer and in advanced metastatic disease. Anthracycline (doxorubicin 
and epirubicin), taxanes (paclitaxel and docetaxel), cyclophosphamides, platinum-based 
agents (cisplatin and carboplatin) can be used alone or in various combinations (Johnston 
2011). 
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1.1.5 Breast cancer genetics 
 
Cancer genomics has revolutionised our understanding of the genetics underlying all 
malignancies. This work is being coordinated by large international consortia, pioneered in 
breast cancer by the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC), the pan-cancer Cancer Genome Atlas program (TCGA), and extended through 
the International Cancer Genomes Consortium (ICGC).  
1.1.5.1 METABRIC 
 
The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), 
conducted a study using around 1000 primary tumours along with a validation set of 
around 1000 tumours with clinical follow-up (Curtis et al. 2012). This study demonstrated 
the relevance of inherited variants and acquired somatic copy number aberrations on 
expression of nearly 50% of genes. Novel subgroups with defined clinical outcomes were 
also identified in this study.  
1.1.5.2 The cancer genome atlas (TCGA) project  
 
TCGA has now characterised the molecular profiles of numerous cancer types, including 
Breast Cancer (Network 2012). This study incorporated six approaches to analyse gene 
expression in a large dataset of breast cancer: DNA copy number arrays, DNA methylation, 
exome sequencing, mRNA arrays, microRNA sequencing and reverse phase protein arrays.  
Whole genome sequencing of samples considered by the TCGA identified just over 30,000 
mutations. This included genes whose mutations were previously associated with breast 
cancer, such as PIK3CA, PTEN, AKT1, TP53, CDH1, RB1 and MAP3K1. Additionally, new 
genes, whose mutations had great significance in breast cancer were also identified. These 
included TBX3, RUNX1, CBFB, AFF2, PIK3R1 and PTPN22 that are involved the 
development of the mammary gland. 
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The study identified that ER-positive/luminal tumours had heterogenous spectrum of 
mutations, copy number changes and patient outcome. These tumours have a luminal 
gene expression signature and have a high frequency of PI3KCA, MAP3K1 and MAP2K4 
mutations. 
Furthermore, two subtypes of HER2-positive tumours were identified: HER2-Enriched 
(HER2E)-mRNA-subtype/HER2-positive and luminal-mRNA-subtype/HER2-positive 
tumours. The former subtype is characterised by DNA amplification of HER2 and 
overexpression of multiple HER2-amplicon associated genes that contribute to around 
50% of clinically HER2-positive tumours. The remainder of HER2-positive tumours are 
classed as the luminal mRNA subtypes. Frequent mutations in the PI3-kinase pathway 
(PIK3CA, PTEN and PI3K1) have been identified and therefore offered new potential 
therapeutic targets in HER2-positive tumours. 
Frequently mutated genes in luminal A subtype include MAP3K1, GATA3, TP53, CDH1, and 
MAP2K4. Mutations in luminal B were more diverse, with high frequency of mutations 
found in TP53 (missense mutations) and PIK3CA. In contrast, basal-like subtype of tumours 
did not harbour mutations in many of the genes commonly mutated in the luminal 
subtype. However, TP53 was most often mutated, present in 80% of cases (mostly 
nonsense and frame-shift mutations). As expected, HER2E subtypes had increased 
frequency of HER2 gene amplification. In addition, TP53 and PIK3CA were also frequently 
mutated in HER2E tumours. 
Analysis of basal-like subtype of tumours, revealed high frequency of loss of function 
mutations in TP53, RB1, BRCA1 and PIK3CA. Furthermore, gene expression signatures 
show enrichment of keratins 5, 6, 7 and proliferative markers. 
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1.1.5.3 Use of genetics in the clinic to predict breast cancer prognosis 
 
Predicting the outcome, once a diagnosis of breast cancer is made, was traditionally 
determined using histopathological factors. The accuracy of predicting outcome using this 
approach is limited in patients with smaller tumours that are of lower grade and in 
patients with negative lymph node status. Reflecting on the molecular tumour 
heterogeneity, demonstrated by DNA sequencing and gene expression profiling, molecular 
biomarkers have been considered as the way forward for personalised approach in 
predicting outcome.  Microarray tests consisting of biomarkers, have been used in the 
clinic to predict recurrence in patients at the early stage of breast cancer. This has been 
applied to see which patients would benefit from chemotherapy.  
A study conducted by van’t Veer et al, is an example of using gene expression of tumour 
samples to determine predictive signatures for distant metastasis. Samples from over 100 
primary breast tumours were used for DNA microarray analysis to see whether a gene 
expression signature predicting distant metastases in lymph node-negative patients can 
be identified (van 't Veer et al. 2002). Clustering, based on the expression of around 5,000 
significant genes gave two main groups – predictive of good and bad prognosis.  This 
predictive tool will aid in deciding the need for systemic adjuvant therapy, ensuring that 
patients undergo treatment if their genetic profile falls into the classification of bad 
prognosis. Furthermore, genes that were found to be overexpressed in the cluster for bad 
prognosis are also worth studying further as therapeutic targets.  
Furthermore, three commercially available genomic biomarker assays include: Oncotype 
DX, (Genomic Health Inc., San Francisco) MammaPrint and PAM50 (Kittaneh, Montero, 
and Glück 2013 ).  
The Oncotype DX assay was developed and validated in patients with hormone receptor-
positive breast cancer, who were at the early stage of disease and were treated with 
23 
 
endocrine therapy (Paik et al. 2004 ). This assay is a real-time PCR-based assay, involving 
21 genes. This assay calculates a recurrence score that predicts recurrence in patients with 
early stage hormone receptor-positive tumours, who were lymph node-negative and had 
5 years of tamoxifen treatment. The recurrence score classifies patients as low-, 
intermediate-, or high-risk. Overall, reduced ER expression, together with increased 
expression of proliferative and invasive markers predicts high risk of recurrences. 
Meanwhile, increased expression of oestrogen-associated genes and GSTM1 and BAG1 
predicts reduced risk of recurrences.  
In contrast to Oncotype DX, MammaPrint and PAM50 have been developed from patients 
of all subtypes of breast cancer. MammaPrint is a 70-gene signature that consists of genes 
associated with tumour progression and metastasis (Tian et al. 2010). This signature 
predicts the risk of 10-year distant metastasis-free survival and classifies patients as low 
risk (>90%) and high risk (<90%). 
PAM 50 (Prediction Analysis of Microarrays) involves a 50-gene microarray that classifies 
invasive breast cancers according to the intrinsic subtypes clinically: luminal A, luminal B, 
HER2-enriched, and basal-like (Parker et al. 2009). Additionally, this test gives values for 
proliferative markers and luminal markers such as ESR1, PGR, and ERBB2. 
1.1.5.4 Overview of other breast cancer signatures 
 
Comparison of gene signatures from similar studies of breast cancer samples shows that 
there is minimal overlap of genes. To investigate this observation further, Huang et al 
considered 33 breast cancer signatures from previous studies, to see whether genes from 
one signature overlapped with any other signatures. This study analysed 33 different 
breast cancer signatures to understand whether there are common functions that are 
associated with the genes across different signatures (Huang, Murphy, and Xu 2018 ). Out 
of 2239 genes, only 238 genes were commonly found in two different signatures. MKI67 
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was the most common gene, a marker of cell proliferation, found amongst 8 of the 
signatures.  
Enrichment analysis of the 2239 genes for biological functions, resulted in 1979 function 
terms, of which 429 were common in at least 2 different signatures. The most common 
terms involved biological functions such as cell cycle, cell death, response to wounding, 
response to organic substance and intracellular signalling cascade. Common functional 
terms between ER-positive and ER-negative cancer included cell death, cell proliferation, 
intracellular signalling cascade, response to hormone stimulus, response to oxygen levels, 
bone development, DNA packaging and skeletal system development. 
1.1.6 Breast cancer in vivo models 
 
In vivo models are important research tools for breast cancer, as they aid the translation 
of in vitro findings to clinical practice.  Pre-clinical studies involve the validation of results 
from in vitro studies in in vivo models that provide a physiologically relevant means of 
studying cancer initiation, invasion and metastasis. There are now many different mouse 
models of breast cancer, that each have their own advantages and flaws and address 
different aspects of breast cancer disease. These studies have contributed to the 
advancements in understanding cancer biology and therapy. 
1.1.6.1. Cancer cell line derived xenografts (CDX) 
 
Cancer cell-line xenografts are the most common and simplest type of model, in which 
cancer cell lines are engrafted in mice. Typically, human cell models are engrafted into 
immunocompromised mice to prevent immune rejection. The cells are engrafted via 
subcutaneous injection (ectopic), or by implanting cells in the mouse mammary gland 
(orthotopic). These models allow the study of cancer initiation, growth and progression to 
invasive and metastatic disease. However, as the cell lines used often derive from 
aggressive tumours, the early initiation of cancer cannot be easily modelled. Further, 
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tumours in CDX models are often homogeneous epithelial breast cancer cells, and as the 
mice are generally immunocompromised, the tumour microenvironment will not be truly 
representative.  
In this project, several murine cell lines originate from mouse tumours. 4T1 cells were 
used that were derived from a spontaneous breast cancer in BALB/cfC3H mice (Dexter et 
al. 1978). Mouse breast cancer cell mBCC#4 were also used, originating from BlgCre p53fl/fl 
Brca1fl/fl mice (Molyneux et al. 2010). E0771 are derived from spontaneous mammary 
tumours in C57BL/6 mouse (Sugiura and Stock 1952). Both mBCC4 and E0771 cells are 
derived on a C57BL/6 background so can be xenografted to immune competent C57 mice. 
As our PKN2 knockout mouse models are also on a C57 background, this provides scope 
for modulating both the tumour cells and the tumour microenvironment. 
1.1.6.2. Patient-derived xenografts (PDXs) 
 
PDX models address some of the limitations of CDXs. PDXs involve primary human 
tumours or cells in immunocompromised mice. As the cancer cells have been hosted in a 
human, it is physiologically more relevant and not subjected to changes due to in vitro 
conditions. Tumours from PDXs show conserved histological and molecular features from 
the donor patients (Hidalgo et al. 2014).  Therefore, this model is suited better to study 
the development of primary tumours, as well as metastatic disease (Hoffman 2015), and 
therapeutic efficacies.  
1.1.6.3 Syngeneic models of breast cancer 
 
In this model, cancer cells derived from mice are transplanted into strain-matched mice. 
This allows the study of cancer initiation and progression in immunocompetent mice. The 
intact immune system in this model, although murine, offers an optimal 
microenvironment to test cancer therapy, particularly immunotherapy (Coffelt and de 
Visser 2015). For example, Johnstone et al developed a syngeneic model of breast cancer 
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metastasis using EO771.LMB cancer cells, derived from a metastatic nodule in an 
orthotopic tumour model in a C57BL/6 mouse (Johnstone et al. 2015 ). 
1.1.6.4. Genetically engineered mouse models (GEMMs) of breast cancer 
 
GEMs allow the monitoring and study of early phases of tumour initiation and 
development. In this model, a tumour spontaneously forms in its native tumour 
microenvironment.  The advantage of GEMMS is the ability to study the native tumour 
microenvironment, due to the intact immune system. Moreover, this model allows for the 
study of manipulating a specific gene in the host organism, leading to the validation of 
oncogenes and tumour suppressor genes. Additionally, this model can be used for knock-
out and knock-in studies of the gene of interest. 
Oncogenic-driven transgenic mice include the MMTV-PyMT model, which is also 
characterised by spontaneous metastatic disease in lymph nodes and lungs. The 
polyomavirus (PyV) middle T antigen is known to have the ability to induce transformation 
of cells and tumourigenesis (Guy, Cardiff, and Muller 1992a). This is mediated by its 
association with tyrosine kinases (such as c-src) and PI3K (Talmage et al. 1989). The 
expression of the middle T antigen in mammary epithelial cells of transgenic mice with the 
MMTV-PyV middle T antigen fusion gene was investigated. This resulted in the formation 
of tumours at multiple foci and frequently associated with metastases in the lung. In this 
project, PyMT-BO1 cells were used, which originate from the MMTV-PyMT breast cancer 
model, isolated from bone metastases (Su et al. 2016). 
Blg-Cre Brca1f/f p53-/+ mice were generated by Molyneux et al to investigate the origin of 
basal-like BRCA1 breast tumours (Molyneux et al. 2010). This model addressed the 
question whether the deletion of BRCA1 in the luminal mammary epithelium (where Blg 
promoter is most active) results in basal-like BRCA1 breast cancer. Tumours generated 
from Blg-Cre Brca1f/f p53-/+ mice are generally invasive ductal carcinomas of no special 
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type, of histological grade 3. These tumours are positive for the K14 and the basal marker 
p63. Thus, histologically and immunohistochemically, these tumours closely resemble 
basal-like BRCA1 tumours in humans. Although genetic analysis of these tumours show 
enrichment for genes associated with ER-negative luminal cells, analysis based on two 
single sample predictor gene sets (SSPs) show that gene expression is typically common 
between ER-negative luminal mammary epithelium and basal-like breast cancer.  
1.1.6.5 CDX in GEMMS 
 
In this project, the effect of inducing systemic PKN2 (a serine/threonine kinase, see 
section 1.2) deletion in mice on the growth of breast cancer xenografts was investigated. 
Rosa26 Cre-ERT2 mice (iCre) were crossed with mice heterozygous for PKN2 knockout, 
allowing for systemic deletion of PKN2, induced by Cre recombinase upon tamoxifen 
treatment. In this model, BO.1 cells from MMTV-PyMT breast cancer model were 
orthotopically injected following treatment of mice with tamoxifen, for induction of PKN2 
deletion. Systemic deletion of PKN2 in the embryo led to lethality at E9.5 (Quétier et al. 
2016). Therefore, an inducible system for knocking out PKN2 was required to study 
tumour growth in adult mice. 
1.2 PKN kinases 
 
Protein Kinase N (PKN) is a family of serine/threonine protein kinases that bear high 
sequence homology with protein kinase C (PKC) and are therefore also known as the PKC-
related kinases (PRKs). PKN kinases belong to the AGC superfamily of protein kinases, 
which also include protein kinase A (PKA; cAMP-dependent protein kinase), PKB/AKT, Rho-
associated kinase (ROCK) and PKC.  
PKN kinases include three isotypes in mammals: PKN1, PKN2 and PKN3. These isotypes 
show high homology within their C-terminal kinase domains but show more divergence in 
their N-terminal regulatory sequences (Palmer and Parker 1995). Thus, the three isotypes 
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are regulated differently, and are sensitive to distinct activators (Oishi et al. 1999). PKN1 
and PKN2 are ubiquitously expressed (Palmer and Parker 1995) (Kitagawa et al. 1995), 
whereas PKN3 expression is restricted to cancer cells, as well as muscle, liver and 
endothelial cells (Oishi et al. 1999). PKN kinases are downstream effectors of Rho GTPases 
(Amano et al. 1996), which are associated with the regulation of actin cytoskeletal 
organisation (Vincent and Settleman 1997). However additional functions have also been 
ascribed to PKN: involvement in vesicular transport (Kawamata et al. 1998), glucose 
transport (Standaert et al. 1998) nuclear translocation (Mukai, Miyahara, et al. 1996) and 
regulation of meiotic maturation and embryonic cell cycle (Stapleton et al. 1998). 
1.2.1 Structure of PKN kinases 
 
The C-terminus contains the serine/threonine kinase domain that has high homology in 
sequence with PKC kinases. At the N-terminus there are three homologous regions (HR) 
consisting of approximately 70 aa that are rich in charged residues, named as HR1, HR2 
and HR3 motifs (Palmer, Ridden, and Parker 1995). The first region forms an antiparallel 
coiled-coiled fold (ACC finger) by two alpha helices (Maesaki et al. 1999). Therefore, this 
region is also known as the ACC domain, which is the structure that binds the small 
GTPase RhoA. This domain also acts as a binding interface for other proteins such as 
anchoring protein CG-NAP (centrosome and Golgi localized PKN associated protein) 
(Takahashi et al. 1999).  
Unlike mammalian PKC isoforms, PKN2 has HR1 domains that are conserved in yeast PKC 
isoforms (Roelants et al. 2017). The HR1 domain means PKN isoforms are regulated by 
Rho, as yeast PKC. Thus, PKN kinases are considered as the human orthologue of yeast 
PKC. 
The HR2 domain consists of about 130 amino acids that precedes the catalytic domain. An 
auto-inhibitory region is found at the C-terminal end of the C2-like domain, which is 
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conserved amongst other PKN isoforms isolated form other organisms (Yoshinaga et al. 
1999). Between the C2-like and the catalytic domain, there is a linker region. In PKN2 and 
PKN3 this linker contains one and two proline-rich regions respectively, which bind Src 
homology 2 (SH3) domains (Feng et al. 1994). This proline-rich region is not found in PKN1. 
1.2.2 Regulation of PKN kinases 
 
1.2.2.1 Activation of PKN Kinase Catalytic Activity 
 
The regulation of kinase activity is commonly shared in members of the AGC kinase family, 
involving phosphorylation at the activation-loop sequence between the upper and lower 
lobe of the kinase domain, at the C-terminal hydrophobic motif (Frodin et al. 2002) and 
turn-motif (Hauge et al. 2007) (Parekh, Ziegler, and Parker 2000). Phosphorylation at the 
latter two sites is required for the interaction between the hydrophobic motif and a 
hydrophobic pocket at the upper lobe of the kinase domain, known as the PIF pocket 
(PDK1 Interacting Fragment) (Balendran et al. 2000). In the members of the PKC family, 
the activation loop, hydrophobic and turn motifs are often constitutively phosphorylated 
(see PDK1 and mTORC2 below), representing a ‘primed’ kinase domain. It has additionally 
been shown that the occupation of the nucleotide-binding pocket by ATP is required for 
the stability of the ‘primed’ conformation (Cameron et al. 2009).  
 
In an inactive conformation, interaction between the primed PKC kinase domain and an 
autoinhibitory pseudosubstrate region within the regulatory domain blocks access to the 
active site. In order for the kinase to be activated, the active site needs to be relieved from 
its interaction with the regulatory domain at the N-terminus, which occurs allosterically. In 
the case of PKC, this allosteric activation typically occurs through biding of lipids to the 
regulatory domain C1 and C2 domains. PKN kinases share homology with PKC kinases at 
both the C-terminal kinase domain (Mukai and Ono 1994) and also share a homologous C2 
domain within the regulatory domain (Mukai and Ono 1994).  Therefore, similar 
30 
 
mechanisms of regulatory autoinhibition have been proposed for the PKN kinases. Binding 
of the C2 domain to lipids, and Rho binding to the HR1 domains (discussed above), are 
thought to relieve kinase domain auto-inhibition by the regulatory domain.  
 
In support of this mechanism, partial hydrolysis of PKN to yield a liberated kinase domain 
results in increased kinase activity independent of unsaturated fatty acid (Mukai et al. 
1994). This gave the first indication that the N-terminus of PKN kinases was required to 
regulate the activity of its kinase.  Direct interaction between the C- and N-terminal 
regions of PKN kinases was demonstrated using yeast two-hybrid assay (Kitagawa et al. 
1996). Furthermore, it was shown that the region between amino acids 39 to 53 in PKN 
kinases may represent an autoinhibitory pseudosubstrate-like region, although this 
remains an area of controversy (Kitagawa et al. 1995). Additionally, an autoinhibitory 
region between residues 455-511 of PKN kinases has also been identified, however 
dependent on arachidonic acid for relief from inhibition (Yoshinaga et al. 1999). This 
region is also involved in auto-inhibition of PKN via the dimerization of PKN2, discussed 
below. 
1.2.2.2. Activation by Rho-family of GTPases 
 
RhoA binds to PKN1 at the first two of three homologous motifs (HR1a and HR1b) of the 
HR1 domain. The homologous HR1 domain in PKN2, also binds GTP-RhoA. There are two 
contact sites for RhoA binding in the HR1 domain – one that requires the conformation of 
a nucleotide-bound state and the other that is nucleotide-independent. HR1a can only 
bind to GTP-bound RhoA, whilst HR1b can bind both GTP- and GDP-bound RhoA (Flynn et 
al. 1998). The N-terminus of PKN has activity to inhibit endogenous GTPase activity of 
RhoA and inhibits the interaction between GAP and RhoA – therefore also inhibiting GAP-
stimulated GTPase activity of RhoA. Thus, the half-life of GTP-bound RhoA is increased 
when bound to PKN kinases (Mukai, Miyahara, et al. 1996).  
31 
 
1.2.2.3 Activation by Lipids and Secondary Messengers 
 
PKN1 is activated in response to arachidonic acid cardiolipin, phospholipids and 
lysophospholipids (Mukai et al. 1994). Activators of PKC kinases such as calcium, 
phosphatidylserine, diacyglycerol and PMA do not have any effect on enhancing the 
kinase activity of PKN1 (Kitagawa et al. 1995). PKN2 and PKN3 on the other hand are 
considerably less sensitive to arachidonic acid (Oishi et al. 1999). Another study by Falk et 
al also demonstrated different sensitivity to lipids by the different PKN isoforms (Falk et al. 
2014). PKN1 was activated by all lipids, except IP3 and DAG, whilst PKN2 was only 
responsive to arachidonic acid and PIP2. PKN3 on the other hand has very low sensitivity 
to arachidonic acid, with enhanced effect on its catalytic activity when levels of 
arachidonic acid are low. 
1.2.2.4 Activation by PDK1 and mTORC2 
 
Actin cytoskeleton rearrangement in response to growth factors is mediated by 
phosphatididylinositol-3-kinase (PI3K) activation (Kotani et al. 1994) (Wennström et al. 
1994) (Martin et al. 1996). Phosphoinositide-dependent protein kinase-1 (PDK1) is a 
downstream effector of PI3K that can phosphorylate and activate proteins from the AGC 
kinase family, including PKN kinases (Le Good et al. 1998) (Kobayashi and Cohen 1999). 
The interaction between PKN kinases and PDK1 occurs between the C-terminus of PKN 
kinases and the kinase domain of PDK1. Thr774 in the activation loop of PKN kinases is 
phosphorylated by PDK1 to activate and increase the catalytic activity, causing actin 
cytoskeleton reorganisation in response to insulin (Dong et al. 2000). 
A study on prostate cancer investigated the role of MTORC2 in regulating PKN1. PKN1 is 
overexpressed in prostate cancer, with increased expression in tumours of high Gleason 
score (Metzger et al. 2008) and in metastatic tumours, compared to primary tumours (Yu 
et al. 2004). It was demonstrated that phosphorylation of PKN1 at the turn motif is 
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mediated by MTORC2, downstream of PI3K (Yang et al. 2017). This allows PKN2 to elicit its 
effect on cancer cell migration, as discussed in 1.2.3.3. 
1.2.2.5 PKN2 dimerisation 
 
An alternative dimer-based autoinhibitory mechanism has also been proposed for PKN2. 
Here intramolecular interactions between two PKN2 molecules sequesters an inactive 
dimer in the cytoplasm prior to allosteric activation by Rho GTPases (Bauer et al. 2012). 
The interaction occurs at the catalytic site between the PKL sequence-binding site 
(residues 455-511) and the N-terminal binding site. The change in the conformation of the 
catalytic domain, inhibits the binding of the C-terminal to the HM/PIF pocket. 
Furthermore, the binding of Rho to the HR1 domain of PKN2 exposes the PIF domain, 
allowing for the activation of PKN2.  
1.2.3 Functions of PKN kinases 
 
PKN kinases are downstream effectors of Rho GTPases (Amano et al. 1996) which are 
strongly associated with regulation of the actin cytoskeleton (Vincent and Settleman 
1997). However, many additional functions have also been ascribed to PKN, including 
involvement in vesicular transport (Kawamata et al. 1998), glucose transport (Standaert et 
al. 1998), nuclear translocation (Mukai, Miyahara, et al. 1996), regulation of meiotic 
maturation and embryonic cell cycle regulation (Stapleton et al. 1998) (Mukai 2003). 
1.2.3.1 PKN is a Rho Effector 
 
(i) Actin cytoskeletal organisation 
Rho family GTPases are known regulators of actin cytoskeleton, through multiple effector 
pathways, including the ROCK, PAK, as well as the PKN kinases. However, the specific role 
of PKN in actin cytoskeleton regulation is not conclusive due to different results from 
various studies.   
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Studies in Drosophila suggests a role for PKN kinases in regulating actin-cytoskeleton 
during dorsal closure at the late stage of Drosophila development (Lu and Settleman 
1999). The movement between actin and myosin is regulated by phosphorylation of their 
light chain (MLC), which regulates processes such as stress fibre formation (Katoh et al. 
2001).  PKN1 phosphorylates CPI-17, which enhances its inhibitory effect on myosin 
phosphatase (Hamaguchi et al. 2000); this increases sensitisation of smooth muscle cells 
to calcium ions.  Calcium ions cause inhibition of myosin phosphatase, therefore 
increasing myosin phosphorylation that is required for contractility in smooth muscle cells. 
 
Another way in which PKN1 is involved in regulating actin-cytoskeleton is by 
phosphorylating related proteins such as caldesmon and G-actin (Mukai et al. 1997). PKN 
kinases phosphorylate head-rod region of intermediate filament proteins, which in turn 
prevents polymerisation of neurofilaments (NFs) (Mukai, Toshimori, et al. 1996), vimentin 
and glial fibrillary acidic proteins (Matsuzawa et al. 1997) – required for regulating 
intermediate filaments. PKN kinases also phosphorylate microtubule-associated protein 
(MAP) tau (Taniguchi et al. 2001). 
 
Furthermore, mass-spectrometry analysis of PKN2-deleted MEFs identified many 
phosphopeptide changes in proteins related to the cytoskeleton and intermediate 
filaments (Quétier et al. 2016). Examples include decreased phosphorylation of anillin, 
which is required for the scaffolding between RhoA, actin, and myosin during cytokinesis 
(Piekny and Glotzer 2008). Phosphorylation of nestin, an intermediate filament protein, 
was also reduced following PKN2 loss.  In the normal mammary gland, nestin is expressed 
in basal and myoepithelial cells (Li et al. 2007). Furthermore, nestin is favourably 
expressed in basal-like and TNBC (Parry et al. 2008). TNBC progression and poor prognosis 
is also associated with nestin expression (Liu et al. 2010). 
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(ii) Role of PKN kinases in cell cycle regulation 
 
To initiate mitosis, Cdc25C dephosphorylates Tyr-15 in Cdc2 to relieve its suppression, 
activating Cdc2/cyclin B histone H1 kinase. Therefore, Cdc25C needs to be tightly 
controlled to regulate mitotic entry. Addition of exogenous and active PKN kinases in 
Xenopus egg extracts, resulted in delayed mitosis. This was due to sustained inhibitory 
phosphorylation of Tyr-15 of Cdc2, mediated by inhibitory phosphorylation of Cdc25C by 
PKN (Misaki et al. 2001).  
The role of PKN2 in mitosis was further investigated in HeLa cells (Schmidt et al. 2007). 
siRNA-mediated depletion of PKN2 in HeLa cells resulted in an increased number of 
binucleated cells after 72 hours, suggesting a role in cytokinesis. However, this effect was 
not observed when PKN1 or PKN3 were depleted. Analysing the localisation of PKN 
kinases during different cell cycle phases revealed accumulation of PKN1 and PKN2 at the 
cleavage furrow and the midbody during telophase and cytokinesis. This localisation of 
PKN2 was lost upon siRNA treatment, leading to the late cytokinesis defect. Further 
observation of PKN2-depleted cells showed delayed G2/M progression and apoptosis in 
nearly a third of binucleated cells. Finally, it was demonstrated that Ect2 mediated the 
phosphorylation of PKN2 by Rho GTPases, causing PKN2 localisation at the cleavage 
furrow. Furthermore, PKN2-depleted cells had reduced phosphorylation of Cdc25B family 
of protein phosphatases. Consequently, dephosphorylated Cdc25B proteins are inactive 
and unable to activate cyclin/Cdk complexes and initiate G2/M transition.  
The role of the PKN in embryonic development was investigated in our recent paper 
(Quétier et al. 2016), which revealed a role for PKN2 in the regulation of mesenchymal cell 
growth. Inducible deletion of PKN2 in MEFS, using a conditional knockout model, 
decreased cell growth, and resulted in an increased proportion of cells at G1/G0 phase 
and loss of cells at S1 phase.  This contrasts with the G2 mitotic arrest observed by 
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Schmidt et al described above (Schmidt et al. 2007). This observation was further 
supported by phosphoproteomic analysis in which deletion of PKN2 in MEFs caused 
decreased phosphorylation of numerous proteins involved in cell cycle (Quétier et al. 
2016).  Apoptosis was not affected in MEFs by PKN2 deletion. Further investigation 
revealed decreased proliferation of the pharyngeal mesoderm, upon PKN2 deletion, 
indicating that the in vitro function in mesenchymal cells in likely conserved in vivo (see 
mouse development section below). 
(iii) Formation of apical junctions in epithelial cells 
Apical junctions are crucial for polarity, permeability and cell-to-cell adhesion in epithelial 
cells. Rho is known to regulate the formation of apical junctions (Nusrat et al. 1995) 
(Smutny et al. 2010), with ROCK being the main downstream effector studied. Inhibiting 
ROCK in colon and breast carcinoma cell line disrupted or inhibited the formation of tight 
junctions (Walsh et al. 2001) (Shewan et al. 2005), but had no effect in other cells such as 
MDCK or HCT116 cells (Sahai and Marshall 2002). This led to the study of other 
downstream effectors of Rho that regulate the form of apical tight junctions.  
A study by Wallace et al, involving an siRNA screen of 28 Rho effectors in human bronchial 
epithelial cells, identified PKN2 as a regulator of apical junctions (Wallace, Magalhaes, and 
Hall 2011). It is postulated the binding of Rho A to PKN2 at the N-terminal, relieves PKN2 
from its auto-inhibitory conformation. Therefore, the activated kinase domain of PKN2 
leads to its interaction with another protein, to allow for its localisation at apical junctions. 
1.2.3.2 Physiological functions 
 
(i) Drosophila and C.Elegans 
 
The role of PKN kinases in normal development was studied in Drosophila, which has a 
single PKN orthologue. PKN kinase in Drosophila was shown to be necessary for dorsal 
closure during embryogenesis, downstream of Rho1 and Rac (Lu and Settleman 1999). 
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Specifically, PKN kinase is involved in a Rac-JNK pathway causing changes in cell shape and 
migration. This action is required to close the opening of the epidermal layer overlying the 
amnioserosa. In Caenorhabditis elegans PKN1 was shown to regulate muscle contraction, 
implying the functional versatility of PKN kinases as Rho effectors (Qadota et al. 2011).  
(ii) Mouse Embryonic development 
 
Our recent paper (Quétier et al. 2016), first demonstrated the role of PKN kinases on 
development, in vivo. Systemic deletion of each individual PKN kinase isoforms, 
demonstrated a PKN2-specific role in mouse embryonic development. PKN2 knockout was 
shown to be lethal in mouse embryos at embryonic day 10 (E10). PKN2 knockout embryos 
at E9.5 had deficient branchial arch formation, failed to undergo axial turning and had an 
underdeveloped mesenchymal compartment. Other abnormalities include cardiovascular 
defects and incomplete neural tube closure. Intriguingly, this study also revealed that 
PKN1 or PKN3 deleted mouse embryos showed normal development, implying a non-
redundant role for the PKN2 isoform.  
We have also demonstrated a role for PKN2 in MEFs in migration. Phosphoproteomic 
analysis, in PKN2-deleted MEFs, showed enrichment of phosphopeptides involved in cell 
cytoskeletal organisation. This corroborates with the finding that deletion of PKN2 in MEFs 
caused decreased migration, demonstrated in scratch wound assays and single cell 
migration assays. The failure of neural crest cells to migrate in vivo observed in PKN2-
deleted embryos is likely to be due to the inability of neural crest cells to migrate through 
the mesoderm in the absence of PKN2. This provides in vivo evidence for a non-redundant 
role of PKN2 in migration suggested by this and other studies (Lachmann et al. 2011). 
Subsequent to our paper, Danno et al and Yang et al independently observed lethality 
between E9.5 and E10 in mice with systemic PKN2 deletion, as well as similar 
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abnormalities in branchial arch formation and neural tube closure (Danno et al. 2017) 
(Yang et al. 2017), confirming the validity of our work.  
1.2.3.3 Function in cancer 
 
(i) Prostate Cancer 
Role of PKN1 in Prostate Cancer 
PKN1 is overexpressed in prostate cancer, with increased expression in tumours of high 
Gleason score (Metzger et al. 2008). PKN1 was demonstrated to activate androgen 
receptor via the transactivation unit 5 (TAU-5) at the N-terminus (Metzger et al. 2003). 
Depleting PKN1 inhibits hormone-dependent proliferation of PCa cells. PKN1 interacts 
with the scaffold protein sperm-associated antigen 9 (SPAG-9/JIP4) to regulate migration-
associated genes (Jilg et al. 2014). Co-localisation of PKN1 with DPA9 is required for the 
phosphorylation of p38 and cell migration. PKN1 knockdown resulted in a slight decrease 
in proliferation of PC-3M-luc2 androgen-independent prostate tumour cell lines, but this 
change was non-significant. However, the rate of apoptosis upon PKN1 depletion 
remained unaffected.  
 
Role of PKN3 in Prostate Cancer  
Constitutively active PI3K signalling is needed for the growth of invasive PC3 prostate 
cancer. Expression profiling has identified PKN3 to be dependent on this PI3K signalling. 
Furthermore, inhibiting PKN3 reduced the growth of prostate cancer cells in the same way 
as seen when p110b (the catalytic subunit of PI3K) was inhibited (Leenders et al. 2004). 
Moreover, conditional PKN3 knockout in a mouse prostate tumour model, published 
during the course of my studies, showed decreased tumour size and metastasis (Mukai et 
al. 2016). 
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(ii) Breast Cancer 
PKN kinases and TNBC  
Evidence for the role of protein kinase N (PKN) kinases in TNBC is found in the literature. 
Comparative genomic hybridisation and gene expression analysis of TNBCs has identified 
PKN1 to be overexpressed when this gene is amplified (Turner et al. 2010). Brough et al 
conducted a functional viability screen in over 30 breast cancer cells. PKN2 (Gene: PRKCL2) 
was identified as a candidate gene for cell viability dependence in TNBC cells, compared to 
non-TNBC cells (Brough et al. 2011). However, the mechanism by which PKN kinases are 
involved in TNBC is unknown. 
Role of PKN3 in Breast cancer 
The interaction of PKN3 with Rho-family GTPases and its role in breast cancer was 
investigated. PKN3 was reported to show preferential binding to Rho C, compared to Rho 
A and Rho B. Rho C has been proved to be a significant driver of breast cancer metastasis 
(Hakem et al. 2005) and its regulation has been associated with more invasive and 
aggressive breast cancers. Therefore, the role of Rho C-binding PKN3 in breast cancer was 
investigated. It was shown that the level of PKN3 expression and activity, as well as Rho C 
level, was highest in TNBC cell lines. Furthermore, TNBC with PKN3 knockdown showed 
reduced growth in 3-D cultures and in an orthotopic breast cancer model (Unsal-Kacmaz 
et al. 2012). 
 
(iii) Migration 
90% of deaths from solid tumours result from distant metastasis, illustrating the 
importance of cancer cell migration and invasion. The role of PKN kinases in cell migration 
has been demonstrated in various cancer cell line models. 
Lachmann et al investigated the individual roles of each PKN kinases isoforms in migration. 
Using bladder tumour cells, with enriched PKN2 expression, the role of the different PKN 
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kinase isoforms was studied - via siRNA knock-down and rescue (Lachmann et al. 2011). It 
was demonstrated that depleting all three isoforms slowed wound healing in 2D scratch 
wound assays. Assessment of migration after depletion of individual isoforms showed the 
requirement of either of PKN1 or PKN2, whilst depletion of PKN3 had no migratory effect. 
In 3D, a 50% reduction in migration was observed with PKN2 depletion compared to 25% 
reduction with PKN1 depletion. Rescue experiments demonstrated the specific 
requirement of PKN2 for migration or chimeras with the regulatory domain of PKN2. 
Similarly, PKN2 deletion in mouse embryo resulted in reduced motility in mouse 
embryonic fibroblasts and disrupted migration of neural crest cells (Quétier et al. 2016).  
 
(iv) Metastasis  
Conditional PKN3 knockout in a mouse prostate tumour model showed decreased tumour 
size and metastasis (Mukai et al. 2016). Thereafter, the role of PKN3 in angiogenesis was 
studied by treating aortic rings from PKN3 knockout mice with fibronectin, vascular 
endothelial growth factors (VEGF), hepatic growth factor (HGF), etc in 3-dimensional 
culture ex-vivo. This resulted in reduced number of microvessel sprouting from the PKN3 
knockout aortic rings, compared to the wild-type controls. In-vivo corneal pocket assay 
also demonstrated poor angiogenesis with PKN3 knockout. However, tumour growth in 
PKN3 knockout mice, compared to wild-type mice showed no significant reduction in 
tumour angiogenesis. Thus, PKN3 in the stroma was not significant for angiogenesis in the 
tumour. On the other hand, embryonic fibroblasts from PKN3 knockout mice showed 
decreased migration in response to various growth factors, such as fibronectin and 
lysophosphatidic acid (LPA). Furthermore, lung metastases after injection of melanoma 
cells in PKN3 knockout mice was reduced in size and number. 
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1.3 Importance of tumour microenvironment & the potential role of PKN2 
 
1.3.1 Tumour microenvironment  
 
Solid tumours are not only composed of cancer cells but also a variety of other cell types 
and an extracellular martrix together forming the tumour stroma or tumour 
microenvironment (TME). The TME is comprised of the extracellular matrix and non-
malignant cells such as endothelial cells, pericytes, immune cells and fibroblasts. The TME 
harbours a variety of cells of mesenchymal origin such as fibroblasts, cancer-associated 
fibroblasts (CAFs), mesenchymal stem cells (MSCs), adipocytes, and endothelial cells. 
Other components of the TME include haematopoietic lineage cell such as lymphoid cells 
and myeloid cells. A major part of the TME is made up of non-cellular components such as 
collagens, proteoglycans, and glycoproteins that form the extracellular matrix (ECM). As 
we have identified roles for PKN2 in fibroblast like cells, this section will primarily focus on 
CAFs.  
1.3.2 Role of fibroblasts and CAFs in TME 
 
Fibroblasts are major contributors of the ECM, arising from different possible origins. CAFs 
can support cancer proliferation, drive tumour progression, invasion and metastasis (Tyan 
et al. 2012; Shekhar et al. 2001). These functions are mediated by their secretion of 
growth factors, ECM-modulating factors (Palmieri et al. 2003) (Orimo et al. 2005) (Dumont 
et al. 2013) and by their ability to migrate and invade through the ECM. CAFs are generally 
characterised by high expression of α-SMA, fibroblast activation protein (FAP), matrix 
metalloproteinases (MMPs), tenascin-C, and platelet-derived growth factor (PDGFRα/β) 
(Sappino et al. 1988) (Scanlan et al. 1994) (Ostman and Heldin 2007). High expression of α-
SMA, the most widely used marker of activated fibroblasts (myofibroblasts and CAFs), has 
been associated with high grade tumours, lymph node metastasis and poor prognosis in 
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breast cancer. However, gene expression in CAFs show variation between different breast 
cancer subtypes (Surowiak et al. 2007) (Vallejos et al. 2012) (Yazhou et al. 2004). 
1.3.2.1 CAF heterogeneity 
 
A study by Costa et al investigated heterogeneity of CAFs in breast cancer and identified 
four distinct subtypes of CAFs called CAF-S1, CAF-S2, CAF-S3, and CAF-S4  (Costa et al. 
2018).  These subtypes are characterized by the expression of six fibroblast markers: FAP, 
integrin β1/CD29, αSMA, S100-A4/FSP1, PDGFRβ, and CAV1. CAF-S1 express all markers, 
except CV1. CAF-S2 generally have low expression of all the markers. CAF-S1 and CAF-S3 
are considered as myofibroblast-like due to the expression of αSMA. CAF-S1 
demonstrated immunosuppressive effect in breast cancer, by enhancing the inhibitory 
effect of regulatory T cell on T effector cell proliferation. 
1.3.2.2 Origins of CAFs 
 
The origins of CAFs within tumours remains inconclusive. One origin of CAFs is the 
fibroblasts that are resident within the TME and are activated by factors such as TGFβ and 
SDF (Kojima et al. 2010). This results in differentiation of fibroblasts into myofibroblasts 
(Rønnov-Jessen et al. 1995). Mesenchymal stem cells also have the capability to 
differentiate into CAFs (Mishra et al. 2008) (Weber et al. 2015).  
Secondly, may derive from mesenchymal stem cells (MSCs). A study by Mishra et al 
demonstrated myofibroblast differentiation of bone marrow-derived MSCs, when treated 
with conditioned media from MDAMB231 cancer cells (Mishra et al. 2008).  The gene 
expression profile of these differentiated MSCs were similar to CAFs. Furthermore, 
another study demonstrated the effect of osteopontin on MSCs differentiation into CAFs, 
mediated by the transcription factor MZF1 as well as TGFβ1. 
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Thirdly, CAFs have shown to arise from epithelial cells that have undergone epithelial-to-
mesenchymal transition (EMT) (Zeisberg et al. 2007). Similarly, endothelial cells have also 
been demonstrated to differentiate into mesenchymal-like cells, via endothelial-to-
mesenchymal transition (Zeisberg et al. 2007).  These cells function as fibroblast in tissue 
remodelling, fibrosis and cancer. 
1.3.3 Prognostic relevance of desmoplastic stroma in breast cancer  
 
The importance of the stroma in breast cancer has been demonstrated in several studies. 
A gene analysis study identified a 50-gene stromal signature that can predict response to 
anthraxanes and taxane-based drugs in the neoadjuvant settings in breast cancer patients 
(Farmer et al. 2009).  In general, a reactive stromal gene signature was associated with 
poor therapeutic response.  
The presence of stroma/desmoplasia in triple-negative breast cancer (TNBC) has been 
linked to bad prognosis (Moorman et al, 2012; Downey et al, 2014; de Kruijf et al, 2011) 
but this is also contradicted in other studies (Kreike et al, 2007). Therefore, therapeutic 
approaches targeting the stromal compartment of tumours have become of interest. 
1.3.4 Role of CAFs in the interaction between cancer and tumour microenvironment 
 
1.3.4.1 Role of CAFs in tumour progression/metastasis 
 
Metastasis requires ECM degradation, invasion/intravasation into lymph nodes or blood 
vessels, extravasation and the ability to proliferate and establish a secondary tumour at 
the new site. CAFs can play an important role in many of these aspects and here I will 
summarise some key known functions. 
1.3.4.2 Effect of CAFs on ECM remodelling  
 
A recent paper investigated the role of CAFs in ECM remodelling of breast tumours (Wang 
et al. 2017). CAFs were shown to affect the assembly and re-organisation of collagen I and 
43 
 
fibronectin, two important components of the ECM. First, CAFs lay down unfolded 
fibronectin fibres, that is followed by a denser matrix of collagen I after remodelling, 
resembling scar tissue after wound healing. Matrix metalloproteins (MMP-2, MMP-9 and 
MMP-12) secreted by CAFs also play an important role in ECM remodelling (Karagiannis et 
al. 2012). CAFs aid metastasis also by upregulating palladin expression and secreting 
proteolytic enzymes to degrade the ECM (Brentnall et al. 2012). 
1.3.4.3 Effect of CAFs on cancer cell invasion  
 
The collective invasion of cancer and fibroblasts were observed under 3D in vitro 
conditions, using organotypic culture model (Gaggioli et al. 2007) (Gaggioli 2008). This 
model involves the culture of cells on top of a gel matrix, composed of collagen I, as well 
as laminins and collagen IV. Cancer cells alone do not show any migration within the gel, 
unlike in the presence of fibroblasts, where invasion of cells down the gel is observed. 
Furthermore, the degree of invasion was dependent on the number of fibroblasts that 
were co-seeded with the epithelial cancer cells. A closer look at the invading cells revealed 
fibroblasts to be at the leading front, followed by cancer cells in tracks of degraded gel 
matrix. 
1.3.4.4 Role of CAFs in EMT 
 
EMT is a process whereby epithelial cells undergo morphological changes and become 
more mesenchymal-like. Cells undergoing EMT lose expression of epithelial marker E-
cadherin and lose apico-basal polarity, whilst increasingly expression of mesenchymal 
markers such as vimentin, N-cadherin and Zeb1. This results in cells that are more motile, 
invasive and less polarised.  
CAFs can trigger EMT in breast epithelial cells, which can that result in cancer stem cell-
like aggressive behaviour, driving cancer metastasis (Soon et al. 2013). Factors such as 
TGF-β, CCL2 and IL-1β drive this process (Yu et al. 2014) (Tsuyada et al. 2012) (P et al. 
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2016). Moreover, CAFs also deposit their own ECM that has been shown to differ from the 
ECM laid down by normal fibroblasts. CAF-deposited ECM is more aligned in pattern 
(Dumont et al. 2013), induces EMT in tumour cells and contains high levels of fibronectin, 
biglycan and ECM-modulating enzyme lysyl oxidase.  
1.3.4.5 Role of CAFs in altering metastatic tropism 
 
Moreover, CAFs has shown to also pay a role in influencing metastatic tropism. For 
example, TNBC, that have a high tendency to metastasise to visceral organs, can alter their 
tropism to form bone metastases through exposure to CAF-secreted CXCL12 and IGF 
(Zhang et al. 2013).  Another way in which CAFs may be involved in influencing the 
metastatic site, is by migrating together with the cancer cells to the metastatic site. This 
has been demonstrated, by Duda et al, in lung metastases (Duda et al. 2010). The 
presence of stromal cells is thought to support the initiation and initial growth of 
secondary tumours in the lung. 
1.3.4.6 Effect of CAFs on tumour drug response 
 
A number of studies provide evidence to suggest the involvement of CAFs in drug 
resistance. Teicher et al observed different susceptibility of cancer cells to chemotherapy 
between in vitro and in vivo conditions (Teicher et al. 1990). Resistance demonstrated in 
vivo was absent when tested in vitro, indicating that factors present in vivo are required 
for developing resistance. In breast and colon cancer, the tumour-stroma ratio is 
predictive of the outcome of patients receiving adjuvant chemotherapy (Dekker et al. 
2013) (Park et al. 2014).  The gene expression profiles of the stroma of breast tumours 
have also shown to be able to predict outcome of patients undergoing neoadjuvant 
chemotherapy (Farmer et al. 2009).  
The TME can affect response to therapy via intrinsic and acquired mechanisms (Klemm 
and Joyce 2015). Intrinsic mechanisms include reduced drug delivery, pro-survival 
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signalling and paracrine signalling loops. Acquired resistance can arise after exposure to 
therapy.  
The ECM provides structural support to the TME, where collagen is a key player and 
contributes to mechanical properties that has implications for intrinsic drug resistance 
(Barocas and Tranquillo 1997). Studies have demonstrated that the amount and 
organisation of collagen affects interstitial diffusion and thereby delivery of drugs from the 
bloodstream. Eliminating collagen in tumours, using collagen-degrading enzyme 
collagenase, resulted in improved diffusion (Netti et al. 2000).  
Tamoxifen resistance is an example that has been attributed to CAFs, mediated by 
upregulation of PI3K/AKT and MAPK/ERK pathways and phosphorylation of ER (Pontiggia 
et al. 2012). Metabolic changes in CAFs driven by cancer cells results in CAFs undergoing 
aerobic glycolysis, inducing oxidative stress and autophagy. This provides adjacent cancer 
cells with nutrients and mediates tamoxifen resistance; mimicked in co-culturing MCF7 
with fibroblasts or supplementing with metabolic substrates such as ketone bodies. This 
mechanism of tamoxifen resistance was overcome by inhibiting the mitochondria in MCF7 
cells. (Martinez-Outschoorn et al. 2011). Factors secreted by CAFs also contribute to drug 
resistance. For example, HGF that activates AKT and MAPK signalling pathways and 
chemokine CCL2 disable drug-induced apoptosis (Tsuyada et al. 2012). 
Furthermore, a recent study identified two different sub-populations of CAFs in ER-
positive breast tumours, that have varying effects on sensitivity to oestrogen (Brechbuhl 
et al. 2017). CD146neg CAFs decrease oestrogen sensitivity and thus induce resistance to 
tamoxifen, by diminishing the expression of ER in tumours. On the other hand, CD146pos 
population of CAFs maintain sensitivity to tamoxifen, due to unaffected levels of ER 
expression.  
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Non-malignant cells within the TME are genetically stable, unlike cancer cells, and are 
therefore stable therapeutic targets. The intrinsic roles of CAFs and their interaction with 
cancer and non-cancerous cells within the TME, makes them potential therapeutic targets. 
Several studies have shown the potential of targeting CAFs directly and indirectly in cancer 
(Togo et al. 2013). Work by Loeffler et al (Loeffler et al. 2006) demonstrated that DNA 
vaccines generated for FAP (specifically overexpressed in fibroblasts within colon, breast, 
and lung carcinomas (Scanlan et al. 1994) can reduce tumour growth in combination with 
doxorubicin. 
1.3.5 Role of TGFβ in tumour stroma and fibroblast activation. 
 
CAFs are activated by factors secreted by cancer cells such as chemokines (e.g. CCL2) 
(Tsuyada et al. 2012), osteopontin (Mao et al. 2013), TGFβ and SDF (Kojima et al. 2010). Of 
these, TGFβ is best understood and further discussed in this project. 
1.3.5.1 TGF signalling pathway 
 
TGFβ1 is a ligand that binds to type II TGF-β receptor (TβRII) that consequently 
transactivates type I TGF-β receptor to initiate downstream signalling (Derynck and Feng 
1997). The two main pathways downstream include canonical SMAD signalling and non-
canonical signalling. SMADs are a family of transcription factors, of which SMAD2 and 
SMAD3 are activated by TGFβ via phosphorylation (Attisano and Wrana 2000). Activated 
SMAD 2 and 3 form complexes with SMAD4, mediating translocation of the active SMAD 
complexes to the nucleus to regulate transcriptional activity. Non-canonical activation 
pathways downstream TGFβ include Rho, Rac/Cdc42, Ras and PI3K (Derynck and Zhang 
2003). 
1.3.5.2 Effect of TGF on fibroblasts and tumour stroma 
 
Enriched expression of TGFβ1 is associated with highly fibrotic tissue and ECM secretion 
(Brenmoehl et al. 2009). Work by Desmoulière et al demonstrated that treatment of 
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fibroblasts with TGFβ induced the expression of αSMA fibres, a marker of cellular 
differentiation into myofibroblasts (Desmoulière et al. 1993). Thus, in response to TGFβ, 
fibroblasts differentiate into myofibroblasts that are highly contractile and contribute to 
ECM and collagen deposition (hence fibrosis). Myofibroblasts are crucial during wound 
healing, however chronic activation of these fibroblasts results in excess collagen and ECM 
as in the case of CAFs in tumours.  
Work by Kojima et al, studied the differentiation process of mammary fibroblasts into 
CAFs during tumour progression. CAFs promote invasive tumour growth through 
autocrine signalling loops such as SDF-1 and TGFβ (Kojima et al. 2010). Cancer cells within 
the TME secrete TGFβ, which stimulates additional TGFβ, as well as SDF-1, secreted by 
fibroblasts. These secretions are maintained, generating a positive feedback loop and lead 
to the activation of fibroblasts into pro-tumourigenic CAFs via auto-and co-stimulatory 
effects of these signalling loops. 
In turn, activated fibroblasts (CAFs) promote tumour growth. For example, CAFs isolated 
from colon cancer secrete pro-invasive factors such as scatter factor/hepatocyte growth 
factor (HGF) and tenascin C, an ECM glycoprotein upregulated in response to TGFβ (De 
Wever et al. 2004). 
Furthermore, a study by Orimo et al demonstrated that breast carcinoma-derived CAFs 
co-implanted with breast carcinoma cells significantly induce tumour growth than normal 
fibroblasts from the same patient, mediated by SDF-1 secretion (Orimo et al. 2005).  
1.3.6 Role of PKN2 in fibroblast activation 
 
Previous study in the lab, revealed that PKN2 deletion in MEFs resulted in their loss of 
ability to contract in collagen gels. Contractility is a phenotype of activated fibroblasts, 
hence indicating that PKN2 is important for this phenotype. Targeting PKN2 in this context 
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may have therapeutic potential of targeting fibroblasts and tumour stroma, to reduce 
their activation and desmoplastic reaction.  
Furthermore, studies in a pulmonary smooth muscle cell line demonstrated disrupted 
TGF-mediated actin re-organisation and differentiation, following treatment with 
inhibitors that target downstream of RhoA, including PKN2 (Deaton et al. 2005). In this 
model, TGF-β1 induced activation of PKN, via phosphorylation, inducing expression of 
smooth muscle cell markers at transcript level. PKN2 depletion mediated by siRNA, also 
attenuated TGF-β1-mediated upregulation of smooth muscle cell markers. A similar 
phenotype was observed when MAPK activity was blocked by SB203580. Together with 
the positive correlation between MAP kinase activity and PKN2 kinase activity, it is 
postulated that p38 MAPK signalling regulating actin reorganisation via PKN2. 
1.4 Project Aims 
 
In vivo studies on mouse embryology in the lab demonstrated a physiological role of PKN2, 
in mouse development; PKN2 knockout in mice embryos showed developmental defects, 
growth retardation collapsed mesenchymal compartment and embryonic lethality at E9.5 
(Quétier et al. 2016). In vitro, conditional PKN2 knockout in immortalised mouse 
embryonic fibroblasts (MEFs) also decreased cell growth and motility. 
As PKN2 demonstrated a role for cell survival in a physiological model in MEFs, we wanted 
to investigate the relevance of PKN expression in breast cancer. Bioinformatic analysis of 
expression profiles from breast cancer datasets were used to study the expression 
patterns of PKN kinases between normal tissue and breast cancer tissue, as well as 
between different breast cancer types. We also wanted to investigate the role of PKN 
kinases in breast cancer cell survival, comparing luminal breast cancer cells with TNBC cells 
that are mesenchymal in phenotype.  
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The dependence on PKN2 in MEFs led us to expand the study to include fibroblasts and 
the tumour stroma, which are important non-cancerous compartments of tumours. 
Work conducted in collaboration with John Marshall’s group has demonstrated that PKN2 
is required in MEFs to support pancreatic cancer cell (PCC) invasion. Knockout of PKN2 
resulted in inhibition or reversal of the invasive phenotype and reversion to a polarised 
epithelial morphology. Interestingly, loss of PKN2 on day 8 after invasion converts invasive 
mesenchymal PCC to polarised epithelial PCC. This begged the question, whether the 
expression of PKN2 in fibroblasts had a significant effect on breast cancer survival and 
invasion, under 3D in vitro conditions. 
Our recent paper demonstrated a role for PKN2 in the mesenchyme of embryos during 
development. Work in the lab also demonstrated that loss of PKN2, in a variety of mouse 
and human fibroblasts, reduced their contractility (a marker of activation) in collagen gels 
in response to TGFβ1. Furthermore, work by our collaborator (Claus Jorgensen, CRUK 
Manchester) identified PKN2 as a top hit from an RNAi screen to identify kinases 
important for TGFβ1-mediated activation of pancreatic fibroblasts. Here we sought to 
examine whether these roles for PKN2 are conserved in breast fibroblasts and primary 
breast CAFs. The clinical relevance of PKN2 in breast cancer stroma was investigated by 
analysing the expression of a panel of PKN2 surrogate markers (that are upregulated in 
activated MEFs upon TGFβ1 and/or BMP4 stimulation) in a stromal gene expression 
dataset (Finak et al. 2008) and whole tumour gene expression dataset from TCGA.  
Moreover, the effect of systemic deletion of PKN2 on tumour growth and stromal activity 
was studied using a mouse orthotopic model. 
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Summary:  
The primary aims of this project are: 
1. To investigate the relevance of PKN kinase expression on breast cancer survival 
and prognosis. 
2. To study the role of PKN2 on TGFβ1-mediated fibroblast activation and investigate 
the clinical relevance of PKN2 surrogate markers in breast cancer stroma. 
3. To examine the effect of fibroblasts and their expression of PKN2 on breast cancer 
cell viability, invasion and chemosensitivity. 
4. To study the effect of global PKN2 deletion on tumour growth and stromal 
activation in a mouse orthotopic model. 
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2. Materials & Methods 
 
2.1 Cell culture 
 
Cells were cultured in sterile, uncoated T25, T75 or T175 flasks (Corning) in humidified 
conditions at 37°C, 10% CO2. Most cells were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM – Sigma, #D6429) and supplemented with Penicillin-Streptomycin (Sigma, 
P4333) and 10% fetal bovine serum (FBS). All cell lines were supplemented with FBS from 
one manufacturer (Sigma, #F9665), except for MEFs (Gibco, #10500-064) and CAFs (Lonza, 
#CC4101J, 2% v/v). The media conditions for the different cell lines are listed (Table 1).  
MEFs were isolated from Rosa26Cre/ERT2 PKN2fl/fl C57B/6J mouse embryo that were 
immortalised using the SV large T-antigen. Primary human breast CAFs were requested by 
the Breast Cancer Tissue Bank at BCI. 
Cell in flasks are washed once in sterile phosphate buffered saline (PBS) and covered in 
2ml of 1X trypsin-EDTA (Sigma, #59418C) and incubated at 37°C for 2-5 minutes. The flask 
is gently tapped to dislodge the detached cells and collected in fresh growth media. The 
number of cells is counted using a haemocytometer to seed for experiments and/or a 
proportion of the collected cell suspension is transferred to a new flask to continue the 
culture.  
2.2 siRNA transfection 
 
Cells were seeded at their appropriate seeding density and treated with siRNA 
(Dharmacon): siCtrl1: D-001210-01-20; siCtrl3: D-001210-03-20; siLuciferase: P-002099-
01-50; sipkn2#3: D-004612-03-20; siPKN2#9: D-004612-09-20; siPKN2#10: D-004612-10-
20; siPKN2#11: D-004612-11-20) the following day (target sequence in Table 2). The 20µM 
siRNA stock is diluted in 1X optiMEM (Gibco, #31985-62) and added to lipofectamine 
RNAiMax (Invitrogen, #13778-150) diluted in optiMEM. After incubation at room 
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temperature for 45 to 60 minutes, the diluted siRNA and transfection reagent is added to 
the cells in media, seeded at least the day before. The volumes of reagents for different 
vessel sizes per well are shown in Table 3. 
Table 1. Cell media conditions for different cell lines 
 
Cell line Growth media Additional Supplements 
SUM159 F12 Ham (Sigma) Insulin (Sigma, #I1882, 1μg/ml), 
hydrocortisone (1μg/ml) 
MDA MB 231 DMEM (Sigma)  
MDA MB 468 DMEM - low glucose 
(Sigma, #D5921)  
L-glutamine 
MCF7 DMEM (Sigma)  
BT474 DMEM (Sigma)  
T47D RPMI 1640 (Sigma) Insulin (Sigma, #I1882) 
4T1 DMEM (Sigma)  
E0771 RPMI (Sigma)  
MMTV DMEM (Sigma)  
mBCC#4 DMEM (Sigma)  
MEFs DMEM (Sigma)  
HMFU19 DMEM /F12H -1:1 (Sigma) Amphotericin B (Sigma, #A2942, 
2.5μg/ml) 
CAFs FGM™-2 Fibroblast Growth 
Medium (Lonza, #BE12-
604F) 
Insulin (Lonza, #CC-4021J, 5μg/ml), 
rhFGF-B (Lonza, #CC4065J, 1ng/ml), 
gentamicin and amphotericin (Lonza, 
#CC4126, 30μg/ml and 15ng/ml 
respectively) 
 
 
Table 2. siRNA target sequence. 
siRNA Target sequence  
siCtrl1 UAGCGACUAAACACAUCAA 
siCtrl3 AUGUAUUGGCCUGUAUUAG 
siLuciferase CAUUCUAUCCUCUAGAGGAUG 
siPKN2#9 GGAGCGCUCUGAUGGACAA 
siPKN2#10 UAGACAGCCUGAUGUGUGA 
siPKN2#11 GUACGCAUCCCUCAACUAG 
 
Table 3. siRNA transfection.  
Reagent volumes per well for different culture vessels. 
Vessel siRNA  RNAi Max optiMEM Media in wells 
24-well plate 0.6μl 0.6μl 50μl 100μl 
6-well plate 2.5μl 2.5μl 100µl 500μl 
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2.3 Inhibitors and cytotoxic assay 
 
Cells are seeded onto 96-well plates at appropriate densities and incubated overnight. The 
next day, different concentrations of inhibitors were prepared by 1 in 3 serial dilution, of 
which 100µl is added per well after removing the culture media. Some wells are treated 
with fresh media or media containing dimethyl sulfoxide (DMSO – Sigma 276855), the 
vehicle of the drug, as control wells. Inhibitors used are bisindolylmaleimide I 
(Calbiochem, #203290), Go6976 (Calbiochem, #365250), PKC412 (Calbiochem, #539648) 
and Y27632 (Calbiochem, #688000). After three doubling times, cell viability was assayed 
using the MTT assay. 
2.4 MTT assay 
 
Cells were seeded on 96 well plates for treatment with inhibitors the next day. At 
endpoint, the appropriate volume of 5X Thiazolyl Blue Tetrazolium Bromide (MTT-Sigma 
M2128) solution is added to the media in wells to make a final concentration of 1x 
(1mg/ml). Plates are incubated at 37°C from 30 to 90 minutes until purple crystals are 
visible under the microscope. Thereafter, MTT-containing media is removed, whilst purple 
formazan crystals remain attached to the plate. These crystals are dissolved in dimethyl 
sulfoxide (DMSO-fisher D/4120PB08) for absorbance to be read at 550nm using a 
spectrophotometer.  
2.5 Western blotting 
 
2.5.1 Preparation of whole cell lysates 
 
Cells in culture are washed once in PBS, and lysed in sample buffer (410mg sucrose in 3% 
SDS and 65mM Tris-HCl pH0.8) and sonicated to reduce viscosity.  To quantify protein 
concentrations, standard solutions of BSA (Sigma Aldrich, UK) were prepared at 0, 0.1, 0.2, 
0.4, 0.8, 1, 1.2, 1.6, 2mg/ml in sample buffer. The Bio-Rad DC protein assay kit (Bio-Rad 
54 
 
laboratories, Hercules, CA, USA) was used according to the manufacturer’s guidelines to 
calculate the protein concentration for each sample. Lysates were diluted in sample buffer 
to adjust the protein concentration between samples. A volume of 4X LDS sample buffer 
(Novex, #NP008) with 10% dithiothreitol (DTT) is added to lysates to make the final 
concentration 1X. This was then heated for 5 minutes at 95°C. 
 
2.5.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transfer 
 
Bis-Tris (4-12%) pre-cast gels (Nusep, #NG11-420) or 8% polyacrylamide gels were used to 
run the samples. Protein lysate samples were loaded per well along with PageRuler Pre-
stained protein ladder (Thermo scientific, #26616) for separation by electrophoresis at 
120V using 1X Tris-Glycine SDS PAGE running buffer (Severn Biotech, #20-6400-10). 
Proteins from the gel are transferred onto a nitrocellulose membrane (GE Healthcare, 
#10600008) by the wet transfer method. A sandwich, composed of 2 sponges, 2 
Whatmann papers, gel, nitrocellulose membrane, 2 Whatmann papers and 2 sponges are 
placed in the transfer unit and placed in the tank. The transfer apparatus is filled with 
transfer buffer (1X Tris-Glycine-Severn Biotech, #20-6300-10), whilst the tank is filled with 
water. The transfer process takes place at 4°C at 35V for 2 hours or at 12V overnight.  
 
2.5.3 Immunoblotting 
 
After transfer, membranes are blocked in 5% w/v non-fat milk (Sigma, #70166) in 1% 
Tween-20 (Bio Chemica, #A1389,0500) and tris-buffered saline (TBS-Severn Biotech, #20-
7301-10) for at least 30 minutes at room temperature and thereafter washed in TBST 
every 5 minutes thrice. Membranes are incubated in primary antibody, diluted in 5% w/v 
bovine serum albumin (BSA-Sigma, #A8022) and TBS-T overnight t 4°C under constant 
rolling motion. Next day, the membranes undergo three 10-minute TBST-T washes before 
incubating in HRP-conjugated secondary antibody (in 5% w/v non-fat milk) for 2 hours at 
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room temperature. Before chemi-luminescent detection, membranes undergo three 10-
minute TBS-T washes. ECL Western blotting detection reagents (GE Healthcare, 
#RPN2106) was added to membranes and incubated for 1 minute before exposing to an 
autoradiographic film and developed in a film processor or exposed and developed in an 
automated chemiluminescent imager (Amersham Imager 600). For low-expressing 
proteins, Luminata Forte (Millipore, #WBLUF0100) or Crescendo (Millipore, #WBLUR0100) 
were used. 
 
2.5.3.1 Primary Antibodies 
 
Table 4. List of primary antibodies for western blotting 
 
Antibody  Supplier Catalogue 
nr 
Species Detects Dilution 
GAPDH Santa 
Cruz 
sc-25778 Rabbit Human/Mouse/Rat 1:2000 
HSC-70 Santa 
Cruz 
sc-7298 Mouse Human/Mouse/Rat 1:2000 
Phospho-PRK1 
(Thr774)/PRK2 
(Thr816) 
CST 2611 Rabbit Human/Mouse/Rat 1:1000 
Phospho-Smad2 
(Ser465/467)/Smad
3 (Ser423/425) 
(D27F4) 
CST 8828 Rabbit Human/Mouse/Rat
/Monkey 
1:1000 
PKN2 R&D 
Systems 
MAB5686 Mouse Human/Mouse/Rat 1:1000 
SMAD2/3 BDT 610843 Mouse Human/Mouse/Rat
/Dog 
1:1000 
 
2.5.3.2 Secondary Antibodies 
 
Table 5. List of secondary antibodies for western blotting. 
Antibody Supplier Catalogue/reference 
number 
Dilution 
ECL Anti-Rabbit IgG HRP-
linked whole antibody 
GE Healthcare NA934V 1:2000 
ECL Anti-Mouse IgG HRP-
linked whole antibody 
GE Healthcare NXA931 1:2000 
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2.6 Inducing PKN2 deletion in MEFs 
 
 
MEFs to be treated are seeded in T75 flasks that should be 70-80% confluent on the day of 
treatment. 4-hydroxy tamoxifen (Sigma) is prepared under the hood in darkness, to avoid 
isomerisation in response to light. 4-hydroxy tamoxifen at 10mM stock is diluted in PBS to 
give a 20μM solution. An appropriate volume of this solution is added to the media in the 
flask, so that the final concentration of 4-hydroxy tamoxifen is 400nm. The flask is 
incubated at 37˚C for 60 to 90 minutes, after which the media in the flask is replaced with 
fresh media. Cells treated with 4-hydroxy tamoxifen can be trypsinised to seed for 
experiments or passaging 24 hours after treatment. PKN2 deletion is apparent by western 
blotting 72 hours after treatment. 
 
2.7 TGFβ1 stimulation in fibroblasts 
 
Recombinant human TGFβ1 (Peprotech, #100-21-10) is reconstituted in 10mM citric acid, 
pH3 to give a 10ng/ml stock solution. Cells to be treated with TGFβ1 are seeded directly 
on plastic tissue culture vessels (6-, 12-, 24-well plates) or on coverslips in the wells. For 
acute stimulation, cells are serum-starved overnight the following day. For both acute and 
long-term treatment, the final concentration was 5ng/ml. On the day of treatment a 
concentrated stock solution is prepared, of which a small volume is added to wells with 
media from the day before.  
 
2.8 Mini-organotypic assay 
 
2.8.1 Experimental set-up 
 
This is a small-scale 3D assay that was used to study the interaction between fibroblasts 
and cancer cells (schematic of experimental set-up shown in Fig. 1). Transwell inserts 
(Costar, #3413) placed onto 24-well plates and the porous membrane (pore size 0.4um) is 
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coated with 300ul collagen (diluted 1:100 in PBS) and incubated at 37°C for 45 minutes. 
The collagen-matrigel gel is prepared (reagents and amounts below) on ice. After 
removing excess collagen from transwells, 20ul of the gel mix was added onto the 
membranes and allowed to set at 37°C for 1 hour. Cell suspensions are prepared in 200ul 
of culture media containing a total of 100,000 cells and added on top of the set gel. The 
slits on the transwell inserts are used to add 600ul of culture media to the bottom to the 
wells. The next day, the media at the bottom of the wells is replaced with 350ul of fresh 
culture media and serum-free media is added on top of the gels. The media is replaced 
every 2-3 days. 
2.8.1.1 Reagents 
 
Reagents required:  
- 525µl collagen type I (Corning, #354236) 
- 175µl Matrigel Basement Membrane Matrix (Corning, #356234) 
- 100µl 10x DMEM (Sigma, #D2429) 
- 100µl cell culture media (DMEM) 
- 100µl filtered FBS (Gibco) 
- Add 25µl per ml 1M NaOH to get bright pink/fuscia color 
 
Figure 1. Mini-organotypic assay set-up 
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2.8.2 Harvesting gels 
 
At endpoint gels are fixed in formalin by adding 200µl above and 600µl below the 
transwell inserts and left overnight. Thereafter the formalin is replaced with 70% v/v 
ethanol for at least 10 minutes. The gels are removed from the transwell inserts using a 
sterile scalpel and placed between two sponges within a cassette and stored in 70% v/v 
ethanol. This is handed in to be paraffinized, embedded, sectioned and H&E stained by the 
pathology services. 
2.8.3 H&E staining quantification 
 
H&E image of gels are converted to a binary image, where positively-stained area become 
black and the remainder white. The area occupied by black pixels can then be calculated. 
This method was used to measure the total cell density, which includes all cells within the 
gels. To count the number of invasive cells, the collective cell area is deleted before 
converting to a binary image. Rather than measuring total area, the individual cells are 
recognised as a particle and counted. The particle size was limited to an arbitrary range 
from 10 to infinity, to avoid small artefacts from the counts. For both total and invasive 
cell measures, gels 1cm in length were used. 
 
2.9 Luciferase assay 
 
2.9.1 Introducing luciferase reporter into cells. 
 
HEK293T cells were used to generate plasmid-containing viral particles. 650,000 HEK293 
cells were seeded per well of a 6-well plate. The next day, the cells are transfected with 
2.5µg of plasmid in 250µl optiMEM, along with 0.6µg of pMD2.G (VSV-G envelope-
expressing plasmid-Addgene) and 1.15µg pCMV (2nd generation lentiviral packaging 
plasmid - Addgene) and 15µl Fugene (Promega, #E2311). After 6-24 hours, fresh media 
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was added to well and left for 48 hours. Viral supernatants were collected, spun for 10 
minutes at 4000rpm and passed through 0.45µm filter.  
 
Cells seeded in 6-well plates the day before are transduced with the viral supernatant, 
which is replaced with fresh media after 24 hours. After 72 hours, plasmid-expressing cells 
are selected with antibiotics for the following 10 days before using in assays. Cancer cells 
transfected with firefly luciferase plasmids were selected in puromycin (Invivogen, #ant-
pr-1) at 2µg/ml, whereas fibroblasts transfected with renilla luciferase plasmids were 
selected in blasticidin (Gibco, #A11139-03) at 20μg/ml. 
 
2.9.2 Experimental set-up 
 
2.9.2.1 Growth (2D & 3D)  
 
Cells are seeded either directly on plastic 96-well clear bottom white plates (Corning, 
#3610) for 2D culture assays or for 3D culture on 40μl of collagen, matrigel or a mixture of 
the two gels (as combined in mini-organotypic assays) that was incubated at 37˚C for 45 to 
60 minutes. Cancer cells and fibroblasts were seeded at various seeding densities 
(depending on cell lines) at 1:2 ratio and incubated for 72 hours, unless stated otherwise. 
 
2.9.2.2 Drug assay 
 
Cells were seeded as for 2D cultures described in 2.8.2.i, but at lower seeding densities, 
and incubated for 72hours. On the third day, the drugs (paclitaxel – Millipore, #580555; 
doxorubicin – Tocris, #2252) were prepared at 3X the desired final concentration by serial 
dilution of which 50μl is added to the cells in 100μl of media to make 1X solution. The 
experiment is terminated 72 hours after drug treatment. 
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2.9.3 Assaying for luciferase reporter activity 
 
Cells seeded on white 96-well plate are washed in PBS and lysed with 20µl per well of Cell 
Culture Lysis Reagent or passive lysis buffer for single- and dual-luciferase assay 
respectively. For single luciferase assay, the lysates undergo once freeze-thaw cycle before 
adding 100µl per well of the luciferase assay substrate (Promega E1510 for single 
luciferase and E1910 for dual luciferase) to detect luminescence at 590nm from the firefly 
luciferase reporter activity. For dual-luciferase this is followed by adding 100µl per well of 
1X Stop & Glo reagent, which quenches the firefly luminescence, to allow detection 
luminescence at 460nm from renilla luciferase activity. Luminescence was read using BMG 
plate reader. 
2.10 in vivo experiments 
 
2.10.1 Subcutaneous injections  
 
Experiments were performed under the Personal Licence number ID I4F848D34 and the 
Project License PPL 70/7449 19b/2. Mice were anaesthetised with isofluorane. 
Cancer cells (MMTV or 4T1) and untreated or 4-hydroxy tamoxifen-treated MEFs (wt or 
PKN2 ko) to be used for injection were harvested from T175 flasks by trypsinisation. Cells 
were washed in PBS twice and finally re-suspended 333,000 cancer cells in 100µl PBS 
alone or with 666,000 MEFs in 100µl PBS. 200µl of cell suspension was injected 
subcutaneously per flank in both flanks of mice. Recovery of mice was monitored. Tumour 
growth was monitored twice weekly by measuring tumour size using digital callipers. Mice 
weights were also monitored twice per week. Mice were maintained until they presented 
with health issues (such as skin ulcerations) or tumour sizes reached the 1440mm3 limit set 
by Home Office and PPL limits. Tumours were excised and fixed in formalin for 24 hours 
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before replacing with 70% ethanol. Fixed tumours were paraffin embedded and sectioned 
by the Pathology department for further immunochemical analysis. 
2.10.2 Orthotopic injections 
 
Experiments were performed at the Francis Crick institute in collaboration with Peter 
Parker. Orthotopic injections were carried out by Marianthi Tatari (Barts Cancer Institute).  
2.10.2.1 Tamoxifen formulation and treatment 
 
Tamoxifen (Sigma, #H7904) is dissolved in ethanol to make 10x solution (165mg in 550µl) 
at 55°C in a thermomixer (800rpm) for 30 minutes (with occasional vortexing). This stock is 
diluted in sunflower oil to make a 1x solution and incubated at 37°C for at least 1-2h in a 
shaker. Mice were administered an appropriate volume of the prepared tamoxifen, at the 
dose of 3mg/20g mouse weight (via oral gavage), thrice within two weeks. 
2.10.2.2 Surgical procedure 
 
The procedure was carried out in a laminar airflow cabinet under sterile conditions. Mice 
were injected intraperitoneally with the analgesic BuprexTM prior to anaesthetising them.   
Mice were put under anaesthesia chamber, containing Isoflurane and oxygen, for up to 5 
minutes.  With the mouse on its back, the mid-lower part of the abdomen is shaved on 
both sides, cleaned with PBS and antiseptic spray. A 2cm-incision is made in the middle of 
the lower abdomen. One mammary gland from each side is injected with 300,000 PyMT 
BO.1 cells in 30µl of Matrigel. The outer skin was closed with surgical staples, after which 
mice were placed in recovery cages with a heater under red light. Mice were observed 
until they returned to normal mobility to be transferred back to normal cages. The 
weights and tumour volumes were measured and monitored every 2-3 days. The 
experiment was terminated two weeks post injection when the mice were culled and the 
tumours were harvested and processed. 
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2.10.2.3 PCR genotyping 
 
Primer sequences:  
Fw: 5’-GGAACTTCGTCGAGATAACTTCG-3’ 
Rv1: 3’ – CCGCCTACTGCGACTATAGAGATATC-5’ 
Rv2: 3’ – CCCTCAGATGAGAAACATAATGAACT-5’ 
2.11 Immunostaining 
 
2.11.1 Immunofluorescence: cell on coverslips 
 
Cell are seeded on coverslips in 6- or 24-well plates to test αSMA expression upon TGFβ1 
treatment. At endpoint, culture media was removed and replaced with 4% PFA v/v (16% 
PFA w/v Alfa Aesar, #3368) diluted in PBS for 20 minutes to fix cells.  After three PBS 
washes, cells are permeabilised with a solution of 1% Triton-X and NH4Cl (50mM) for 20 
minutes and thereafter washed in PBS three times. Cells were blocked in a solution of 10% 
FBS with 0.1% Tween for 1 hour. Next, cells were incubated in primary antibody (mouse 
SMA, Dako, #M0851, 1:250 dilution), diluted in the blocking solution, for 2 hours at room 
temperature. After three washes in PBS, cells were incubated with secondary antibody 
(Goat Anti-Mouse Alexa FLuor-488, Invitrogen, #A11001, 1:200 dilution) and DAPI (Sigma, 
#D9542 at 1µg/ml final concentration), diluted in the blocking solution, for 1 hour. Before 
mounting the coverslips onto glass slides with mowiol, coverslips were washed three 
times in PBS and once in distilled water. Coverslips were left to dry at room temperature 
overnight before imaging or stored at -20°C. 
 
2.11.2 Immunofluorescence: paraffin sections 
 
Paraffin sections on glass slides are de-waxed in xylene for 5 minutes (x2) and hydrated 
through a series of graded ethanol solutions (100%, 80%, 70%, 50% v/v in water), followed 
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by PBS wash. For antigen retrieval, slides are placed in boiling citrate buffer (0.01M 
solution of tri-sodium citrate with pH adjusted to 6) for 8 minutes in the microwave. After 
cooling down and PBS wash, slides are placed in 0.2% triton/PBS for 5 minutes for 
permeabilisation and blocked in PBSABC (2% BSA and 10% FBS solution in PBS) for 1 hour. 
Primary antibody is diluted in blocking solution (PBSABC) and applied on required area and 
incubated overnight at 4°C. The next day, slides are washed in PBSABC for 2 minutes thrice 
before incubating in secondary antibody (diluted in PBSABC) for 1 hour at room 
temperature. Thereafter, after three 5-minute PBSABC washed and incubated in DAPI 
(1:5000 dilution) for 15 minutes at room temperature. Finally, after three PBS washes, 
slides are mounted onto coverslips using mowiol. 
 
2.11.3 Immunohistochemistry 
 
Paraffin sections on glass slides are de-waxed in xylene for 5 minutes, twice and hydrated 
through a series of graded ethanol solutions (100% twice, 80%, 70%, 50% v/v in water) for 
2 minutes each, followed by a two-minute wash in distilled water. Slides are washed in 
30% hydrogen peroxide solution in methanol for 15 minutes between the two 100% 
ethanol washes. Slides are then placed in pre-heated citrate buffer (0.01M, pH6) for 10 
minutes. After cooling down the slides in water, followed by two PBS washes, slides are 
incubated in avidin and biotin (Vector laboratories SP-2001) for 10 minutes each and 
washed in PBS twice. Thereafter, the slides are placed in blocking buffer (3 drops of goat 
serum in 10ml PBS -Normal Goat Serum Blocking Solution, Vector Laboratories, #S-1000) 
for 10 minutes and washed in PBS twice. Primary antibody was prepared in PBS and added 
to slides for overnight incubation at 4˚C in humidified chambers. 
The following day, ABC Reagent (Vector ELITE ABC Kit, Vector laboratories, #PK-6200) was 
prepared and incubated at 4˚C for 30 minutes – 2 drops of Reagent A and 2 drops of 
Reagent B in 5ml PBS. Meanwhile, primary antibody is washed off with PBS twice and 
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incubated with biotinylated anti-mouse or anti-rabbit secondary antibody (provided in the 
Vector ELITE ABC Kit) for 40 minutes at room temperature. Slides were washed in PBS 
twice, before incubating with the ABC reagent for 30 minutes. After two PBS washes, 
slides were incubated with DAB (Dako, #K3468) for 2-5 minutes until dark brown staining 
is visible to the naked eye. After washing off the DAB with PBS and then water, sections 
were counterstained with Mayer’s haematoxylin (Dako, #S3309) for 2 minutes. Finally, 
slides were washed in water to wash off the haematoxylin and dehydrated through the 
series of graded ethanol in reverse from lowest to highest and cleared in xylene. 
Dehydrated sections were mounted onto glass coverslips with DPX (VWR, #360294H) and 
left to dry at room temperature overnight. 
For anti-mouse primary antibody staining on mouse tissue, an additional blocking step is 
required between blocking with goat serum and incubating with the primary antibody. 
Two drops of the Mouse IgG Blocking Reagent (MOM kit, Vector Laboratories, BMK-2202) 
in 2.5ml PBS is added to the sections for 10 minutes and washed off with two PBS washes. 
Thereafter, a stock solution of protein concentrate (provided in the kit) is diluted in 7.5ml 
PBS (solution referred to as diluent and added to sections for 5 minutes. This is tapped off 
before adding the primary antibody for overnight incubation. The following day, after 
washing off the primary antibody, the sections are incubated in Biotinylated Anti-Mouse 
IgG Reagent (2 drops in 5ml of diluent) for 40 minutes. Slides are washed with PBS twice, 
before incubating in ABC reagent. 
 
2.11.4 Primary antibodies for IHC and IF 
 
Table 6. List of primary antibodies for IHC and IF 
Antibody  Supplier Catalogue nr Reactivity IF Conc IHC Conc 
Mouse SMA 
Clone 1A4 
Dako M0851 Human 1:250 1:500 
Endomucin Santa Cruz SC-65495 Mouse, rat - 1:200 
Rabbit Ki67 
Clone SP6 
Abcam AB16667 Human, 
Mouse 
- 1:100 
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2.11.5 Quantifying Sirius red and α-SMA staining 
 
 
Stained sections were scanned using the Pannormamic 250 High Throughput Scanner. The 
scanned sections can be viewed on the Pannoramic Viewer software. Per tumour, multiple 
835μm by 450μm approximate sections that collectively covered approximately 80-90% of 
the whole tumour were selected. The DensitoQuant program under the image analysis 
module of Pannoramic Viewer was used to measure the pixel area and intensity of the 
stainings. After selecting the areas of tumours to be analysed, the threshold is set on the 
DensitoQuant program, to stratify weak-, moderate- and strong-positive staining. For 
analysing α-SMA staining, the blue tolerance level was adjusted to represent the area 
occupied by nuclei and cytoplasm. Once the thresholds are set, the parameters are 
measured for all the sections within a tumour, tumour after tumour.  
2.12 Statistical analysis 
 
Statistical analysis was determined using an unpaired t-test or one-way analysis of 
variance (ANOVA), followed by a Bonferroni post-hoc test where appropriate. All 
statistical analyses were performed using GraphPad Prism 4.0 software (San Diego, CA, 
USA). Significance was assessed in all experiments as a probability value of P<0.05 (*), 
P<0.01 (**) and P<0.001 (***). 
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3. Results 
 
3.1 Role of PKN kinases in breast cancer 
 
Breast cancer is the most common cause of cancer-related deaths, after lung cancer, in 
women. Therefore, novel therapeutic agents are required to improve patient survival. As 
discussed in 1.2.3.3, PKN kinases have been demonstrated to be involved in breast cancer 
proliferation, invasion and metastasis. Therefore, the potential of these kinases as novel 
therapeutic targets in breast cancer was investigated. Firstly, the expression of the PKN 
kinase isoforms (PKN1, 2 and 3) and their prognostic relevance in breast cancer patients 
was analysed.  
3.1.1 Clinical implications of PKN kinase expression on breast cancer survival 
3.1.1.1 PKN kinase expression profile in breast cancer 
 
To understand the clinical implications of PKN kinase expression in breast cancer patients, 
the expression levels of PKN kinases were first investigated. Analysis of PKN kinase 
expression levels across all available breast cancer datasets showed no significant 
differences between the three PKN kinase isoforms in normal individuals and patients with 
different subtypes of breast cancer (Fig. 2). This comparison includes between patients with 
luminal A, luminal B, Her 2, basal and TNBC. The data was also divided to compare patients 
with TNBC and non-TNBC. Overall, there were no differences in PKN kinase expression 
across different breast cancer types nor in comparison to normal samples. 
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Figure 2. PKN kinase expression profile across different breast cancer subtypes 
These plots show the expression values (log2 expression) of A) PKN1, B) PKN2 and C) PKN3 in 
different molecular subtypes of breast cancer and normal samples. The number of samples in each 
subtype is shown in the box below the plots. Each sample was assigned to a PAM50 molecular 
subtype based on the expression of the intrinsic gene list (Parker et al. 2009) - LumA, LumB, Basal-
like, HER2-enriched, normal-like. The TN and non-TN definitions are also based on molecular 
classifications. The ER, PR and HER2 receptor status of each sample were defined by implementing 
functions within the MCLUST R library. The MCLUST algorithm was set to calculate the Bayesian 
Information Criterion (BIC) for a 2-component Gaussian distribution model. TN samples were 
isolated and the levels of gene expression compared to samples allocated to the non-TN group. 
 
3.1.1.2 Analysing the effect of PKN kinase expression on breast cancer survival  
 
Despite the lack of association between PKN kinase expression levels across different 
subtypes of breast cancer, the correlation between PKN kinase expression and survival was 
investigated using an online Kaplan-Meyer analysis tool (Györffy et al. 2010). The 
correlation between PKN kinase expression and relapse-free survival was analysed, as this 
had the best number of patients for breast cancer.  This analysis was automated for 
selecting the best performing threshold for defining low and high PKN kinase expression 
and involved only the best probe sets selected by JetSet algorithms. As multiple probes can 
detect a gene, Li et al developed this JetSet scoring system to assign one probe for a given 
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gene that scores best in three criteria: high specificity, ability to detect splice variants and 
unaffected by transcript degradation (Li et al. 2011). 
The PAM50 single sample predictor (Parker et al. 2009) as applied to the breast cancer data 
to assign each sample to one of the five molecular subtypes (luminal A, luminal B, Her2+, 
normal breast-like or basal). Similarly, triple negative samples were also determined, as 
described by Lehmann et al, on the empirical expression distributions of ER, PR and Her2 
(Lehmann, Bauer, Chen, Sanders, Chakravarthy, and JA 2011). 
The expression levels of PKN kinase expression was plotted for each group (Fraley et al. 
2012). Systematic comparisons were made between different combinations of PKN kinase 
isoforms and breast cancer classifications. The most intriguing comparisons are those 
involving comparisons between TNBC, non-TNBC, basal and mesenchymal-like breast 
cancer, due to the effect of PKN2 knockout in our inducible MEFs and the destructive effect 
on the mesodermal compartment of mice embryo upon systemic PKN2 deletion (Quétier et 
al. 2016).  
Amongst all breast cancer datasets, high PKN1 expression has a significant (P<0.001) but 
modestly better RFS than patients with low PKN1 levels (Fig. 3A). This survival advantage is 
more apparent in patients with basal and ER-negative breast cancer (Fig. 3B, C), with no 
significant differences in ER-positive patients (Fig. 3D). Similar patterns were observed for 
the PKN3 isoform. Elevated PKN3 expression is associated with better RFS across all breast 
cancer data sets (Fig.5A). In basal, ER-negative and ER-positive breast cancer low PKN3 
expression has a moderate but non-significant positive effect on RFS (Fig. 5B, C, D). 
In contrast, PKN2 expression had no impact on RFS across all breast cancer datasets (Fig. 
4A) and in basal breast cancer (Fig. 4B). However, this global analysis masks significant 
differences in behaviour between disease subtypes. There is significantly improved RFS in 
basal (P=0.0067) and ER-negative (P=0.0028) breast cancer patients with low PKN2 
69 
 
expression (Fig. 4C), whereas the converse is true for ER-positive patients (Fig.4D). As 
dependence on PKN2 in TNBC for cell survival has recently been demonstrated in several 
studies, the RFS for patients with low and high PKN2 expression was further investigated. 
Interestingly, analysis of overall TNBC data showed no difference in RFS between low and 
high PKN2-expressing patients (Fig.4E). We next analysed distinct subsets of TNBC using the 
Pietenpol classifications (Chen et al. 2012).  
 
Figure 3. PKN1 expression analysis on breast cancer survival 
Figure showing probability of relapse free survival (RFS) in patients with low and high PKN1 
expression, generated using an online tool (Györffy et al. 2010). PKN high and low expression 
threshold was selected at best cut-off for best performing threshold. PKN1 (affymetrix ID: 
202161_at) was analysed for its prognostic relevance in A. all (n=3951), B. intrinsic basal (n=618), C. 
ER-negative (n=801) and D. ER-positive (n=2061) breast cancer.  
 
70 
 
 
Figure 4. PKN2 expression analysis of breast cancer survival 
Figure showing probability of relapse free survival (RFS) in patients with low and high PKN2 
expression, generated using an online tool (Györffy et al. 2010). High and low expression threshold 
was selected at best cut-off for best performing threshold.  Out of three PKN2 probes, the one 
classed as the best probe by Jetset algorithm was chosen (affymetrix ID: 212628_at). A. All types of 
breast cancers, B. Intrinsic basal subtype C. ER-negative, D. ER-positive, E. TNBC – ER-negative, PR-
negative and HER2-negative, and the Pietenpol subtypes:  F. Basal-like 1 (BL1), G. Basal-like 2 (BL2) 
and H. Mesenchymal-like (ML). Number of patients at risk shown below the plots. 
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Those patients with TNBC classified as basal-like (BL1, BL2) or mesenchymal-like (ML), and 
with low PKN2 expression, have significantly improved RFS survival (Fig.4F, G, H). 
However, the low number of patients involved in this analysis must be considered 
(detailed in figure 4). Additionally, as mentioned above, intrinsic basal breast cancer 
classification shows the same pattern of behaviour (Fig. 4C). Together, these data suggest 
that high PKN2 expression is associated with poor survival in a subset of basal-like and 
mesenchymal-like breast cancer patients, in contrast to the PKN1 and PKN3 isoforms. This 
is particularly interesting as we have demonstrated that systemic deletion of PKN2 in mice 
embryo resulted in abnormal development of the mesodermal compartment (Quétier et 
al. 2016). Furthermore, MEFs from these embryos show dependence on PKN2 for 
proliferation in vitro. 
 
Figure 5. PKN3 breast cancer survival analysis.  
Figure showing probability of relapse free survival (RFS) in patients with low and high PKN3 
expression considering A. all breast cancer types, B. basal, C. ER-negative and D. ER-positive breast 
cancers. High and low expression threshold was selected at best cut-off for best performing 
threshold.  Amongst three probes for PKN3, the one classed as the best probe set by Jetset 
algorithms was chosen (affymetrix ID: 226299_at). Plot generated using an online tool (Györffy et 
al. 2010). Number of patients at risk for each time point is indicated in numbers under the graphs.  
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In the following section, the effect of genetic and pharmacological inhibition of PKN 
kinases on viability of breast cancer cell lines in vitro will be discussed.  
3.1.2 Effect of PKN kinases on breast cancer cell viability 
 
The involvement of PKN kinases in cell cycle regulation has been demonstrated in 
physiological models, such as in Xenopus egg extracts (Misaki et al. 2001) and HeLa cells 
(Schmidt et al. 2007). Furthermore, our lab has demonstrated a role for PKN2 in the 
regulation of cell proliferation during development (Quétier et al. 2016). Induced 
conditional deletion of PKN2 at mid-gestation decreased proliferation of mesodermal cells 
in vivo and this growth defect was also observed in MEFs cell lines derived from this mouse 
model.  Growth arrest resulted in an increased proportion of cells at G1/G0 phase and loss 
of cells in S phase, in PKN2-deleted MEFs.  This observation was further supported by the 
finding of decreased phosphorylation of proteins involved in cell cycle regulation in PKN2-
deleted MEFs from phospho-proteomic analysis (Quétier et al. 2016). These findings have 
subsequently been corroborated in another PKN2 mouse knockout mouse model (Danno et 
al. 2017).  
Moreover, PKN kinases have also been implicated in cancer cell proliferation. Metzger et al 
demonstrated dependence of androgen-driven prostate cancer cells on PKN1 for 
proliferation (Metzger et al. 2008), whilst androgen-independent prostate cancer cell 
proliferation was unaffected by PKN1 expression (Jilg et al. 2014). Reduced PKN3 expression 
and activity downstream of PI3K resulted in reduced proliferation of PI3K-driven prostate 
cancer cells (Leenders et al. 2004).  
Furthermore, the improved RFS in patients with basal breast cancer and 
basal/mesenchymal-like TNBC with low PKN2 expression was kept in mind and therefore, 
three TNBC and three non-TNBC cell lines were used for these studies. TNBC is the most 
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aggressive subtype of breast cancer and has poor prognosis due to unavailability of targeted 
therapy. PKN1 is overexpressed in TNBC (Turner et al. 2010). PKN2 was identified as a 
candidate gene for cell viability, selectively in TNBC cell lines, amongst a screen of 30 cell 
lines of various subtypes of breast cancer (Brough et al. 2011). These studies suggest that 
PKN kinases may play a role in TNBC cell proliferation.  
3.1.2.1 Assessing the effect of targeting PKN kinases in breast cancer cell lines using siRNA 
 
The effect of siRNA-mediated depletion of the three individual PKN kinase isoforms was 
tested on three TNBC cell lines (MDAMB231, SUM159 and MDAMB468) and three luminal 
breast cancer cell lines (MCF7, BT4T4 and T47D). Cells were transfected with a control siRNA 
(siCtrl or siLuciferase) or Dharmacon siRNA smart-pools, targeting the three PKN kinase 
isoforms individually. Cell viability was assayed using the MTT assay after three doubling 
times in 2D culture (Fig.6). The doubling times for each cell line was determined by 
recording cell counts over several days to calculate the approximate number of days 
required for the cell numbers to double.  
SUM159 and MDAMB231 showed significantly decreased viability upon PKN2 or PKN3 
depletion (Fig.6A, B), whilst MDAMB231 also showed reduced viability upon PKN1 loss. 
MDAMB468, MCF7, BT474 and T47D cell survival was unaffected by any PKN kinase isoform 
knockdown (Fig. 6C, D, E, F). Intriguingly, the two TNBC lines affected most by PKN deletion 
- MDAMB231 and SUM159 - are mesenchymal-like cell lines. This indicates a potential 
dependency on PKN kinases for cell viability in TNBC compared to luminal breast cancer 
cells, with most significant effect on viability in those with mesenchymal morphologies. 
Interestingly, we recently reported mesenchymal cell specific growth dependency on PKN2 
during development (Quétier et al. 2016), perhaps suggesting a conserved function in 
mesenchymal phenotype cells. 
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3.1.2.2 siRNA deconvolution to validate the effect of PKN2 depletion in MDAMB231 and 
SUM159 on cell survival.  
 
A role for PKN3 in the proliferation of TNBC has already been demonstrated in-vitro (3D 
culture) and in vivo (orthotopic tumours) (Unsal-Kacmaz et al. 2012). Therefore, we decided 
to focus on the novel role of PKN2 in breast cancer. 
 
 
Figure 6. Effect of PKN2 loss in breast cancer cell viability in 2D culture.  
Three TNBC cell lines: A. MDAMB231, B. SUM159, C. MDAMB468 and three non-TNBC cell lines: D. 
MCF7, E. BT474 and F. T47D were treated with control siRNAs (siCtrl1 or siLuciferase) or siRNA 
targeting the PKN kinases (siPKN1, siPKN2, siPKN3) for 3 doubling times. MTT assay was used to 
assess cell viability. Surviving fractions were normalised to control siRNA. ANOVA analysis was used 
to compare siCtrl or siLuciferase with surviving fractions of each siPKN isoforms. A, B, C, D: 
Collaboration with postdoctoral colleague Ivan Quétier. Data represents the mean +/- SD for n=3 
biological repeats carried out in at least triplicates. Statistical analysis was carried out using ANOVA 
followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***).  
 
 
MDAMB231 and SUM159 showed significant reduction in cell survival upon PKN2 loss, 
mediated by the Dharmacon SMARTpool of four individual PKN2-targeting siRNAs 
(siPKN2#3, siPKN2#9, siPKN2 #10 and siPKN2 #11). To validate this effect, and control for 
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off-target effects, the siPKN2 pool was deconvoluted (four siRNAs used individually) and 
compared to the effect of two control siRNAs in MDAMB231 (Fig 7A) and SUM159 (Fig.7B). 
Three of four PKN2-targeting siRNAs resulted in reduced cell viability in both cell lines, of 
which two constructs (siPKN2#9 and siPKN2#11) reached statistical significance (P<0.01).  
Although this confirms dependence on PKN2 for viability, the effects were relatively 
modest. Subsequently, the effect of PKN2 depletion on cancer viability in 3D culture was 
investigated in MDAMB231 cell line to see whether there were similar or enhanced viability 
in more physiologically-relevant conditions.  
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Figure 7. siPKN2 deconvolution in two PKN2-dependent cell lines for validation and testing for 
off-target effects 
A. MDAMB231 and B. SUM159 were treated with control siRNAs (two of siCtrl1, siCtrl2 and siLuc) 
and four individual siPKN2 constructs (siPKN2#9, siPKN2#10, siPKN2#10) for three doubling times 
and assessed for cell viability by MTT assay. Surviving fractions were normalised to the average of 
control siCtrl1. Data represents the mean +/- SD for n=3 biological repeats carried out in at least 
triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: 
P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
3.1.2.3 Assessing the effect of PKN2 depletion on MDAMB231 cell viability and invasion in 
3D culture. 
 
Depletion of PKN3 was demonstrated to reduce proliferation and metastasis of breast 
orthotopic tumours in vivo and invasion in in vitro 3D models (Unsal-Kacmaz et al. 2012). 
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Focusing on MDMB231 cells, a common model to study metastatic breast cancer in vivo, 
the effect of PKN2 depletion on cell viability and invasion was studied in 3D culture.  
MDAMB231, wild-type or treated with control- or PKN2-targeting siRNA for 24 hours, were 
seeded onto a gel composed of collagen and Matrigel. This gel composition aims to mimic 
the extracellular matrix compartment of tumours (Marshall 2011). The mixture of collagen 
and Matrigel is supplemented with serum and culture media and placed on a membrane 
with a pore size of 0.4µm of a transwell insert. These gels in transwells are placed in a 24-
well plate containing media, where cells in media suspension are added on top of the 
solidified gel. Here, the cell viability, and invasion into the gel across a chemotactic gradient 
can be assessed in 3D.  
The gels are fixed after 5 days, embedded in paraffin, sectioned and stained with H&E to 
visualise the cells within the gel (Fig.8A). Overall, the reduced number of PKN2-depleted 
cells (Fig.8A iv, v, vi) is visually apparent from the H&E stained sections, compared to control 
cell conditions. To assess the variability between replicates and between individual 
experiments, we wanted to describe the behaviour of these cells within the gels 
quantitatively.  
Image J software was used to quantify the area occupied by all cells (total cell density) and 
invasion as described in chapter 2.5. We compared the effects between control and PKN2-
targeting siRNA. Each quantitative parameter was normalised to siCtrl1-treated cells. Cells 
treated with siPKN2#9 and siPKN2#10 showed a small reduction in total cell density 
compared to siCtrl3 cells, however cell density was similar to that of siCtrl1 cells (Fig.8Bi). 
Further, differences in total cell density did not reach statistical significance between any 
conditions. In contrast to total cell density, both control siRNA–treated cells showed 
similarities in invasion parameters (Fig.8B ii, iii). In these cases, two of three PKN2-targeting 
siRNAs (#9, #10 and #11) significantly reduced invasive cell count and area compared to 
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siCtrl1 cells.  These findings indicate that the total number of cells were unaffected by PKN2 
depletion in 3D, whilst the number of invading cells were reduced upon PKN2 loss.  
 
Figure 8. MDAMB231 growth and invasion in 3D mini-organotypic gels 
MDAMB231 cells were seeded onto collagen/matrigel gels. After 5 days the gels were fixed and 
stained with H&E. Brightfield images of the gels show Ai) MDAMB231 cells untreated (wt) or pre-
treated with control siRNA- ii) siCtrl1, iii) siCtrl2 or siPKN2 – iv) siPKN#9, v) siPKN2#10, vi): 
siPKN2#11. These images are converted into a binary image; stained areas become black and the 
remaining background is white. Bi) The total area of black pixels was quantified to indicate total 
area occupied by cells (total cell density) B(ii). The number of single cells were counted using the 
particle analysis tool in Image J. B(iii) The area of black pixels occupied by invading cells was 
quantified. Values are normalised to siCtrl1 values to give relative fold change. C(i) and C(ii): 
Western blots showing PKN2 expression of cells treated with control or PKN2-targeting siRNAs in 
MDAMB231 from two biological repeats. Data represents the mean +/- SD for n=2 biological 
repeats carried out in triplicates. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). n=2. 
78 
 
3.1.2.4 Assessing the effect of pharmacological inhibition of PKN2 kinases on breast cancer 
cell viability. 
 
Targeting PKN isoforms by genetic means indicated a degree of dependency for viability in 
TNBC cell lines on PKN2 and PKN3. The effect of targeting PKN kinase activity 
pharmacologically resulted in similar differential effects between mesenchymal-like TNBC 
cells and luminal breast cancer cells. This study was conducted with two PKN-dependent 
TNBC cell lines (MDAMB231 and SUM159) and the two PKN-independent luminal breast 
cancer cell lines (MCF7 and T47D). As there are no specific inhibitors of PKN kinases, less 
selective inhibitors that have shown significant potency for PKN kinases have been used 
(Davies et al. 2000); (Falk et al. 2014); (Kohler et al. 2012).  
Table 7 lists the potency of some of the inhibitors used against PKN isoforms and some of 
the significant off-target inhibitory activities on other kinases.  Bisindolylmaleimide 1 (Bis 
1) and PKC412 have high potency against PKN2, as well as other targets such as protein 
kinase C kinases (PKC kinases), fibroblast growth factor receptor 1 (FGFR1), 3-
phosphoinositide dependent protein kinases (PDK kinases), and ribosomal protein S6 
kinase B1 (p70S6K) (Table 7Ai, 1Bi).  Bis 1 and PKC412 have higher binding affinity to PKN1, 
followed by PKN2 for Bis 1 and PKN3 for PKC412 (Table 1A ii, 1B ii). CEP701, also known as 
Lestaurtinib, has an IC50 value of 8.6nM against PKN1 (Kohler et al. 2012). Compared to 
PKN1 and PKN2, this drug has higher binding affinity to other kinases such as mitogen-
activated protein kinase 3 (ERK1), insulin-like growth factor I receptor (IGFR1), mechanistic 
target of rapamycin kinase (MTOR) and epidermal growth factor receptor (EGFR1) (Table 
7C). Go6976 has high potency against PKN2, as well as other kinases such as protein 
kinase C-alpha (PKCα), Janus kinase 2 (JAK2), cyclin dependent kinase 5 (CDK5), PDK1 and 
FGFR1 (Table 7D). Y27632 is primarily a Rho associated coiled-coil containing protein 
kinase (ROCK) inhibitor. It has a IC50 value of 0.6μM against PKN2 and 0.8μM against ROCK 
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II (Davies et al. 2000).  Y27632 has higher potency against PKN2 than PKN1 (Table 7E i), 
which is reflected by the lower Ki binding affinity value for PKN2 than PKN1 (Table 7E ii).  
Table 7. Inhibitory activity of Bis 1 
Inhibitory activity of Bis I in (Ai), PKC412 (Bi), Go6976 (D), and Y2732 (Ei) on PKN1 and/or PKN2, as 
well as some of the other off-targets. Ki values demonstrating differential PKN kinase isoform 
selectivity of (A ii) Bis 1, (B ii) PKC412 and (Eii) Y27632 [2] (Falk et al. 2014). C. Inhibitor binding 
affinity of CEP701 to PKN1 and PKN2 and some of the other off-targets. Inhibitory activity of drugs 
on kinases determined using [1] DiscoveRx KINOMEscan® platform (Anastassiadis et al. 2011); (Gao 
et al. 2013); (Wodicka et al. 2010). [3] (Davis et al. 2011). 
 
 
These commercially available inhibitors, which also block other kinases, were tested for 
their effect on cell viability after three doubling times in 2D culture by MTT assay. 
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Effect of Bisindolylmaleimide I (Bis I) treatment on breast cancer survival 
Bis I is a potent inhibitor of PKC kinases, as well as PKN1 and PKN2. Each cell line was initially 
tested with a range of different doses and thereafter treated with the chosen dose range 
for final analysis (Fig. 9). Calculations of IC50 values for the dose-response curves for each 
cell line (summarised in Table 8A) demonstrates increased sensitivity in PKN-dependent 
MDAMB231 and SUM159 cells than PKN-independent MCF7 and T47D.  
 
Figure 9. Dose-response curves of breast cancer cells treated with Bisindolylmaleimide I 
A. MDAMB231 (n=3), B. SUM159 (n=3), C. MCF7 (n=3) and D. T47D (n=2) were treated with 
bisindolylmaleimide I (Bis I) 24h after seeding onto 96-well plates. Cell viability was assessed using 
MTT assay, after three doubling times. Cells were treated at the following concentrations: 0.1, 0.3, 
1, 3, 10 and 30µM. Log10 of concentration (M) is plotted against values normalised to DMSO 
condition (plot before x-axis break) +/- SD for n=3 biological repeats carried out in at least 
triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: 
P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
Effect of PKC412 on breast cancer survival 
PKC412, also known as midostaurin, is a staurosporine-derived PKC inhibitor (Gesher 1998) 
and subsequently recognised as a FLT3 inhibitor (Weisberg et al. 2002). This inhibitor is FDA 
81 
 
approved for AML treatment (Stone et al. 2017) in patients with FLT3 mutation, in addition 
to standard chemotherapy. Data from a kinase profiling screen indicates high potency for 
several other kinases such as FGFR1, FGFR2, PKC kinases and PKN2 (Table 2B i).  
The dose-response curve for T47D cells showed a biphasic pattern at the tested dose range 
(Fig.10D). However, the other cell lines showed inhibitory response to the tested doses 
(Fig.10A, B and C). The IC50 values (Table 3B) suggests that the two PKN-dependent cell lines 
have higher sensitivity to PKC412 than MCF7, supported by the biphasic survival pattern 
shown by T47D cells. 
 
Figure 10. Dose-response curves of breast cancer cells treated with PKC412 
A. MDAMB231 (n=3), B. SUM159 (n=3), C. MCF7 (n=3) and D. T47D (n=2) were treated with PKC412 
the following day after seeding the cells onto 96-well plates. MDAMB231, SUSM159 and MCF7 
were treated at the following concentrations: 0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 30µM. T47D cells 
were treated at the following concentration: 0.3, 1, 3, 10, 30 and 100 µM. Cell viability was 
assessed using MTT assay, after three doubling times. Log10 of concentration (M) is plotted against 
values normalised to DMSO condition (plot before x-axis break) +/- SD for n=3 biological repeats 
carried out in at least triplicates. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***).  
82 
 
Effect of CEP701 on breast cancer survival 
CEP701, also known as lestaurtinib, has been involved in clinical trials as a JAK2 inhibitor to 
treat myeloproliferative neoplasms (Hexner et al. 2014) and as a FLT3 inhibitor to treat 
patients with acute myeloid leukemia (Knapper et al. 2006). Treating the four cell lines in 
question with this inhibitor (Fig.11) similarly showed increased sensitivity in SUM159 and 
MCF7 cells than MDAMB231 and T47D cells (IC50 values summarised in Table 3C).  
 
 
Figure 11. Dose-response curves of breast cancer cells treated with CEP701 
A. MDAMB231 (n=3), B. SUM159 (n=3), C. MCF7 (n=3) and D. T47D (n=3) were treated with CEP701 
the following day after seeding the cells onto 96-well plates. Cell viability was assessed using MTT 
assay, after three doubling times. MDAMB231, SUSM159 and MCF7 were treated at the following 
concentrations: 0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 30µM. T47D cells were treated at the following 
concentration: 0.3, 1, 3, 10 and 30µM. Log10 of concentration (M) is plotted against values 
normalised to DMSO condition (plot before x-axis break) +/- SD for n=3 biological repeats carried 
out in at least triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni 
post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Effect of Go67976 on breast cancer survival 
An indolocarbazole with a similar structure to staurosporine, Go6976 is a potent inhibitor 
of FLT3 and JAK2 and is known to have anti-proliferative effects in AML cells (Grandage et 
al. 2006); (Yoshida et al. 2014). In addition, Go9676 has high potency against PKC kinases 
and PKN2 (Table 7D). Amongst the four tested cell lines MDAMB231 was the least sensitive, 
whereas T47D showed highest sensitivity (Fig.12A, D) (IC50 values summarised in Table 3D).  
 
 
Figure 12. Dose-response curves of breast cancer cells treated with Go6976 
A. MDAMB231 (n=3), B. SUM159 (n=3), C. MCF7 (n=3) and D. T47D (n=3) were treated with Go6976 
the following day after seeding the cells onto 96-well plates. Cell viability was assessed using MTT 
assay, after three doubling times. MDAMB231, SUSM159 and MCF7 were treated at the following 
concentrations: 0.1, 0.3, 1, 3, 10 and 30µM.  T47D cells were treated at the following 
concentration: 0.3, 1, 3, 10 and 30µM. Log10 of concentration (M) is plotted against values 
normalised to DMSO condition (plot before x-axis break) +/- SD for n=3 biological repeats carried 
out in at least triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni 
post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Effect of Y27632 on breast cancer survival 
This drug is widely used as a Rho kinase inhibitor (Ishizaki et al. 1996 ) and has been studied 
in neurodegenerative diseases (Bauer et al. 2009); (Liu et al. 2014) and in hypertension as a 
vasodilator (Uehata et al. 1997).  Furthermore, treating prostate and breast cancer cells 
with Y27632, in addition to fibroblast cells, increases proliferation of cancer cells (Liu et al. 
2012).  
This inhibitor had no anti-proliferative effect on any of the cell lines at the tested dose range 
(Fig.13). This could be explained by the relatively low potency for PKN2 reported by Davies 
et al (IC50 =600nM) in a cell-based kinase inhibitor screen (Davies et al. 2000).  
 
Figure 13. Dose-response curves of breast cancer cells treated with Y27632 
A. MDAMB231 (n=3), B. SUM159 (n=3), C. MCF7 (n=3) and D. T47D (n=2) were treated with Y27632 
the following day after seeding the cells onto 96-well plates. Cell viability was assessed using MTT 
assay, after three doubling times. All cells were treated at the following concentrations: 0.1, 0.3, 1, 
3, 10 and 30µM.  Log10 of concentration (M) is plotted against values normalised to DMSO 
condition (plot before x-axis break) +/- SD for n=3 biological repeats carried out in at least 
triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: 
P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Overall, Bis I and PKC412 elicited enhanced anti-proliferative effects in PKN-dependent cell 
lines MDAMB231 and SUM159, when compared with PKN-independent MCF7 and T47D 
cells (Table 3A, B). CEP701 and Go6976 showed varying effects on the four different cell 
lines, which did not correlate with PKN expression dependence (Table 3C, D). No sensitivity 
was found in response to Y27632 at the tested range of doses. However, as these inhibitors 
target many other kinases, validating PKN2 as an anti-proliferative pharmacological target 
is limited. Therefore, genetic targeting of PKN currently remains a more desirable approach. 
Table 8. Summary of PKN kinase inhibitor activities 
IC50 values of A. Bis 1, B. PKC412 (IC50 values could not be calculated in T47D cells from the 
resulting dose-response curve), C. CEP701 and D. Go6976 in the tested TNBC (orange cells) or 
luminal (blue cells) breast cancer cell lines. 
 
 
3.1.3 Summary  
 
Ultimately the aim of our study was to examine whether targeting the PKN kinases might 
inhibit TNBC tumour growth and metastasis. To support this, results discussed in this 
chapter and other independent studies (Brough et al. 2011); (Lin et al. 2017) show a strong 
association between PKN2 and TNBC for cell survival.  
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The difference in viability with siRNA was however relatively moderate and replicating these 
results using shRNA presented with technical difficulties. Additionally, during the course of 
our work, a study on the role of PKN3 in breast tumour angiogenesis and metastasis was 
published (Mukai et al. 2016) and a separate study describing the role of PKN2 in TNBC cells 
(Lin et al. 2017).  
Furthermore, a selective PKN kinase inhibitor is required to translate any findings from 
targeting this kinase to the clinic. A recent study (Lin et al. 2017) demonstrated potent 
selective inhibition of four TNBC cell line viability compared with four other non-TNBC cell 
lines using the PKC targeting inhibitor chelerythrine. Chelerythrine was then shown to 
induce apoptosis in the TNBC lines. They also demonstrated that knockdown of PKN2 in the 
four TNBC and four non-TNBC showed selective anti-proliferative effects specifically in 
TNBC cell line, corroborating our findings. They subsequently attribute Chelerythrine TNBC 
selectivity to its ability to inhibit of PKN2. The TNBC cell lines used in these studies are 
mesenchymal in phenotype (for e.g. MDAMB231 and SUM159) and/or classified as ML or 
BL TNBC cell lines (for e.g. MDAMB468, Cal-120 and BT549) (Lehmann, Bauer, Chen, 
Sanders, Chakravarthy, Shyr, et al. 2011).  
However, this is questionable, as chelerythrine is not a PKN2-specific inhibitor. The MRC 
kinase profiling inhibitor database reports that chelerythrine is a very poor inhibitor of PKN2 
(only 8% inhibition of PKN2 kinase activity at 10µM), whereas Tie2 activity is inhibited by 
97% and FGFR1 by 56% (Anastassiadis et al. 2011); (Gao et al. 2013). Furthermore, 
chelerythrine also has high potency against PKC, with an IC50 value of 0.66μM against 
(Herbert et al. 1990).  
Do mesenchymal cells depend on PKN2 to proliferate?  
Several lines of evidence from independent studies suggest that we may have identified a 
mesenchymal cell-specific role for PKN2 in the regulation of cell growth. Firstly, systemic 
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deletion of only PKN2 but not PKN1 or PKN3 has detrimental effect on mesenchymal cell 
growth both in vivo and in vitro during embryonic development (Quétier et al. 2016). 
Secondly, genetic depletion of PKN kinases reduced cell viability of MDAMB231 and 
SUM159 breast cancer cells that have mesenchymal phenotypes. These cell lines had 
reduced viability when treated with two non-specific PKN kinase inhibitors Bis 1 and 
PKC412, compared to luminal breast cancer cell lines MCF7 and T47D. These data also agree 
with the findings from an independent functional viability screen in breast cancer cells 
(Brough et al. 2011), which identified PKN2 as a candidate gene for targeting cell viability in 
TNBC cells. Several other TNBC cell line hits identified in this screen, showing dependency 
on PKN2, also display mesenchymal phenotypes. Similarly, since conducting our study, Lin 
et al also reported the specific requirement of PKN2 exclusively in TNBC cells, compared to 
other breast cancer cells, for cell growth in-vitro and in-vivo (Lin et al. 2017), which 
corroborates our findings. 
While the role of PKN2 mechanistically remains a focus in the lab, the relatively modest 
effect on TNBC growth, and the publication of competing studies, prompted us to change 
focus to examine a role for PKN2 in cancer-associated fibroblasts, one of the most significant 
mesenchymal phenotype cell types in many solid tumours, including those of the breast and 
pancreas.  In breast cancer, fibroblast activation plays an important role in the tumour 
microenvironment and affects tumour progression, metastasis and drug response. Further, 
data from our lab has strongly implicated PKN2 in the regulation of pancreatic cancer 
associated fibroblasts. Therefore, the role of PKN2 in breast fibroblasts and how this affects 
their interaction with breast cancer cells was investigated.  
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3.2 Role of PKN2 in TGFβ1-mediated fibroblast activation 
 
Fibroblasts within the TME become activated into CAFs in response to factors secreted by 
cancer cells, including TGFβ and PDGF (Ostman and Augsten 2009). Activated CAFs induce 
scar like fibrosis, through production of ECM proteins (desmoplasia), blocking entry of 
tumour-infiltrating immune cells and anti-cancer drugs (Orimo et al. 2005). Increased ECM 
deposition and tissue stiffness associated with many tumours further enhances CAF 
activation through mechanosensing pathways in a positive feedback loop. CAFs also secrete 
ECM remodelling enzymes, as well as growth factors and cytokines, which promote 
angiogenesis, inflammation, cell motility and invasion (Tyan et al. 2012); (Shekhar et al. 
2001); (Soon et al. 2013). High expression of α-SMA, an important marker of activated 
fibroblasts (myofibroblasts and CAFs), which has been associated with high grade tumours, 
lymph node metastasis and poor prognosis in breast cancer (Yazhou et al. 2004); (Surowiak 
et al. 2006); (Surowiak et al. 2007). These findings suggest that studying the regulation of 
CAF activation in the stroma may provide important therapeutic targets. 
Our recent report demonstrated a role for PKN2 in the mesenchyme of embryos during 
development (Quétier et al. 2016). Importantly, embryo morphogenesis defects indicate a 
loss of contractility within the mesenchymal compartment and this is accompanied by 
severe angiogenic defects. Work in the lab (in collaboration with John Marshall) further 
demonstrated that loss of PKN2, in a variety of mouse and human fibroblasts, reduced their 
contractility - a phenotypic marker of activation - in collagen gels, in response to TGFβ1 (Fig. 
14). Together, these data suggest that PKN2 is critical for activation of fibroblasts both in 
vitro and in vivo, with potential implications for the activation of fibroblasts into CAFs in 
tumours.  
Here we sought to examine whether PKN2 loss impacts on the activation of fibroblasts in 
breast cancer. As models, we used immortalised human breast fibroblasts (HMFU19) and 
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primary human breast cancer CAFs. We also used inducible conditional PKN2 knockout 
MEFs as a surrogate model, where we have previously identified a defect in TGFβ1-
induced collagen contractility (Fig.14 - data not shown). We also focused on the induction 
of α-SMA fibres as a marker of fibroblast activation. Acute TGFβ1-mediated SMAD 
signalling was also investigated to probe for PKN2’s mechanism of action.
 
Figure 14. Collagen contraction assay to assess effect of PKN2 deletion in fibroblasts on activation 
A. Human lung fibroblasts, treated with control or PKN2-targeting siRNA were seeded in collagen 
gels. The following day, normal culture media with or without TGFβ1 is added to gels. i) Images of 
gels. Gels with control siRNA treated cells, treated with TGFβ1, contracted compared to vehicle-
treated gels. There was no contraction in response to TGFβ1 in gels with siPKN2 treated cells. ii) 
Over 11 days, the fold change in gels size decreased for siControl cells and remained unchanged for 
siPKN2 fibroblasts. B. Similar collagen contraction assays were done in other fibroblasts, comparing 
those that express PKN2 (+PKN2) and those without PKN2 (-PKN2). These fibroblasts include MEFs, 
mouse lung fibroblasts (MLFs), human fibroblast-like fetal lung cells (WI-38), and human pancreatic 
stellate cells (PS1). All fibroblasts show reduced gel contraction upon TGFβ1-induction with PKN2 
loss. 
 
3.2.1 Role of PKN2 in TGFβ-1 mediated induction of α-SMA fibres in fibroblasts 
 
Work by Desmoulière et al demonstrated that treatment of fibroblasts with TGFβ induced 
the expression of α-SMA fibres, a marker of cellular differentiation (Desmoulière et al. 
1993); (Chaponnier and Gabbiani 2004). Thus, fibroblasts differentiate into myofibroblasts 
in response to TGFβ, that are highly contractile and contribute to ECM and collagen 
deposition and consequent fibrosis. The presence of many α-SMA-expressing 
myofibroblasts has been associated with high grade tumours and low overall survival in 
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breast cancer (Surowiak et al. 2006); (Yang et al. 2017); targeting these myofibroblasts has 
been proposed as a potential therapeutic opportunity. 
Previous work in the lab demonstrated reduced contractility in PKN2-depleted fibroblast 
models in response to TGFβ1, raising the possibility that targeting PKN2 may be beneficial 
for supressing CAF activation in tumours. Therefore, the ability of wt and PKN2 
deleted/depleted MEFs and CAFs to express α-SMA fibres in response to TGFβ1 was tested. 
MEFs (wt and PKN2 ko) were seeded onto glass coverslips in 24-well plates and treated the 
following day with TGFβ1 (5ng/ml) or vehicle control. Primary breast CAFs were treated 
with control siRNAs or a pool of PKN2-targeting siRNAs (siPKN2#9, siPKN2#10, siPKN2#11). 
After 72 hours, these CAFs were trypsinised and seeded onto coverslips and treated the 
following day with TGFβ1 (5ng/ml) or vehicle control. Fibroblasts were fixed 72 hours post 
TGFβ1 treatment. Three biological experiments were conducted per fibroblast model.  The 
fixed cells on coverslips were immunostained for α-SMA, counterstained with DAPI and 
images were acquired on an LSM710 confocal microscope. Multiple images were acquired 
per condition to image cells that overlap minimally with neighbouring cells and to have a 
minimum of 20 cells per condition. Each image was analysed by counting the total number 
of cells, α-SMA-positive cells and grading the α-SMA brightness per cell (low, medium or 
high). The percentage of α-SMA-positive cells was scored, to quantify differences in the 
levels of α-SMA-positive cells, between untreated and TGFβ1-treated fibroblasts that do or 
do not express PKN2.  
3.2.1.1 TGFβ1-mediated activation in MEFs is suppressed upon PKN2 deletion 
More than 50 MEFs per condition were analysed for the expression of α-SMA fibres. Under 
basal conditions, approximately 40% of cells were found to express α-SMA (Fig. 15Ai, Ci – 
WT-TGF) and this was not significantly reduced upon deletion of PKN2 (Fig. 15Aii, 2Ci). There 
was a significant increase in α-SMA-positive cells in TGFβ1-treated compared to vehicle-
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treated wt MEFs (Fig. 15A, B, Ci). This induction was not seen in PKN2-deleted MEFs and the 
percentage of α-SMA-positive cells was significantly lower in TGFβ1-treated PKN2 ko MEFs 
compared to TGFβ1-treated wt MEFs (Fig. 15Ci). Furthermore, α-SMA-positive cells were 
categorised according to the brightness of α-SMA immunostain as low, medium and high. 
There was a significant increase in wt MEFs, with medium-level α-SMA brightness, when 
stimulated with TGFβ1 (Fig. 15C iii).  In contrast, there was no significant increase in TGFβ1-
treated PKN2 ko MEFs, with medium brightness, when stimulated with TGFβ1. Further, the 
percentage of α-SMA medium brightness cells was significantly lower in the TGFβ1 
stimulated PKN2 ko cells than in TGFβ1 stimulated wt cells. Due to high variation observed 
for some conditions, there were no statistically significant differences between untreated 
or TGFβ1-treated cells, graded as low or high brightness, regardless of PKN2 expression (Fig. 
15C ii, iv). Overall, the percentage of α-SMA positive cells following TGF induction is 
reduced upon PKN2 loss. This helps explain the previous observation of reduced 
contractility of TGFβ1-stimulated MEFs in collagen gels, when PKN2 was deleted as α-SMA 
positivity has been directly correlated with cell contractility (Hinz et al. 2001). 
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Figure 15. -SMA fibre induction in TGF1-stimulated wt and PKN2 ko MEFs 
MEFs (wt and PKN2 ko) seeded on coverslips were treated with 5ng/ml TGFβ1 or vehicle for 72h. At 
endpoint, cells were fixed and stained for α-SMA (green) and with DAPI (blue) for nuclei. In wt MEFs, 
there was an increased percentage of α-SMA-positive cells when stimulated with TGFβ1 (Aii) 
compared to untreated cells (Ai). In PKN2 ko cells treated with TGFβ1 (Bi), the increase in α-SMA was 
marginal compared to non-treated cells (Bii). Total number of α-SMA positive MEFs was counted and 
expressed as percentage of total cells (Ci). The brightness of α-SMA fibres for each cell was 
categorised as low, medium, high and expressed as percentage of total cells (Ci, ii, iii). Data 
represents the mean +/- SD for n=3 biological repeats carried out in duplicate coverslips. Statistical 
analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), 
P<0.001 (***). 
3.2.1.2 TGFβ1-mediated activation of primary CAFs and the effect of PKN2 deletion 
Primary cancer-associated fibroblasts (CAFs) from human patients were obtained from the 
Breast Cancer Tissue Bank, through collaboration with Prof. Louise Jones (Barts Cancer 
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Institute). CAFs are predominantly activated forms of resident fibroblasts in the tumour 
stroma and therefore often have high basal expression of α-SMA. Nevertheless, TGFβ1 was 
used to see whether the expression of α-SMA can be further stimulated and whether it will 
be affected by PKN2 expression.  
Culturing primary CAFs presented with challenges due to their slow proliferation in culture 
and their propensity to arrest through senescence after very few cell passages. 
Furthermore, the number of cells seeded per condition was lower than that for MEFs, as 
CAFs have a larger surface area; at high densities, with overlapping cells, quantification of 
α-SMA was difficult. Therefore, the number of cells available for analysis ranged from 20 to 
50 cells per condition. Surprisingly, the percentage of CAFs expressing α-SMA in basal 
conditions was quite low (10-40%). There was an overall increase in the percentage of α-
SMA-positive cells upon TGFβ1 treatment in wt and control siRNA-treated CAFs in all three 
biological replicates (Fig. 16A, B, Di). However, there were no changes in siPKN2-treated 
CAFs in the percentage of α-SMA-positive cells upon TGFβ1 treatment (Fig. 16C, Di). There 
was significant variation in the base line percentage, which meant comparison of raw 
percentage differences did not reach statistical significance (Fig. 16Dii). To overcome this, 
the change in percentage of α-SMA-positive cells for each experiment was compared (Fig. 
16D iii). The percentage change in α-SMA-expressing, PKN2-depleted CAFs between 
untreated and TGFβ1-treated cells was significantly lower compared to control cells 
(untreated and control siRNA-treated cells (Fig. 16D iii). Overall, these data show 
suppression of α-SMA induction in PKN2 depleted CAFs when stimulated with TGFβ1, 
consistent with the observations in MEFs. 
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Figure 16. Induction of α-SMA fibres in CAFs and the effect upon PKN2 loss. 
CAFs, wild-type(wt) or pre-treated with control siRNA (siLuc) or PKN2-targeting siRNA (siPKN2) were 
seeded onto coverslips and treated with 5ng/ml TGFβ1 or vehicle for 72h. Cells at endpoint were 
fixed and immunostained for α-SMA (green) and with DAPI (blue).  Images were acquired using an 
LSM710 confocal microscope (A, B, C). The total number of α-SMA-expressing cells were counted and 
expressed as percentage of total cells and plotted on a matched dot plot to visualise the individual 
biological experiments (Di). For siLuc cells (non-targeting control) the values for two experiments are 
very similar and the plot overlaps, hence the solid line rather that the dashed lines, and apparent 
lack of a third experimental replicate. Total percentage of α-SMA-positive cells for the three 
biological experiments (Dii). The matched dot plot shows variation in basal levels of α-SMA-
expressing cells between different cell conditions and experiments. Therefore, the changes in 
percentage of α-SMA-positive cells between untreated and TGFβ1-treated cells were plotted (Diii). 
Data represents the mean +/- SD for n=3 biological repeats carried out in duplicate coverslips. 
Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), 
P<0.01 (**), P<0.001 (***). 
3.2.2 Effect of PKN2 loss on acute signalling in fibroblasts upon TGFβ stimulation 
Reduced α-SMA fibres in TGFβ1-activated, PKN2-deleted/depleted fibroblasts were 
observed in MEFs and CAFs. The role of PKN2 in suppressing α-SMA fibre formation might 
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lead to normalising an activated stroma. To exploit this pathway as a therapeutic target, the 
mechanism of PKN2’s role in fibroblast activation needs to be investigated. Therefore, the 
immediate signalling pathway downstream of acute TGFβ1 stimulation was compared 
between wild-type and PKN2 deleted/depleted fibroblasts. Fibroblasts were 
deleted/depleted of PKN2 and serum-starved. The following day, stock TGFβ1 solution or 
culture media (for control cells) was spiked into the cell media. The addition of a small 
volume to the existing media reduces shear force on cells that is known to affect signalling 
downstream of TGFβ1 (Ahamed et al. 2008).  
Protein lysates were collected across a time-course of stimulation and tested for canonical 
TGFβ-activated SMAD signalling, one of the main pathways responsible for TGFβ functions. 
In this pathway TGFβ binds to TGFβ type II serine/threonine kinase receptor (TβRII) and 
recruits type I receptor (TβRI) to form an oligomeric receptor complex (Yamashita et al. 
1994). This complex results in phosphorylation and conformational change of TβRI by TβRII, 
leading to its activation. This leads to a signalling cascade involving the phosphorylation of 
SMAD2 and SMAD3, which form complexes with a transcription factor SMAD4. Finally, this 
complex translocates to the nucleus to mediate transcriptional activity. 
3.2.2.1 PKN2 deletion and TGF1 stimulation across a timecourse in MEFs 
MEFs (wt and PKN2 ko) were seeded onto 12-well plates in normal culture media and 
serum-starved the following day in 0.5% FBS media. The next day, TGFβ1 stock solution or 
normal culture media (vehicle) for control cells was added to the cells in media, to give a 
final concentration of 5ng/ml. Following stimulation for 5, 10, 30 and 60 minutes, cell were 
placed on ice, media was removed, cells were washed once in ice-cold PBS and lysed in lysis 
buffer.  
MEFs were treated with TGFβ1 for 5, 10 30 and 60 minutes to study the kinetic of increasing 
phosphorylation of SMAD2/3. SMAD phosphorylation was detected after 5 minutes, which 
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increased up to 30 minutes after stimulation.  Both wt and PKN2 ko MEFs showed near 
identical patterns and amplitude of SMAD2/3 phosphorylation (Fig. 17).  
 
Figure 17. SMAD2/3 phosphorylation in wt & PKN2 ko MEFs after short-term TGFβ1 stimulation 
MEFs were seeded, serum-starved overnight and treated the following day with 5ng/ml TGFβ1 for 
0, 5,10, 30 and 60 minutes. Protein lysates were collected, separated by PAGE-SDS electrophoresis 
and blotted for the expression of PKN2, phosphorylation of SMAD2/3 (pSMAD2/3) and protein load 
controls GAPDH and HSC70 (Ai). Densitometry of bands was quantified using Image J tool to 
understand the changes in relative levels of pSMAD2/3 to the loading control HSC70 (ii). Data 
represents n=2 biological repeats. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
3.2.2.2 PKN2 depletion and TGFβ1 stimulation in HMFU19 immortalised breast fibroblasts 
Immortalised human mammary fibroblasts were obtained from Mike Allen (Barts Cancer 
Institute). These fibroblasts were immortalized by Professor Mike O’Hare, using hTERT and 
SV40 large tumour antigen (O'Hare et al. 2001). These cells were not included in our study 
of α-SMA fibres, as siRNA transfected cells expressed α-SMA fibres without stimulation and 
did not respond further to long-term TGFβ1 stimulation to induce increased α-SMA fibre 
formation. Nonetheless, the role of PKN2 on acute TGFβ1 stimulation was assessed in 
HMFU19, alongside MEFs and CAFs, to compare a range of fibroblast models.  
HMFU19 were transfected with control siRNA (siLuc) and two individual PKN2-targeting 
siRNAs (siPKN2#9 and siPKN2#10). Transfected fibroblasts were seeded onto 12-well plates, 
three to four days post-transfection. The following day, TGFβ1 stock solution was added to 
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the cells in media to give a final concentration of 5ng/ml. Normal culture media was added 
to control cells. HMFU19 were seeded and stimulated with TGFβ1 in 0.5% FBS media. 
Protein lysates were collected at various timepoints: 0, 5, 10 and 30 minutes.  
HMFU19 retained the ability to respond to TGFβ1 stimulation after 5, 10, and 30 minutes 
by inducing SMAD2/3 phosphorylation, regardless of PKN2 loss (Fig. 18). Control siRNA and 
PKN2 siRNA-treated cells showed increasing phosphorylation of SMAD2/ 3 with increasing 
time exposed to TGFβ1. There was a small reduction in SMAD2/3 phosphorylation at 30 
minutes in siPKN2-treated HMU19, compared to control siRNA cells, though further 
replicates are required to assess statistical significance.  
 
Figure 18. SMAD2/3 phosphorylation in HMFU19 fibroblasts upon acute TGFβ1 stimulation 
HMFU19 cells were transfected with control siRNA (siLuc) or two PKN2-targeting siRNAs 
individually (siPKN2#9 and siPKN2#10) before seeding for TGFβ1 stimulation. Cells were starved 
overnight in reduced serum media and stimulated with 5ng/ml TGFβ1 for 0, 5, 10 and 30 minutes. 
Protein lysates were collected, separated by SDS-PAGE electrophoresis and blotted for the levels of 
phosho-PKN1 and phospho-PKN2 (pPKN1/2), phospho-SMAD2/3 (pSMAD2/3) and protein load 
control GAPDH (Ai). Densitometry of bands was quantified using Image J tool to understand the 
changes in relative levels of pSMAD2/3 to the loading control GAPDH (ii). Data represents the mean 
+/- SD for n=2 biological repeats. 
 
3.2.2.3 Acute TGFβ1-mediated SMAD signalling in PKN2-deleted CAFs 
CAFs were also transfected with siLuc but PKN2 was supressed using a pool of three PKN2-
targeting siRNAs (siPKN2#9, siPKN2#10, and siPKN2 #11) as transfection efficiency was 
often poor with these cells and cell numbers were limited. As the culture of primary CAFs 
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presented with challenges, due to limited passaging and slow proliferation, the number of 
cells available for the experiment was limited. Thus, for PKN2 depletion a pool of PKN2-
targeting siRNAs was used. Cells were seeded under the same culture conditions as for 
HMFU19, except that the culture media was supplemented with 2% FBS, as CAFs did not 
survive in 0.5% FBS media when previously tested. However, due to the low number of cells 
available, only one time-point of TGFβ1 stimulation (30 minutes) was tested. 
The experiment in CAFs was consistent with MEFs and HMFU19, in that loss of PKN2 
expression did not hinder SMAD2/3 phosphorylation following TGFβ1 stimulation for 30 
minutes (Fig. 19). Further experiments are required to confirm these results in a panel of 
primary CAFs. Although repeats of this experiment were conducted, protein 
concentrations were too low to detect SMAD2/3 phosphorylation. 
 Together, the data from multiple fibroblast models, suggest that PKN2 is dispensable for 
canonical SMAD2/3 signalling downstream of acute TGFβ1 stimulation. 
 
Figure 19. Assessing SMAD2/3 phosphorylation in CAFs after acute stimulation of CAFs with 
TGFβ1 
Wild-type (wt) or CAFs transfected with control siRNA (siLuc) or PKN2-targeting siRNA (siPKN2) 
were seeded and starved in reduced serum media overnight. The following day, the CAFs were 
stimulated with 5ng/ml TGFβ1 or vehicle for 30 minutes. Levels of phosho-PKN1 and phospho-PKN2 
(pPKN1/2), phospho-SMAD2/3 (pSMAD2/3) and protein load control GAPDH was assessed by 
western blotting (i). Bands were quantified by densitometry using Image J tool to reveal changes in 
SMAD2/3 phosphorylation (ii). Data represents one biological experiment carried. 
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3.2.3 Expression of PKN2 surrogate markers in breast cancer and their prognostic 
relevance 
We next wished to assess whether the role of PKN2 in fibroblast activation has prognostic 
relevance in breast cancer. The expression of PKN2 may not itself be a useful biomarker 
for stromal activation, as it is known to be ubiquitously expressed in normal tissue and 
previous gene expression analysis showed no difference in PKN2 expression between 
normal tissue and breast tumours or between different breast cancer types (Section 
3.1.1). Similarly, assessment of PKN2 protein expression across a panel of fibroblast 
lysates from breast cancer patients (provided by Iain Goulding, Breast Cancer Now Tissue 
Bank) showed no difference in PKN2 expression between matched protein lysates of 
normal and cancer-associated fibroblasts (Fig.20).  
 
Table 9. Details of patients from which CAFs were obtained 
Tissue type refers to whether the fibroblasts were obtained from normal surrounding tissue (S) or 
from the tumour (T). Patients had either invasive ductal carcinoma (IDC) or invasive lobular 
carcinoma (ILC). 
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Figure 20. Protein expression of PKN2 in CAFs and normal fibroblasts from breast cancer patients 
A. Western Blot showing level of PKN2, α-SMA and GAPDH protein levels. B. Densitometry of PKN2 
bands, normalised against the loading control GAPDH to quantify the relative PKN2 expression 
between different patients from normal surrounding and tumour-associated fibroblasts. 
 
Analysis of α-SMA fibres in several fibroblasts has shown reduced α-SMA fibres upon PKN2 
depleted/deletion, when activated by TGFβ. However, expression of α-SMA was not 
detectable from the protein lysates of fibroblasts from some patients in the panel. 
Expression of α-SMA was detectable in fibroblasts from three of the patients, which 
showed different patterns between normal and cancer-associated fibroblasts. In patient 
1902 and 1997, expression of α-SMA was in fact higher in fibroblasts from normal 
surrounding tissue compared to fibroblasts from tumour. Increased expression of α-SMA 
in tumour-associated fibroblasts, compared to normal fibroblasts, was shown by patient 
1939. Significantly, high -SMA did not correlate with enhanced PKN2 expression (Fig. 20). 
Overall, a-SMA expression appears to be variable between individual patient samples, and 
further, in cell lines, a-SMA was not enriched in tumour stroma, compared to surrounding 
stroma in individual cases. Together, this analysis indicates that PKN2 expression may not 
be a differential factor between normal and tumour-associated stroma.  
 
Work on MEFs and pancreatic fibroblasts has shown similar protein expression of α-SMA 
in untreated and TGFβ-treated fibroblasts, despite increased α-SMA fibres in the TGFβ-
treated fibroblasts, visible by immunostaining. This suggests that the amount of α-SMA 
may be similar between non-activated and activated fibroblasts in these models, but the 
amount of α-SMA that polymerise to form fibres changes. Hence, although PKN2 deletion 
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is associated with low α-SMA fibres, the expression levels of α-SMA may not be sufficient 
to differentiate normal and activated stroma. 
 
While PKN2 expression alone does not correlate with myofibroblast phenotypes from 
patients, loss of PKN2 does result in a blockade in fibroblast activation in our experimental 
models. We therefore sought to develop a surrogate panel of markers to assess the 
potential effects of PKN2 suppression on the activation state of stromal fibroblasts. 
Examining how this surrogate panel relates to prognosis in breast cancer might then give 
some indication about the potential value of targeting PKN2. 
3.2.3.1 Selecting surrogate markers of PKN2-related fibroblast activation 
In collaboration with Ivan Quétier and Claus Jorgenson, changes in gene expression 
between non-activated and activated wild-type and PKN2-ko MEFs was analysed. From 
this, genes downregulated in stimulated PKN2 ko MEFs were selected as surrogate 
markers for the effect of PKN2 loss in suppressing stromal activation. MEFs were seeded 
on collagen gels for 3D culture and stimulated with TGFβ1 or BMP4 (another ligand of 
TGFβ receptors upstream of SMAD signalling) for 24, 48 and 72 h. At the end of 
stimulation, MEF RNA was extracted from the collagen gels using TRIzol and cDNA was 
generated using TaqMan (Applied Biosystems) reverse transcription. Expression levels of 
stromal genes was assessed using a custom Fluidigm expression assay panel in 
collaboration with Claus Jorgensen (Manchester CRUK). 
From this data, 12 genes that showed reduced mRNA expression in PKN2 ko MEFs compared 
to wt MEFs, upon TGFβ1 or BMP4 stimulation, were selected as surrogate markers for PKN2 
suppression and hence low activation status (Fig. 21, see appendix Fig.1, 2, 3 for excluded 
genes).  These genes have various functions that have implications on cell survival, 
differentiation and interaction with ECM and are therefore relevant in cancer (Table 9).   
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The panel of genes was analysed for their relevance in breast cancer survival of patients. A 
similar study was conducted in breast cancer, using IGF-1 induced genes in primary breast 
fibroblasts, as the signature (Rajski et al. 2010). This IGF-1 study revealed increased 
likelihood of metastasis and low overall survival in patients at the early and advanced stage 
of breast cancer with high IGF-1 expression profile genes. Another study in pancreatic ductal 
adenocarcinoma (PDAC) generated two stromal signatures that distinguish between normal 
and activated stroma (Moffitt et al. 2015). The gene signature identified in this study for 
activated stroma also includes THBS2, COL1A1, FAP, CDH11, ITGA11 and POSTN in common 
with our signature. 
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Figure 21. Changes in gene transcript levels upon stimulation in MEFs 
Fold change represented is relative to wt MEFs treated with vehicle. CTGF and THBS2 showed 
significant reduction between wt and ko MEFs upon TGFβ stimulation (B, L). BAMBI, GLI1, IGF1, 
IGF2, OGN and POSTN were significantly downregulated in ko MEFs, compared to wt MEFs, when 
stimulated with BMP4 (A, C, G, H, J, K). CDH11 was downregulated in ko MEFs at 24h and 72h, 
compared to wt MEFs, when stimulated with BMP4 (Di, iii). At 24h, COL1A1 was downregulated in 
ko MEFs in response to BMP4 stimulation (Ei). At 48h and 72h, COL1A1 was reduced in ko MEFs in 
response to both TGFβ and BMP4 (Eii, iii). Gene expression of ITGA11 was reduced in ko MEFs 
consistently at 24, 48 and 72h in response to BMP4 (Fi, ii, iii). Although some of these markers did 
not reach statistical significance at specific timepoints, they were included as changes were 
consistent across the timecourse. Data represents the mean +/- SD for n=3 biological repeats. 
Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), 
P<0.01 (**), P<0.001 (***). 
104 
 
 
Table 10. Functions of chosen surrogate markers of PKN2 
Gene Functions 
Osteoglycin (OGN) Expressed in normal breast connective tissue, compared 
to tumour stroma. (Bozoky et al. 2014); (Hu et al. 2018) 
Insulin like growth factor 1, 
2 (IGF1/2) 
Produced by stromal cells in connective tissues of 
mammary gland. Switch from IGF1 to IGF2 synthesis 
seen in stromal cells of malignant mammary glands. 
Potential prognostic stromal marker in breast and lung 
cancer. (Marshman and Streuli 2002); (Yee et al. 1989); 
(Rajski et al. 2010) 
GLI Family Zinc Finger 1 
(GLI1) 
Stem cell proliferation (Merchant et al. 2010). Stromal 
expression a prognostic predictor in breast cancer 
(O'Toole et al. 2011). 
Cadherin 11 (CDH11) Expressed in mesenchyme and epithelial cells that have 
undergone EMT. Mediates cancer invasion and 
metastasis (Tamura et al. 2008); (Huang et al. 2010) 
Thrombospondin 2 
(THBS2) 
Cell-to-cell and cell-to-matrix interactions; anti-
tumorigenic and anti-angiogenic (Lopes et al. 2003); 
(Good et al. 1990); (Streit et al. 2002) 
Periostin (POSTN) Tissue development, wound healing, epithelial cell 
adhesion and migration; cancer stem cell maintenance 
and metastasis. (Hamilton 2008); (Lambert et al. 2016) 
Collagen, Type I, Alpha 1 
(COL1A1) 
Secreted factor in ECM. Induces EMT in hepatoma cells 
(Yang et al. 2014).  
Integrin Subunit Alpha 11 
(ITGA11) 
Induces myofibroblast activation and differentiation, 
regulated by hedgehog signalling pathway. Highly 
expressed in fibrotic diseases. (Bansal et al. 2017)  
Connective Tissue Growth 
Factor (CTGF) 
Abundantly expressed in CAFs, therapeutic monoclonal 
antibodies developed (Xing, Saidou, and Watabe 2010). 
Secreted factor in TME that aids tumour infiltration 
(Emon et al. 2018). 
BMP and activin 
membrane bound inhibitor 
(BAMBI) 
Antagonizes TGF-β1 signalling (Onichtchouk et al. 1999). 
Effect on cancer progression differs according to cancer 
type (Tang et al. 2018). 
Fibroblast activation 
protein (FAP) 
Cell surface protein expressed specifically on activated 
fibroblasts. (Garin-Chesa, Old, and Rettig 1990) 
 
3.2.3.2 Bioinformatic analysis to understand clinical relevance of PKN2 surrogate markers 
Understanding expression patterns and correlations between the surrogate markers of 
PKN2 using stromal dataset from breast cancer patients. 
Targeting PKN2 genetically in fibroblasts allowed us to define a panel of markers 
associated with PKN2 status in activated fibroblasts. We hypothesised that targeting PKN2 
is likely to supress this signature and sought here to explore whether such an altered 
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signature might be desirable in a prognostic, or even therapeutic, setting; should low 
expression of these markers be associated with better disease outcome it would support 
efforts to target PKN2 as a potential therapy.  Commonly, whole tumour samples are used 
to analyse gene expression for prognostic indications. This comprises both tumour cells 
and many other cell types found in the surrounding stroma. It is now known that the 
stroma in breast cancer impacts tumour progression and outcome (Finak et al. 2008); 
(Cleator et al. 2006); (Farmer et al. 2009).  Therefore, the relevance of our surrogate PKN2 
gene signature specifically in breast tumour stroma was investigated for any prognostic 
value. 
Firstly, we examined the stromal gene expression dataset from breast cancer patients 
from Finak et al (Finak et al. 2008). Stromal tissue from patients with breast cancer with 
matched normal surrounding stroma was dissected using laser capture microscopy. The 
expression of the 12 genes in our stromal signature, in addition to PKN2, was compared 
between tumour-associated stroma and normal stroma. Expression of PKN2 and THBS2 
did not differ between normal and tumour-associated stroma. All other genes, apart from 
CTGF and BAMBI, were expressed at much higher levels in tumour-associated stroma, 
compared to normal stroma (Fig.24). In contrast, BAMBI and CTGF are expressed at much 
lower levels in tumour stroma compared to normal stroma. The low expression of BAMBI, 
in comparison to the other genes that are activated upon TGFβ, could be explained by its 
inhibitory action on TGFβ signalling (Onichtchouk et al. 1999). The differential expression 
of the genes in the signature between normal and tumour-associated stroma indicates 
that the chosen genes are generally selective for activated tumour-associated stroma.  
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Figure 22. Expression of PKN2 surrogate markers in normal tissue and tumour stroma 
Comparison of average gene expression between normal (blue bars) and matched tumour-
associated stroma (red bars), using data from Finak et al (Finak et al. 2008). For expression 
statistics, GraphPad Prism’s multiple t-test tool was used with false discovery rate (FDR) set at 1%. 
Significantly different expression between normal and tumour-associated stromal expression is 
indicated by * above the bar for tumour-associated stroma (red) in the compared pair P<0.05 (*). 
 
Before investigating the prognostic relevance of our stromal gene signature in breast 
cancer, Pearson Product Moment Correlation Coefficient (PMCC) was applied to the Finak 
et al data to define the relationship between the genes in our signature. 
In agreement with the average expression analysis, genes (except CTFG and BAMBI) in our 
signature mostly show positive correlation with each other in tumour-associated stroma, 
(Fig. 24A).  In addition to CTGF and BAMBI, POSTN and THBS2 are negatively correlated 
with other genes in the signature in the stroma of normal tissue (Fig. 24B).  However, the 
darker shades of red on the correlogram represent stronger correlation (higher correlation 
co-efficient) between the genes that are positively correlated in normal stroma. This could 
indicate reduced heterogeneity in normal stroma compared to tumour-associated stroma, 
where more genes are positively but weakly correlated. PKN2 expression, however, shows 
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little correlation with the signature, perhaps in line with our observation that PKN2 
expression is not different between normal fibroblasts and CAFs. 
 
Figure 23. Correlogram demonstrating correlation between genes in the stromal signature 
A. Normal stroma and B. Tumour-associated stromal gene expression correlogram. Key represents 
colour-coding according to the value of Pearson’s correlation co-efficient. Data obtained from Finak 
et al (Finak et al. 2008).  
 
The presence of stroma/desmoplasia in TNBC has been linked to bad prognosis in several 
studies (Moorman et al, 2012; de Kruijf et al, 2011). Interestingly, in luminal tumours, 
increased stromal content can predict better outcome (Downey et al. 2014) indicating that 
the stromal response can have both positive and negative prognostic value depending on 
disease type. The expression of our stromal markers in the stromal dataset from Finak et 
al was compared between TNBC and non-TNBC breast cancer stroma. More genes showed 
anti-correlation in the stroma of TNBC patients whilst more genes are positively correlated 
in the stroma of non-TNBC patients (Fig.24). This could be due to the known heterogeneity 
of TNBC. The anti-correlation in TNBC might suggest that expression of stroma in these 
patients does not follow the pattern of a PKN2 signature stroma. However, the major 
limitation of the dataset for TNBC cases is the low numbers (n=14).   
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Figure 24. Correlation of PKN2 surrogate marker expression in TNBC and non-TNBC 
Correlogram depicting association of genes in the signature in patients with A. TNBC and B. non-
TNBC tumours. Data obtained from Finak et al (Finak et al. 2008). 
 
Finak et al compared the gene expression profiles of tumour stroma with patient-matched 
normal tissue and identified a set of genes that were differentially expressed between the 
two types of tissue. Of these genes, 200 genes with the greatest difference in expression 
between normal and tumour stroma were used to perform cluster analysis. This resulted in 
three clusters, whose characteristics were related to disease outcome: good, poor and 
mixed outcomes (cluster 1, 2 and 3 respectively. The relevance of surrogate PKN2 marker 
expressions in patients in the three different clusters were investigated, alongside a 
comparison with the actual outcome data. 
Comparing the stromal expression of genes in the signature between the different actual 
outcomes of patients showed significantly reduced expression of IGF1 and OGN in patients 
with poor outcome (Fig. 25A). These patterns of gene were also observed when considering 
the predicted outcome clustering by Finak et al (Fig. 25B), with the addition of reduced Gli1 
expression in the poor outcome cluster. Interestingly, correlation analysis of the surrogate 
PKN2 marker genes in patients with predicted poor outcome compared with predicted good 
outcome shows significant differences regarding both CTGF and BAMBI; while BAMBI and 
CTGF anti-correlate with the signature in the good outcome cluster, BAMBI is positively 
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correlated, and CTGF show no correlation in the bad outcome cluster (Fig. 26). This indicates 
that the positive association of BAMBI with other genes in the stromal signature is linked to 
poor outcome. This suggests that the expression status of BAMBI relative to the other genes 
in the PKN2 signature may have clinical importance.  
 
Figure 25. Gene expression in stroma of patients of different outcomes.  
Comparison of stromal marker gene expression between patients according to A. actual outcome 
and B. Finak outcome cluster. Data obtained from Finak et al (Finak et al. 2008).  For expression 
statistics, GraphPad Prism’s multiple t-test tool was used with false discovery rate (FDR) set at 1%. 
Significantly different expression between good and poor outcome is indicate by *. 
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Figure 26. Correlation of PKN2 surrogate markers by predicted outcome 
Correlogram depicted Pearson's correlation between genes in stromal signature. A. Patients with 
predicted good outcome and B. predicted poor outcome. Data obtained from Finak et al (Finak et 
al. 2008). 
 
Expression profile heatmap and clustering of PKN2 surrogate markers from stromal 
samples of breast cancer patients 
To look at the PKN2 signature genes in an unbiased way we next carry out hierarchical 
clustering of the Finak patient stromal samples according to their expression patterns of 
the 12 surrogate PKN2 genes and PKN2 (in collaboration with Professor Claude Chelala, 
analysis carried out by Dr Emanuela Gadaleta). This generated two clusters (here termed 
Cluster A and Cluster B), one of which (Cluster A) included all the patients with actual poor 
outcome (Fig. 27); this is a statistically significant enrichment (2-test -test; p=0.0003).  
Cluster A was moderately, but not significantly enriched for HER2-positive patients (2-
test; p= 0.19) and - unsurprisingly given the outcome data - significantly enriched for grade 
3 tumours (2-test -test; p=0.018). There was significant overlap with the poor outcome 
predicted by the clustering analysis generated by Finak et al, but importantly, our 
signature was significantly better at clustering the poor outcome patients from the 
stromal data set than the Finak panel.  
We next compared the expression of the different signature genes to identify specific 
pattern changes. The poor outcome group was characterised by low expression of OGN 
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and IG1 and high expression of BAMBI (Fig. 28). Interestingly, these marker expression 
differences were not observed in the clustering conducted by Finak et al. This shows our 
clustering to be a powerful way of defining important prognostic differences in this 
dataset. 
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Figure 27. Expression heat map and clustering analysis of PKN2 surrogate markers in stromal 
dataset from Finak et al.  
Hierarchical clustering of Finak patient stromal samples according to their expression patterns of 
the 12 surrogate PKN2 genes and PKN2. Patients, with the exception of a single outlier (E1527 – 
left most patient), cluster into two groups (A and B). Cluster B contains all patients with actual 
poor outcome. Abbreviations: recur (recurrence); LN (Lymph Node Spread). C1, C2 and C3 refer 
to clusters defined in Finak et al (Finak et al. 2008): C1(good); C2 (mixed); C3 (poor). G1, G2 and 
G3 refer to tumour grade. 
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Figure 28. Comparison of protein expression between good and poor outcome. 
This analysis revealed differences in OGN IGF1 and BAMBI. Expression of OGN and IGF1 is lower in 
patients with poor outcome. High expression of BAMBI is associated with poor outcome. Data 
obtained from Finak et al (Finak et al. 2008). GraphPad Prism’s multiple t-test tool was used with 
false discovery rate (FDR) set at 5%. N=30 (good outcome), N=22 (poor outcome). 
 
Survival analysis of OGF, IGF and BAMBI expression in the stroma of breast cancer patients 
Together these data suggest that supressing OGN and IGF1 expression – potentially by 
targeting PKN2 - may be undesirable in breast cancer. The prognostic relevance (relapse-
free survival - RFS) of these genes, as well as BAMBI - which was highly expressed in 
patients with poor outcome, was tested in whole tumour datasets using the online Km 
plot tool (Györffy et al. 2010).  
Low expression of OGN was associated with reduced RFS when considering all breast 
cancer data, as well as in basal and luminal A intrinsic subtypes (Fig. 29). There were no 
significant changes in RFS between TNBC patients with low and high expression of OGN, 
which was also observed in the different TNBC pietenpol classifications. These 
observations therefore corroborate with the finding of reduced expression of OGN in 
tumour stroma being clustered with patients with poor outcome. 
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Figure 29. Effect of OGN expression on RFS 
Figures show probability of relapse free survival (RFS) in patients with A. all, B. basal and C. luminal 
A subtype of breast cancer with low and high expression of OGN. Plots were generated using an 
online tool (Györffy et al. 2010). High and low expression threshold was selected at best cut-off for 
best performing threshold. Number of patients shown below plots. 
 
IGF-1 expression is able to stratify patients into prognostic risk groups across multiple 
breast cancer groups (All, TN, Basal, Basal-like2 and Mesenchymal; Fig. 30). Considering all 
breast cancer data there is a slightly reduced RFS in patients with low IGF-1 expression up 
to 200 months, after which this differential is lost (Fig. 30A, p<0.001 HR 0.7). There is a 
clearer reduction in RFS in patients with basal subtype of breast cancer and low IGF-1 
expression (Fig. 30C). Considering TNBC, overall patients with ER-, PR- and HER2-negative 
breast cancer and low IGF-1 expression had significantly reduced RFS (Fig. 30B), which was 
also seen when considering basal-like 2 and mesenchymal subtypes of TNBC (Fig. 30D and 
E). The negative effect of low IGF-1 expression on outcome seem to have more relevance 
in TNBC patients. Together, this analysis again correlates well with our clustering analysis 
of the Finak dataset on patient outcome. 
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Figure 30. Effect of IGF-1 expression on breast cancer RFS 
Figures show probability of relapse free survival (RFS) in patients with A. all, B. ER, PR and HER2 
negative C. basal D. basal-like 2 TNBC and E. mesenchymal TNBC subtypes of breast cancer with 
low and high expression of IGF-1. Plots were generated using an online tool (Györffy et al. 2010). 
High and low expression threshold was selected at best cut-off for best performing threshold. 
Number of patients shown below plots. 
 
Patients expressing high levels of BAMBI had reduced RFS, when considering all breast 
cancer patients (Fig. 31A).  High expression of BAMBI is associated with improved RFS in 
the Her2+, Basal and the Basal-like 1 breast cancer (Fig. 31B, C and D). These observations 
support the finding from the stromal expression and clustering analysis. In contrast, in 
mesenchymal subtype of TNBC, high expression of BAMBI is related to increased RFS (Fig. 
31E). 
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Figure 31. Effect of BAMBI expression on RFS 
Figures show probability of relapse free survival (RFS) in patients with A. all, B.  HER2-negative C. 
basal D. basal-like 1 TNBC and E. mesenchymal TNBC subtypes of breast cancer with low and high 
expression of BAMBI. Plots were generated using an online tool (Györffy et al. 2010). High and low 
expression threshold was selected at best cut-off for best performing threshold. Number of 
patients shown below plots. 
 
In summary, clustering of stromal expression of PKN2 surrogate markers, which resulted 
in a cluster related to good outcome and another into poor outcome, suggests a potential 
importance of these genes in predicting outcome.  In particular, OGN, IGF1 and BAMBI 
were differentially expressed between patients with poor and good outcome. Stromal 
OGN and IGF1 expression was lower in patients with poor outcome. This was reflected in 
reduced RFS when considering who breast tumour datasets, when comparing patients 
with low and high expression of OGN and IGF1. Expression of stromal BAMBI was higher in 
patients with poor outcome. This observation was reflected in RFS when considering 
whole tumour datasets of most breast cancer types in general. Thus, modulating OGN and 
IGF1 to induce expression and modulating BAMBI to suppress expression may be 
beneficial in breast cancer. 
117 
 
Expression analysis of PKN2 stromal markers in whole tumour TCGA dataset 
A limitation of using the stromal dataset from Finak et al is the low number of samples. To 
address this issue and to widen the investigation of PKN2’s relevance in breast cancer 
survival, whole tumour samples were also clustered using our surrogate signature. We 
acknowledge that this may be severely affected by the complex mix of cell types in these 
samples.  We started with the TCGA dataset and studied the expression levels across 
different breast cancer types (in collaboration with Professor Clause Chelala, analysis 
carried out by Dr Emanuela Gadaleta and Dr Ai Nagano). The heat map indicates a weak 
association between basal breast cancer and low expression of the genes in the stromal 
signature (Figure 32A). Interestingly, amongst the different TNBC subtypes, BL2 and MSL 
tumours were associated with high expression of the surrogate markers (Figure 31B). This 
set of genes were also analysed for the effect on survival. There were no significant 
differences in breast cancer survival between patients expressing high or low levels of the 
PKN2 surrogate markers (Figure 33). 
 
Figure 32. Hierarchical clustering of PKN2 surrogate markers’ expression in whole breast tumour 
dataset. 
Expression heat map of the 12 PKN2 surrogate markers and PKN2 analysed from whole tumour 
TCGA dataset in patients with A. basal, HER2, luminal A, luminal B breast cancer and normal tissue. 
B. The expressions of the surrogate markers were also analysed in patients with TNBC grouped by 
the difference TNBC subtypes. 
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Figure 33. Survival analysis of breast cancer based on PKN2 surrogate marker expression 
Based on low and high expression of PKN2 surrogate markers in A. basal, B. Her2, C. luminal A and 
D. luminal B breast cancers. Patients were assigned to risk groups based on the median 
dichotomisation of mRNA expression intensities. Number of patients shown below plots. 
 
Thus, data from analysing the expression of surrogate PKN2 markers in whole tumour 
datasets, suggests enrichment in mesenchymal/basal-like subtypes of TNBC, that may be 
reflective of increased stromal activation in these subtypes. Survival analysis of this 
dataset showed no implication of global expressions of these surrogate markers on RFS. 
However, these surrogate markers are specific for stromal expression and therefore any 
potential effects on outcome may be diluted by other cancer cell types in whole tumour 
datasets.  
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3.2.4 Summary 
The induction of α-SMA fibres upon long-term TGFβ1 stimulation in fibroblasts, a marker of 
activation, was assessed and compared between wt and PKN2 deleted or depleted 
fibroblasts. PKN2 loss in MEFs reduced the induction of α-SMA-expressing cells upon TGFβ1 
treatment. There was also a reduction in the induction of α-SMA-expressing cells in PKN2-
depleted CAFs upon TGFβ1 treatment. This indicates a role of PKN2 in fibroblast activation, 
which has an impact on several aspects of tumour biology including proliferation, invasion 
and progression. 
Similar experiments in mouse pancreatic stellate cells (pancreatic fibroblasts), by Elizabeth 
Murray in our lab, showed reduced α-SMA fibres in PKN2 deleted cells (KO) upon TGFβ1 
stimulation, compared to unstimulated and stimulated wt cells (figure 34). Furthermore, an 
RNAi screen by our collaborator (Claus Jorgensen, CRUK Manchester) identified PKN2 as a 
top hit kinase for TGFβ1-mediated activation of pancreatic fibroblasts. Together these data 
appear to indicate a conserved role for PKN2 in the activation of fibroblasts from multiple 
tissues, including the breast, pancreas and during embryo development. 
We next sought to understand the mechanism that underlies the function of PKN2 in 
fibroblast activation. As a starting point, we examined acute signalling pathway 
downstream of TGFβ1 stimulation in several modes. Overall, MEFs, HMU19 fibroblasts and 
CAFs retained their canonical SMAD signalling in response to acute TGFβ1 stimulation. The 
phosphorylation of SMAD2 and SMAD3 was induced, in response to acute TGFβ1 treatment 
in these fibroblasts, regardless of their PKN2 expression levels. This implies that the defect 
in TGFβ1 responsiveness does not result from loss of TGFβ1 receptors or their proximal 
coupling to canonical signalling cascades. 
120 
 
 
Figure 34. SMA fibre quantification in mouse pancreatic stellate cells. 
Pancreatic stellate cells, wild-type (wt) or with PKN2 knockout (ko) were treated with TGFβ or 
untreated (CTRL) for 72h. Cells were fixed and stained for αSMA and quantified. Experiment and 
quantification done by Elizabeth Murray in collaboration with Nuria Gavaria. The values normalized 
to wt CTRL cells are shown for three biological cells carried out in duplicate coverslips. Data 
represents the mean +/- SD. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
Although acute TGFβ1 was unaffected by PKN2 loss, other related signalling pathways may 
be affected. Quantitative mass spectrometry (MS) analysis and KSEA of serum-induced 
activation of MEFs revealed differences between wt and PKN2 ko MEFs in phosphorylation 
of proteins that have been associated downstream of TGFβ1 (Quétier et al. 2016). This 
includes downregulation of p70S6K (Fig. 35A) and upregulation of YAP (Fig. 35B). Therefore, 
the phosphorylation of these proteins can be assessed in response to TGFβ1 upon PKN2 
loss.  
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Figure 35. Quantitative mass spectrometry (MS) analysis and kinase substrate enrichment 
analysis (KSEA) following activated wt (Veh) and PKN2 ko (4-OHT) MEFs in response to  serum. 
This experiment investigated the effect of PKN2 expression in stimulating MEFs. A, B (i) MEFs were 
serum starved (0.5% FBS) and re-stimulated (10% FBS) for 15 minutes prior to LC-MS/MS analysis (n 
= 4). m is the number of kinase substrate peptides quantified, relative to control extracts. (Quétier 
et al. 2016) . A(ii) Phosphorylation level of p70 S6K, relative to total protein in non-stimulated 
(white bars) and serum-stimulated (grey bars) wt (Veh) and PKN2-deleted (4-OHT) MEFs, 
determined by western blot (n=3) and quantified using densitometry. 
 
Subsequently, the ability of PKN2-deleted MEFs to mediate translocation of the SMAD2/3/4 
complex to the nucleus can be assessed. Furthermore, SMAD reporter cell lines have been 
generated in the lab to investigate the potential of transcriptional regulation and activation 
by the SMAD2/3/4 complex, in PKN2-deleted MEFs.  
These studies suggest a role for PKN2 in fibroblast activation. Next, we wanted to see 
whether PKN2 in the stroma has any effect on breast cancer survival. PKN2 deletion was 
associated with reduced fibroblast activation, when assessing αSMA fibres in our fibroblast 
models. As PKN2 cannot solely be responsible in modulating stromal phenotypes, a panel 
of surrogate markers that accompany the phenotype of reduced stromal activation state 
upon PKN2 deletion was chosen. These genes were investigated for expression profiles and 
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prognostic relevance in breast cancer, considering both whole tumour datasets and stromal 
datasets only.  
Expression of the surrogate markers of PKN2 were differentially expressed in normal and 
tumour stroma. Clustering analysis of the stromal dataset from Finak et al, based on the 12 
surrogate PKN2 markers revealed two clusters, one of which (Cluster B) contained all the 
patients with actual poor outcome. This new cluster was also enriched for patients with 
predicted poor outcome, according to the gene signature used by Finak et al. Of the 13 
genes, the expression of OGN, IGF-1 and BAMBI were differentially expressed between 
these two newly defined good and bad outcome clusters (Fig. 28) 
The effect of OGN, IGF-1 and BAMBI expressions individually followed similar pattern that 
was observed with the clustering analysis, based on the predictive outcome clustered by 
Finak et al. This indicates that modulating the expression of these genes may have potential 
as therapeutic targets in breast cancer stroma. 
Overall, data in this chapter support the fact that PKN2 suppression reduces fibroblast 
activation. The prognostic relevance of this phenotype was investigated by examining the 
expression of PKN2 and a panel of surrogate markers associated with reduced fibroblast 
activation upon PKN2 loss, in stromal and whole tumour breast cancer datasets. In the 
stroma, clustering identified two groups, defined by good and bad outcome - with 
differential expression of OGN, IGF and BAMBI between the two groups. In the stroma, 
low expression of OGN and IGF1, along with high expression of BAMBI, was associated 
with poor outcome. These observations were corroborated in survival analysis (RFS) of 
whole tumour datasets, in breast cancer overall. Thus, supressing PKN2 may normalise 
stroma to improve breast cancer survival, however the suppression of OGN and IGF1 may 
not be beneficial. 
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3.3 Exploring a role for PKN2 in stromal fibroblast regulation of breast cancer 
cell phenotypes 
 
Studies in our laboratory on the role of PKN2 in embryogenesis suggest a role in the 
regulation of EMT and mesenchymal cell growth and contractility (Quétier et al. 2016). 
These roles appear to be conserved in various fibroblast lines and in mesenchymal TNBC 
cell lines. This prompted us to broaden our studies to examine the role of PKN2 in breast 
cancer stromal fibroblasts (CAFs) and to ask whether modulating PKN2 might alter 
interactions with breast cancer cells. CAFs play an important role in supporting breast 
cancer growth and invasion and have also been shown to affect chemotherapeutic drug 
sensitivity ((Cohen et al. 2017), (Orimo and Weinberg 2006), (Tao et al. 2017)). In a related 
project on pancreatic cancer, deletion of PKN2 from pancreatic fibroblasts (pancreatic 
stellate cells), reduced their ability to support pancreatic cancer cell invasion in 3D 
collagen-matrigel gels. Here we sought to see if similar mechanisms might occur in breast 
cancer.  
 
3.3.1 Does PKN2 modulate fibroblasts to support breast cancer cell growth, 
migration and invasion in 3D cultures? 
 
To mimic the physiological environment and interactions between different cell types, we 
co-cultured breast cancer cells lines with fibroblasts in 3D mini-organotypic assays. The 
effect of PKN2 depletion in fibroblasts on the interaction with breast cancer cells was 
initially studied using MEFs obtained from our inducible PKN2 conditional knockout mice 
(Rosa26 Cre ERT2 PKN2flox). As described in section 2.5 and 3.1.1.3. these cells allow us to 
delete PKN2 expression completely and thus provide useful surrogate to explore effect of 
stromal PKN2 loss.  
Untreated MEFs (wt MEFs) or MEFs induced for PKN2 deletion (PKN2 ko MEFs) were co-
seeded with mouse breast cancer cell lines to study their interaction in mini-organotypic 
gels. At endpoint, the gels are fixed, paraffinized, sectioned and stained with H&E to 
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visualise the cells. H&E images can be used for quantification, by converting the H&E 
stained areas to black pixels. The quantification of the area occupied by black pixels 
therefore gives an unbiased indication of the area occupied by cells within the gel. In 
addition, the invading cells can be quantified individually to give invasive cell counts. Here, 
I will describe the interaction between MEFs and four different mouse cancer models: 
4T1, mBBC#4 (BlgCre p53fl/fl Brca1fl/fl basal model), E0771 and PyMT.BO1 (MMTV-PyMT 
derived). 
3.3.1.1 Effect of PKN2 expression in MEFs on 4T1 breast cancer cells in 3D mini-organotypic 
co-culture assays 
 
4T1 breast cancer cell lines were originally derived from a spontaneous breast cancer 
model in BALB/cfC3H mice (Dexter et al. 1978). These cells are well known to metastasise 
to the liver, bone and lungs and are therefore used to study metastatic breast cancer 
progression (Heppner, Miller, and Shekhar 2000). 4T1 cells are considered as TNBC, 
express the epithelial markers E-cadherin and ZO-1 but also exhibit some mesenchymal 
cell characteristics, such as high invasive potential (Ferrari-Amorotti et al. 2014).  
 
4T1 cells were cultured alone or co-cultured with wt or PKN2 ko MEFs, for four days in 
collagen-matrigel gels. H&E stains reveal that interaction between 4T1 and MEFs is 
required for efficient cell invasion (Fig.36 Aii, iii), whereas no cells have invaded the gel 
when 4T1 cell were seeded alone (Fig. 36Ai). This is supported by the cell counts of 
invading cells in each condition (Fig. 36B ii). Furthermore, there is a significant decrease in 
invading cells when 4T1 cells are co-cultured in PKN2-deleted MEFs, compared to co-
culture in wt MEFs. This suggests that loss of PKN2 in MEFs affects cell invasion in this 
model.  
Gels were fixed, sectioned and stained (by Elizabeth Murray) with cytokeratin to identify 
the proportion of cancer cells in the co-culture conditions. Staining indicated that the 
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majority of cell are invading epithelial cancer cells (Fig. 36C). Positive identification of 
fibroblasts was more difficult as mesenchymal markers are also expressed by subsets of 
cancer cells; 4T1 cells have been shown to exhibit mesenchymal phenotypes and can 
undergo EMT. We were unfortunately unable to conclusively stain the co-cultured 
fibroblasts unambiguously. 
 
3.3.1.2 Effect of PKN2 expression in MEFs on mBCC#4 breast cancer cells in 3D mini-
organotypic co-culture assays  
 
Mouse breast cancer cell mBCC#4 (A kind gift from Prof. Matt Smalley, Cardiff University), 
originate from BlgCre p53fl/fl Brca1fl/fl mice described by Molyneux et al (Molyneux et al. 
2010). This model was developed to investigate whether the deletion of BRCA1 in the 
luminal mammary epithelium (where Blg promoter is most active) results in basal-like 
BRCA1 breast cancer (Molyneux et al. 2010). Tumours generated from Blg-Cre Brca1f/f 
p53-/+ mice are generally invasive ductal carcinomas of no special type, of histological 
grade 3. These tumours are positive for the K14, K14 and the basal marker p63. Thus, 
histologically and immunohistochemically, these tumours closely resemble basal-like 
BRCA1 tumours in humans.  
 
After 11 days of culture in organotypic gels, the addition of MEFs was once again found to 
enhance growth.  Further, there was a small decrease in cell pixel area when mBCC#4 cells 
were co-cultured with PKN2 ko MEFs, compared to wt MEFs (Fig. 37Bi). Further 
examination is required to identify whether this phenotype is due to the reduced survival 
of PKN2-deleted MEFs or due to reduced cancer cell survival. However, there were no 
changes in the number of invading cells between the different conditions (Fig. 37 Bii).  
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Figure 36. 4T1 & MEF 3D collagen-matrigel assay 
A. H&E images of collagen/Matrigel gels seeded with i) 4T1 cells alone or co-cultured with ii) wild-
type (wt) MEFs or iii) PKN2 ko MEFs. These images were converted to a binary image, to quantify 
Bi) total area occupied by black pixels (H&E stained area) and ii) number of invading cells using 
Image J software. Two to three replicate gels were seeded per condition, where two or three 
sections of gels (1cm in length) per replicate within a condition was quantified. C. IHC staining for 
pan-cytokeratin to identify 4T1 cancer cells (Elizabeth Murray). Scale bars represent 200 μm. Data 
represents the mean +/- SD for n=3 biological repeats carried out in triplicates. Statistical analysis 
was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), 
P<0.001 (***). 
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Figure 37. mBCC#4 & MEF 3D collagen-matrigel gels 
A. H&E images of collagen/Matrigel gels seeded with i) mBCC#4 cells alone or co-cultured with ii) 
wild-type (wt) MEFs or iii) PKN2 ko MEFs. These images were converted to a binary image, to quantify 
Bi) total area occupied by black pixels (H&E stained area) and ii) number of invading cells using Image 
J software. Three replicate gels were seeded per condition, where two or three sections of gels (1cm 
in length) per replicate within a condition was quantified. Data represents the mean +/- SD for n=3 
biological repeats carried out in triplicates. Statistical analysis was carried out using ANOVA followed 
by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
3.3.1.3 Effect of PKN2 expression in MEFs on E0771 breast cancer cells in 3D mini-
organotypic co-culture assays 
 
E0771 is a basal-like breast cancer cell line, derived from spontaneous mammary tumours 
in C57BL/6 mouse (Sugiura and Stock 1952). There were no differences in total cell pixels 
between co-cultures with wt MEFs and PKN2 ko MEFs (Fig. 38A and 38B), and growth of 
these cultures was not promoted significantly by the inclusion of MEFs. Further, under the 
tested conditions, cancer-fibroblasts interaction did not result in cell invasion. These cells 
did not penetrate and invade into the gels. This implies that the fibroblasts do not 
enhance growth or invasion of E0771 cells and that this interaction is also unaffected by 
loss of fibroblast PKN2 expression.  
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Figure 38. E077 & MEF 3D Collagen-matrigel assay.  
A. H&E images of collagen/Matrigel gels seeded with i) E0771 cells alone or co-cultured with ii) wild-type (wt) 
MEFs or iii) PKN2 ko MEFs. These images were converted to a binary image, to quantify B. total area occupied 
by black pixels (H&E stained area). Data represents the mean +/- SD for n=3 biological repeats carried out in 
triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), 
P<0.01 (**), P<0.001 (***). 
 
3.3.1.4 Effect of PKN2 expression in MEFs on PyMT-BO1 breast cancer cells in 3D mini-
organotypic co-culture assays. 
PyMT-BO1 cells are a subline derived from the MMTV-PyMT breast cancer model, isolated 
from bone metastases (Su et al. 2016) (see section 1.1.6.4). MMTV-PyMT is a genetic 
mouse model where tumour formation is induced by MMTV promoter driven expression 
of the Polyoma Middle T-antigen (PyMT) specifically in breast epithelial cells. These cells 
originate from C57BL/6 mice and thus were subsequently employed in in vivo tumour 
study in this project, where syngeneic C57BL/6 lines were required. Female mice form 
multifocal tumours in their mammary glands, which progress to metastatic disease (Guy, 
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Cardiff, and Muller 1992b). PyMT-BO1 cells are characterised as luminal-like breast cancer 
cells. 
Collagen-matrigel organotypic assays with these cells has shown large variation in 
behaviour. Overall, there no significant differences in total cell pixel area between wt 
MEFs and PKN2 ko MEFs (Fig. 39Bi). There were no differences upon PKN2 loss in MEFs in 
the number of invading cells into the gel (Fig. 39Bii).  
Although mini-organotypic assays provide a 3D physiological setting to study cancer cell 
and fibroblast interaction, this assay also has its limitations. This assay has a high degree 
of variability (as observed with the PyMT-BO1 cell line), quantitation is complex and the 
protocol requires adaption for different cell models. Additionally, the assay is costly in 
terms of both reagents and time. Furthermore, differentiating between distinct cell 
populations by requires staining for epithelial and mesenchymal marker that presented 
with technical challenges in some cases. For this reason, we sought to develop more easily 
quantifiable models for measuring the heterotypic interactions between cancer cells and 
fibroblasts. 
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Figure 39 PyMT-BO1 & MEF 3D collagen-matrigel assay 
A. H&E images of collagen/Matrigel gels seeded with i) PyMT-BO1 cells alone (MMTV) or co-
cultured with ii) wild-type (wt) MEFs or iii) PKN2 ko MEFs. These images were converted to a binary 
image, to quantify B. total area occupied by black pixels (H&E stained area). Data represents the 
mean +/- SD for n=3 biological repeats carried out in triplicates. Statistical analysis was carried out 
using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
3.3.2 Developing new in vitro models to explore cancer-fibroblast interaction 
Due to the limitations of mini-organotypic assay mentioned above, we sought to develop a 
higher throughput luminescent system to study the interaction between cancer cells and 
fibroblasts in 2D and 3D cultures.  To achieve this, a panel of cancer cell lines expressing 
firefly luciferase (FFL) reporter and fibroblast cell lines expressing Renilla luciferase (RL) 
reporter were generated. These cells were co-cultured, in 2D and 3D, and the cell viability 
of the cancer cells and fibroblasts was measured using a dual luciferase reporter system 
(Promega). Labelling the cancer and stromal components (fibroblasts) of these co-cultures 
allows the study of both compartments independently but simultaneously in co-culture.  
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Initial studies involved seeding firefly luciferase-expressing cancer cells with non-labelled 
MEFs from our inducible PKN2 conditional knockout mice. MEFs were untreated (wt MEFs) 
or pre-treated with 4-hydroxy tamoxifen (4-OHT) to induce PKN2 knockout (PKN2 ko MEFs) 
before co-culturing with labelled cancer cells. Cells were seeded on 96 well plates, as for 
standard 2D culture, or on top of small collagen and/or matrigel gels for 3D culturing. After 
72h, cell viability of the labelled cancer cells (in mono-culture or within co-cultures with 
MEFs) was measured using the single luciferase assay (Fig. 40).   
 
Figure 40. Schematic of single/dual luciferase assay protocol 
Cancer cells, labelled with firefly luciferase reporter are cultured alone or with unlabelled/renilla 
luciferase reported-labelled fibroblasts (with/without PKN2 deletion). The cells are cultured in 96-
well plates for 72hours, before lysing the cells to assay for the firefly luciferase activity 
(luminescence detected at 590nm. The viability of fibroblasts in co-culture with the cancer cell can 
be identified by adding a Stop & Glo substrate that quenched the firefly signal from cancer cells, 
allowing the activity of renilla luciferase to be detected by luminescence at 460nm.  
 
3.3.2.1 Luciferase reporter assay to assess effect of PKN2 expression in fibroblasts on cancer 
cell viability 
Two mouse breast cancer cell lines PyMT-BO1 and 4T1 were labelled with firefly luciferase 
reporter for the mouse co-culture models. Proliferation of PyMT-BO1 cells proved to benefit 
dramatically from the presence of either wt and PKN2 ko MEFs in 2D and 3D culture (Fig. 
41). Interestingly, Matrigel provided significant support to PyMT-BO1 cell proliferation in 
mono-culture, and consequently limited the growth enhancing effect of co-culture with 
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fibroblasts (Fig. 41B). This is likely to be explained by the presence of extracellular matrix 
proteins and growth factors within Matrigel (Vukicevic et al. 1992), which in co-culture are 
provided by fibroblasts. These observations correlated with the behaviour seen in the 
organotypic assays. 
 
Figure 41. Effect of PKN2 expression in MEFs on PyMT BO1 cancer cells using luciferase reporter 
assays 
PyMT-BO1 (MMTV) cells labelled with firefly luciferase (FFL) reporter were seeded Ai) under 
normal 2D conditions or ii) on top of gels for 3D conditions alone (black), co-cultured with wt MEFs 
(blue) or with ko MEFs (green). After three days, lysates were collected and assayed for the activity 
of the firefly luciferase reporter from the cancer cell using the Promega luciferase assay. Raw 
arbitrary values (RLU) are presented. Data represents the mean +/- SD for n=3 biological repeats 
carried out in triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni 
post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
In contrast, 4T1 cells showed no proliferative enhancement in the presence of MEFs and no 
difference with PKN2 ko MEFs (Fig. 42A, B). This result was surprising, as the increase in 
total cell number seen with mini-organotypic gels in the co-culture conditions was dramatic 
and significantly attenuated upon PKN2 loss in MEFs. The direct interaction of 4T1 cells with 
fibroblasts in mini-organotypics may result in pre-conditioning of MEFs by 4T1 cells, which 
are known to release TGF and other factors that activate fibroblasts (Nam et al. 2008). 
Therefore, we tested whether activating MEFs, prior to co-culture, might have a positive 
effect on 4T1 viability. MEFs were pre-activated with TGFβ1 for 72 hours before co-culturing 
with 4T1 cells for another 72h (Fig. 42C). However, activated MEFs also had no impact on 
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their interaction with 4T1 cells suggesting that the basal activation status of MEFs has no 
effect on 4T1 cell viability or proliferation. The effect of 4T1-MEF interaction on 4T1 survival 
was tested in 3D conditions. Cells were seeded on top of collagen (Fig. 42C), Matrigel (Fig. 
42D) or a mixture of these gels (as used in mini-organotypic assays – Fig. 42E). The survival 
of 4T1 cells were also not affected by the co-culture of fibroblasts or PKN2 expression in 
MEFs under these 3D conditions. Matrigel closely mimics the ECM and is supplemented with 
growth factors (Vukicevic et al. 1992). The absence of enhanced cancer cell survival in the 
presence of fibroblasts, when seeded in Matrigel, suggests that 4T1 are self-sufficient for 
their survival, perhaps via autocrine secretion of growth factors.  
 
 
Figure 42. Effect of PKN2 expression in MEFs on 4T1 cancer cells using luciferase reporter assays 
4T1 cells labelled with firefly luciferase (FFL) reporter were seeded A. under normal 2D conditions. 
B. wt and ko MEFs were pre-treated with 5ng/ml TGFβ1 for three days to activate them prior to 
seeding with 4T1 cells in 2D culture. The mono-culture of 4T1 and co-cultures with wt and ko MEFs 
were seeded on top of 40µl of C. collagen, D. matrigel and E. a mixture of collagen and matrigel as 
for mini-organotypic assays. After three days, lysates were collected and assayed for the activity of 
the firefly luciferase reporter from the cancer cell using the Promega luciferase assay. Data 
represents the mean +/- SD for n=3 biological repeats carried out in at least triplicates. Statistical 
analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), 
P<0.001 (***). 
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Subsequently, the viability of MEFs in these co-cultures was investigated. MEFs labelled 
with a renilla luciferase reporter were cultured alone or with firefly luciferase-labelled 4T1 
for 72 hours before measuring cell viability. A dual luciferase assay kit (Promega) was used 
to obtain the differential signals from the two cell populations in the co-culture. 
Interestingly, 4T1 cells enhanced the proliferation of both wt and PKN2 ko MEFs, (Fig. 43). 
The small increase in wt MEF proliferation in the presence of 4T1, compared to the larger 
increase in PKN2 ko MEFs, could be due to the previously described basal difference in 
MEF proliferation upon PKN2 loss (Quétier et al. 2016). As PKN2 ko MEFs proliferate 
slower at basal level, after conditioning by 4T1 cells, there perhaps remains more capacity 
for growth enhancement in these cells. Interestingly, it suggests that the previously 
identified growth defect in PKN2 ko MEFs may be reversed by paracrine signals from the 
4T1 cells. Identifying the growth enhancing factors is potentially an interesting future 
direction of research. 
 
Figure 43. Effect of PKN2 expression in MEFs on PyMT BO1 cancer cells and MEFs using dual 
luciferase reporter assays  
4T1 cells labelled with firefly luciferase reporter were seeded under normal 2D conditions alone 
(black), co-cultured with wt MEFs (blue) or with ko MEFs (green). wt MEFs (unfilled blue) and ko 
MEFs (unfilled green) were also seeded alone. After three days, lysates were collected and assayed 
for the activity of A. firefly luciferase (FFL) reporter from the cancer cell using the Promega dual 
luciferase assay and the activity of B. renilla luciferase (RL) reporter from the MEFs using the Stop & 
Glo reagent in the kit, which quenches the signal from the luciferase reporter at 590nm and gives a 
signal at 460nm. Data represents the mean +/- SD for n=3 biological repeats carried out in 
triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: 
P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
Having used our iPKN2 MEFs with mouse cancer cell lines as a tractable system for deleting 
PKN2 and optimising dual-luciferase assays, we next wished to translate findings to more 
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disease relevant human breast cancer models. We used human immortalised breast 
fibroblasts (HMFU19) and primary human CAFs, alongside MEFs to establish the role of 
PKN2 loss on the viability of human breast cancer cell lines. 
Two human breast cancer cell lines, MCF7 and MDAMB231 were labelled with firefly 
luciferase and co-seeded with wt or PKN2 ko MEFs initially. These cancer cell lines were 
chosen to represent two different breast cancer types, luminal and TNBC respectively, 
where previously TNBC cells have shown direct PKN2-dependency for survival.  
Viability of MCF7 was enhanced by the presence of both wt and ko MEFs (Fig.44 Ai). The 
viability of wt and PKN2 ko MEFs were unaffected when co-cultured with MCF7 (solid bars 
in Fig.44 Aii). As previously described, PKN2 ko MEFs have lower viability that wt MEFs in 
mono-culture. This was also observed here when co-cultured with MCF7 cells. Similarly, 
viability of MDAMB231 was enhanced by the presence of both wt and PKN2 ko MEFs 
(Fig.44Bi). However, there was a significant reduction in cancer cell viability when cultured 
with PKN2 ko MEFs when compared to culture with wt MEFs. The viability of MEFs in mono-
culture and co-culture with MDAMB231 followed similar patterns to MCF7 co-cultures 
(Fig.44Bii). This suggests that PKN2 ko may affect paracrine signalling to MDAMB231 cells, 
either by altering the secretome or by reducing the absolute numbers of fibroblasts in the 
co-culture. 
To assess the effect of fibroblasts on breast cancer viability, more relevant breast fibroblast 
models were used. A human mammary fibroblast cell line (HMFU19) was labelled with 
renilla luciferase reporter and two unlabelled human primary cancer-associated fibroblasts 
(CAFs) were used in 2D co-culture assays. MCF7 and MDAMB231 cell proliferation increased 
in co-culture with HMFU19 (Fig. 45Ai and Fig. 45Bi), whilst the proliferation of the 
fibroblasts was unaffected (Fig. 45Aii and Fig. 10Bii).  
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Figure 44. Effect of PKN2 deletion in MEFs on breast cancer cell viability 
A) MCF7 cells and B) MDAMB231 (MDA231) cells were cultures alone (black bars) or co-cultured 
with wt MEFs (blue bars) or PKN2 ko MEFs (green bars) for 72h. At endpoint, cells were lysed and 
assayed for the activity of firefly luciferase from cancer cells, detected at 590nm (Ai, Bi). Stop & Glo 
substrate is added to quench this signal and luminescence at 460nm is detected from the renilla 
luciferase activity from MEFs (Aii and Bii). Raw arbitrary values (RLU) are normalised to the cancer 
mono-culture condition values to represent the fold change fold change. Data represents the mean 
+/- SD for n=3 biological repeats carried out in least triplicates. Statistical analysis was carried out 
using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 45. Effect of human mammary fibroblast on breast cancer viability 
A) MCF and B) MDAMB231 (MDA231) were cultured alone (black bars) or co-cultured with 
Immortalised human breast fibroblast cell line HMFU19 (HMF – blue bars) for 72h. At end-point, 
cells were lysed to assay for the firefly luciferase activity from cancer cells (Ai and Bi: n=3) and 
thereafter for the renilla luciferase activity (Aii and Bii: n=2). Arbitrary raw values (RLU) are shown. 
Data represents the mean +/- SD for n=2 or 3 biological repeats carried out in triplicates. Statistical 
analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), 
P<0.001 (***). 
 
Two different unlabelled CAF cell lines, 1997 and 1939, were tested for their effect on 
cancer cell proliferation or viability and for any changes upon PKN2 depletion in CAFs.  
Unusual differences in proliferation levels of cancer cells in co-culture with CAFs, between 
different siRNA conditions, needed to be considered when interpreting the results. 
Untreated 1997 and 1939 CAFs both decreased MCF7 survival (compared to 
monocultures). However, control siRNA-treated CAFs did not have the same suppressive 
effect on MCF7 survival (Fig. 46A, B). This was consistent for both CAF lines used. Of 
potential interest, MCF7 survival was significantly lower when in co-culture with PKN2-
depleted CAFs when compared to control siRNA treated CAFs. While the unusual 
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behaviour of the controls limits interpretation, it is tempting to speculate that PKN2 
deletion may impact on the ability of CAFs to support MCF7 viability. Further control and 
PKN2 siRNAs could be used to clarify these results. 
 
In initial experiments MDAMB231 and 1997 CAFS were seeded at 1:2 ratio and gave 
sufficient luminescence signal, there was increased MDAMB231 survival when in co-culture 
with control or PKN2-depleted 1997 (Fig. 46Ci). Similar enhancement of MDAMB231 
survival was observed with control or PKN2-depleted 1939. In some experiments, 
MDAMB231 cells, when cultured alone did not give sufficient luminescence signal when 
assayed for luciferase activity at the end of some co-culture assays. This was under normal 
co-culture conditions, with cancer: fibroblast ratio of 1:2 and suggests that MDA231 cell 
proliferation is low when cultured alone at low cell densities, in the absence of growth 
supporting fibroblasts.  
To increase the number of MDAMB231 cells for better signal, whilst seeding the same 
total number of cancer and fibroblast cells, the ratio of cancer to fibroblast was changed 
to 2:1.  At this ratio, there were no significant differences in MDAMB231 survival between 
mono-cultures and co-cultures with control or PKN2-depleted 1997 or 1939 CAFs (Fig. 46 
Cii, Dii). Overall, MDAMB231 survival was improved when cultured with 1939 and 1997 at 
the ratio of 1:2. At 2:1 ratio, there were no changes in MDAMB231 survival between 
mono- and co-culture conditions. These effects were unaffected by PKN2 depletion in 
CAFs.  
 
MCF7 cells and 231 cells show contrasting behaviours when co-cultured with CAFs, as 
MDAMB231 benefit from the presence of CAFs, whilst survival of MCF7 was reduced when 
co-cultured with CAFs. This contrasts with the previous observation where MEFs enhanced 
survival of both cancer cell types. Furthermore, the survival advantage in MDAMB231 cells 
is also dependent on the ratio of co-cultured cells. Together, these data suggest that CAFs 
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may have both growth-enhancing and -suppressive effects, dependent on the cancer 
model. This perhaps relates to the conflicting data on the prognostic relevance of CAFs 
and fibrosis in distinct disease types. In TNBC, enhanced fibrosis gives a poor prognosis, 
whereas in luminal breast cancer this is not the case. 
 
 
Figure 46. Effect of human primary CAFs on breast cancer cell viability 
MCF7 and MDAMB231, labelled with firefly luciferase reporter, were cultured alone (black bars) or 
co-cultured with two different unlabelled CAFs: 1997 and 1939 (blue bars). After three days, lysates 
were collected and assayed for the activity of firefly luciferase (FFL) reporter from cancer cells. 
MCF7 co-culture assays were done under normal culture conditions with cancer to fibroblast ratio 
of 1:2 (A, B). Under these conditions, c-culture of MDAMB231 with 1997 only gave sufficient signal 
in one experiment (Ci) and all three experiments with 1939 (Di). Therefore, the cancer to fibroblast 
ratio was changed to 2:1 for MDAMB231 co-cultures with 1997 (Cii) and 1939 (Dii). Ci: n=1; A and 
Dii: n=2; B, Cii and Di: n=3. Data represents the mean +/- SD for experiments carried out in 
triplicates. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: 
P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
To summarise, in the mouse model, PyMT-BO1 cell lines showed increased viability of the 
cancer cells when in co-culture with MEFs (regardless of PKN2 loss). On the other hand, in 
co-cultures of 4T1 and MEFs, rather the MEFs have increased viability when in contact 
with 4T1, compared to when cultured alone.  
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In the human model, co-cultures of MCF7 & MDAMB231 with HMFU19, showed increased 
viability in the cancer cells, with no difference in HMFU19 viability. This observation was 
recapitulated when MEFs were co-cultured with these human cancer lines; encouragingly, 
deletion of PKN2 from MEFs appeared to attenuate the growth enhancement of both 
MCF7 and MDA231 cells. This suggests that modulating PKN2 in fibroblasts may provide a 
route for altering stromal support of tumour cells.   CAFs did not support survival of MCF7 
cancer cells, whilst supporting survival of MDAMB231 depending on the ratio of 
fibroblasts present. 
3.3.2.2 Drug response of CAFs to doxorubicin and paclitaxel and the effect of PKN2 depletion 
CAFs are known to decrease the sensitivity of cancer cells to chemotherapeutic drugs. For 
example, secretion of HGF by fibroblast has been described in resistance to BRAF kinase 
inhibitor in melanoma (Straussman et al. 2012) and resistance to lapatinib in HER2+ breast 
cancer (Watson et al. 2018). Secretion of chemokines by CAF have also been related to 
chemoresistance. For example, studies in pancreatic cancer have demonstrated that 
secretion of chemokine CXCL12 results in resistance to gemcitabine (Singh et al. 2010). 
Furthermore, secretion of IL-6 by CAFs leads to resistance to erlotinib in lung cancer (Yao 
et al. 2010).  Therefore, we wanted to investigate whether 1939 and 1997 CAFs have 
similar protective effects, and whether loss of PKN2 in these CAFs affects the sensitivity of 
breast cancer cells. The single or dual luciferase assays provide a great platform to study 
the response to drugs in both cell types simultaneously.  
 
To study the effect of PKN2 loss in CAFs on drug sensitivity in cancer cells, CAFs were pre-
treated with a control siRNA and a pool of three PKN2-targeting siRNAs and co-seeded 
with cancer cells for 72 hours before drug treatment and assayed for cell viability after 72 
hours.  
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The effect of PKN2 deletion in CAFs on sensitivity to doxorubicin in MCF7 was tested. As 
previously described, MCF7 culture with CAFs suppressed their growth (Fig. 46A and 46B). 
Compared to wt CAFs (both 1939 and 1997), control siRNA-treated (siC3) CAFs had more 
positive effect on MCF7 survival. As the CAFs treated with control siRNA did not have 
similar effect on MCF7 survival as wt CAFs as expected, the reduced survival of MCF7 with 
PKN2-deleted CAFs is difficult to interpret conclusively. However, doxorubicin was found 
to have a dose dependent inhibitory effect on the growth of MCF7 cells and this sensitivity 
was only marginally affected by the inclusion of CAFs to the assay (Fig. 47). Perhaps 
importantly, PKN2 depleted 1997 cells and untreated wt 1997 CAFs show very similar 
patterns of sensitivity to doxorubicin. This does not support suppression of PKN2 in this 
model as a mechanism to increase drug sensitivity. 
 
 
Figure 47. MCF7 sensitivity to doxorubicin and the effect from CAFs 
MCF7, labelled with firefly luciferase, were seeded alone (black), with wt (blue), siC3-treated (light-
blue) or siPKN2-treated (green) A. 1939 (n=3) or B. 1997 (n=2) CAFs. After 72h, these cells were 
treated with vehicle control or doxorubicin at 0.03, 0.3 and 1μM for another 72h. At endpoint, 
lysates were collected and assayed for the activity of firefly luciferase (FFL) reporter from MCF7 
cancer cells. Raw arbitrary values (RLU) are presented. Data represents the mean +/- SD for n=2 or 
3 biological repeats carried out in triplicates. Statistical analysis was carried out using ANOVA 
followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
MDAMB231 were treated with two standard chemotherapy drugs used in breast cancer, 
doxorubicin and paclitaxel, in monoculture or in co-culture with two different CAFs (1997 
and 1939). MDAMB231 were not sensitive to doxorubicin at the tested dose range in the 
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co-culture assay with 1939 (Fig. 48 Ai). The effect of CAFs and their expression of PKN2 on 
drug sensitivity is difficult to interpret from these results due to the large variation within 
technical and biological repeats and unusual kinetic of cell survival in some cell lines. 
Furthermore, CAFs treated with control siRNA did not behave comparably to wt CAFs. 
However, broadly there was no protection by CAFs (or PKN2 expression) from sensitivity to 
doxorubicin and paclitaxel in cancer cells. 
 
Figure 48. MDAMB231 & CAF sensitivity to doxorubicin and paclitaxel 
MDAMB231 (MDA231) cells, labelled with firefly luciferase, were seeded alone (black), with wt 
(blue), siC3-treated (light-blue) or siPKN2-treated (green) A. 1939 or B. 1997 CAFs. After 72h, these 
cells were treated with vehicle control, doxorubicin (Ai, Bi) or paclitaxel (Aii, Bii) for another 72h. At 
endpoint, lysates were collected and assayed for the activity of firefly luciferase (FFL) reporter from 
MDAMB231 cancer cells. Raw arbitrary values (RLU) are presented. Data represents the mean +/- 
SD for n=2 biological repeats carried out in triplicates. Statistical analysis was carried out using 
ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
Optimisation of the dose range is also required, for example for MDAMB231 where 
doxorubicin had no anti-proliferative effect with 1939 CAFs and gave different results with 
1997 CAFs across two experiments. Better tools to delete PKN2 in human fibroblasts are 
required to understand its role on cancer cells’ drug response. 
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3.3.3 Assessing effect of PKN2 in MEFs in mixed cell breast cancer xenografts  
Fibroblasts have been shown to support tumour growth in vivo, using mixed cell 
xenografts. Chatterjee et al examined the effect of fibroblasts of different origins on 
MDAMB231 proliferation, by co-injecting them into immunodeficient mice (Chatterjee et 
al. 2018). Tumours from cancer and fibroblast co-injections had increased growth 
compared with cancer cell alone. Another similar study demonstrated increased tumour 
growth when MDAMB231 cells were co-injected with fibroblasts, which was attributed to 
increased tumour vascularisation (Limoge et al. 2017). Furthermore, Olsen et al tested the 
effect of co-injecting mammary fibroblasts with a derivative of MCF7 cell lines on tumour 
growth, with and without oestrogen supplementation in in vivo mixed-cell xenografts 
(Olsen et al. 2010). This revealed increase tumour growth when fibroblasts were co-
injected, which was unaffected by supplementation of oestrogen. 
Given these published studies, we sought to examine the effect of fibroblasts, and their 
PKN2 status, on breast cancer growth, using mixed cell xenografts. Due to the in vivo 
setting, siRNA-mediated PKN2 suppression could not be employed, as the effect will only 
be transient. Therefore, MEFs from our inducible PKN2 conditional knockout mice (Rosa26 
Cre ERT2 PKN2flox) were used, as PKN2 deletion can be induced and the effect is long-term.  
In mini-organotypic assays, co-culture of 4T1 cancer cells and MEFs resulted in increased 
cell proliferation and invasion, which was suppressed when MEF PKN2 was deleted. 
Therefore, this cancer cell line was tested in vivo to examine the effect of co-injecting 
fibroblasts (MEFs) - with or without PKN2 - on tumour growth. As 4T1 cells are derived 
from BALBc mice, these co-injection experiments were conducted in CD1 nu/nu 
immunosuppressed mice.  
PyMT-BO1 cells (MMTV-PyMT derived) co-cultured with MEFs in the collagen/matrigel 
gels also showed increased growth compared with PyMT-BO1 cells alone, although no 
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differences were observed between wild-type and PKN2 ko MEFs. This cancer cell line was 
also tested in vivo and as it shares the same origin of mice as our MEFs (C57 BL/6 mice), 
this combination of cells could be injected in immune-competent C57BL/6 mice.  We co-
injected these combinations of cells subcutaneously into mice to study the role of PKN2 in 
fibroblasts in vivo.  
MEFs from our conditional PKN2 knockout mouse model were untreated (wt MEFs) or 
pre-treated with 4-hydroxy tamoxifen (4-OHT) to induce PKN2 deletion (PKN2 ko MEFs) 
before co-injecting with cancer cells subcutaneously into the mice. 330000 cells per 100μl 
PBS were injected into both flanks or co-injected with wt MEFs in the left flank and PKN2 
ko MEFs in the right flank (an additional 660,000 cells) of CD1 nu/nu mice (for 4T1 
tumours) or C57BL6 mice (for PyMT-BO1 tumours). 
At endpoint, tumours were harvested, fixed and sectioned. Tumours were stained with 
Sirius red to study whether loss of PKN2 in MEFs affected fibrous and desmoplastic 
composition of tumours. The stained sections were analysed to quantify the number of 
pixels with positively stained areas as a ratio to total pixels. PyMT-BO1 tumours were also 
stained for SMA, another marker of desmoplasia and fibrosis. 
3.3.3.1 Effect of PKN2 expression in MEFs on tumour growth and desmoplasia when co-
injected with 4T1 breast cancer cells in vivo 
Tumour volume was measured from day 6 and thereafter every 2-3 days (Fig. 49A), and 
tumours weighed at endpoint (Fig. 49B). 4T1 tumours were harvested two weeks after 
injection. To our surprise, there were no changes in tumour volumes at any time point 
between the mono-culture and co-culture conditions. This was reflected in the tumour 
weights at endpoint. Although PKN2 loss in MEFs had no effect on tumour growth, 
fibroblast activation studies in the previous chapter suggest a possibility of reduced 
stromal activation and hence desmoplastic tissue upon PKN2 loss. 
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To investigate this, tumours were stained with Sirius Red to identify areas of collagen 
deposition. The stained sections were quantified for number of pixels positive for Sirius 
red staining (represented as RPT – ratio of positive to total pixels). This is to investigate 
differences in the desmoplastic nature of tumours and the level of activated stroma within 
the tumour. There were no significant differences between tumours from mice injected 
with cancer cells only, compared to mice co-injected with MEFs (Fig. 50).  
 
Figure 49. Volumes and weights of tumours in mice co-injected with wt or PKN2 ko MEFs and 4T1 
breast cancer cells 
CD1 nu/nu mice were injected with 4T1 cancer cells alone (black, n=8) or co-injected with wt MEFs 
(blue, n=7) or ko MEFs (green, n=8). A. Tumour volume was measured using a digital caliper from 
day 6 to day 14. Data represents the mean values +/- SD of biological repeats.  B. Weights of 
excised tumours were measured after the mice were culled at endpoint. Data represents the raw 
values +/- SD. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc 
test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 50. Sirius red staining of 4T1 and MEF tumours 
Sections of the excised tumours were fixed in 4% PFA, paraffinised and sectioned. These sections 
were stained with Sirius red (A, B and C) and imaged using Pannoramic 250 High Throughput 
Scanner. The images can were viewed and the staining quantified using the Pannoramic Viewer 
software. At a fixed magnification, over 30 sections covering the inner part of the tumour of a 
tumour was selected (all with similar area) for quantification. The threshold was set to detect the 
pink/red areas of stained sections using the DensitoQuant tool in the Image Analysis modules. D. 
The ratio of number of pixels positive for Sirius red staining to total pixels (RPT) is presented. Data 
represents the mean +/- SD for biological repeats (4T1 only: n=9; 4T1 and wt MEFs: n=8; 4T1 and 
PKN2 ko MEFs: n=8). Statistical analysis was carried out using ANOVA followed by Bonferroni post-
hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
3.3.3.2 Effect of PKN2 expression in MEFs on tumour growth and desmoplasia when co-
injected with PyMT-BO1 breast cancer cells in vivo  
PyMT-BO1 tumour volumes were measured from day 6 and monitored every three days 
(Fig. 51A), with tumours weighed at endpoint on day 12 (Fig. 51B). Over time, tumour 
volumes were higher when cancer cells and MEFs were co-injected, but PKN2 deletion in 
MEFs had no impact. Similarly, tumour weights at endpoint were higher in the co-injected 
mice, with no changes upon PKN2 deletion. Tumours from cancer and PKN2 ko MEFs co-
injections had higher weights than MMTV cancer cell only tumours, but this did not reach 
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statistical significance. This data implies that tumour growth is enhanced in the presence 
of MEFs, but that this growth enhancement is unaffected by the deletion of PKN2. For this 
cell model, this concurs with the pattern of behaviour observed in organotypic assays. 
Tumours were stained with Sirius red and -SMA and quantified as for the 4T1 tumours. 
The RPT for -SMA was similar between the different conditions (Fig. 52). The percentage 
of α-SMA-stained pixels out of total pixel was highest in tumours with wt MEFs, although 
differences were not statistically significant. Tumours of PyMT-BO1 co-injected with ko 
MEFs had an RPT for α-SMA similar to tumours from mice injected with PyMT-BO1 cells 
only. Compared to PyMT-BO1 & wt MEF tumours, RPT for Sirius red was also slightly lower 
in tumours with PKN2 ko MEFs (Fig.53). While these data show a trend towards wt MEFS 
inducing more a-SMA and Sirius red positive, no firm conclusions can be made due to the 
high variation in this data. Increased cohort size may have revealed more statistically 
robust data to support our in vitro studies. 
 
Figure 51. Volumes and weights of tumours in mice co-injected with wt or PKN2 ko MEFs and 
PyMT.BO1 breast cancer cells 
C57/BL6 mice were injected with PyMT.BO1 (MMTV) cancer cells alone (black, n=5) or co-injected 
with wt MEFs (blue, n=9) or ko MEFs (green, n=9). A. Tumour volume was measured using a digital 
caliper from day 6 to day 12. Data represents the mean +/- SD of biological repeats. B. Weights of 
excised tumours were measured after the mice were culled at endpoint. Data represents the raw 
values +/- SD. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc 
test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 52. α-SMA staining of MMTV tumours  
 Sections of the excised tumours were fixed in 4% PFA, paraffinised and sectioned. These sections 
were stained with α-SMA (A, B and C) and imaged using Pannoramic 250 High Throughput Scanner. 
D) The images were viewed and the staining quantified using the Pannoramic Viewer software. At a 
fixed magnification, over 25 sections covering the inner part (to avoid the outer edge that is 
artificially intense in staining) of the tumour were selected (all with similar area) for quantification. 
The threshold was set to detect the areas of stained sections using the DensitoQuant tool in the 
Image Analysis modules. The ratio of number of pixels positive for α-SMA staining to total pixels 
(RPT) is presented. Data represents the mean +/- SD of biological repeats (MMTV only: n=5; MMTV 
& wt MEFs: n=9; MMTV & ko MEFs: n=9). Statistical analysis was carried out using ANOVA followed 
by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 53. Sirius red staining of MMTV tumours 
Fixed tumours MMTC subcutaneous tumours were stained with Sirius Red (A, B and C). D. At a fixed 
magnification, over 25 sections covering the inner part of the tumour, were selected for 
quantification. The threshold was set to detect the areas of stained sections using the 
DensitoQuant tool in the Image Analysis modules. The ratio of number of pixels positive for Sirius 
Red staining to total pixels (RPT) is presented. Data represents the mean  +/- SD of biological 
repeats (MMTV only: n=5; MMTV & wt MEFs: n=9; MMTV & ko MEFs: n=9). Statistical analysis was 
carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 
(***). 
 
Unfortunately, despite significant efforts, we struggled to conclusively identify the origins 
of fibroblasts in tumours. Firstly, the tumours grown from cancer cells alone contained 
numerous α-SMA positive cells indicating recruitment of host fibroblasts to the tumours in 
the absence of co-injected MEFs. Secondly, we were unable to stain the GFP reporter 
expressed in our co-injected MEFs due to technical difficulties, perhaps associated with 
low GFP expression. Therefore, the proportion of injected MEFs versus recruited 
fibroblasts within the tumour remains unknown, making it difficult to attribute the 
observed phenotype to PKN2 loss in tumour fibroblasts. Recruitment of host fibroblasts to 
tumours may in fact explain the failure to recapitulate the enhancement of 4T1 cell 
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growth in vivo as recruitment of PKN2 wt host fibroblast could mask any effects of co-
injected MEFs. 
3.3.4 Summary 
3.3.4.1 Assessing interaction between fibroblasts and cancer cells using mini-organotypic 
assays 
 
Mini-organotypic assays provided a useful tool to study the interaction between wt and 
PKN2 ko MEFs with cancer cells in 3D culture, with the collagen/Matrigel mix mimicking 
the ECM of the tumour microenvironment. The presence of fibroblasts with 4T1 increased 
cell invasion in the gel, which was significantly reduced when PKN2 was deleted in MEFs.  
3.3.4.2 Assessing interaction between fibroblasts and cancer cells using luciferase assays 
 
We also developed a dual luciferase assay to provide a simple cost-effective method for 
examining the growth enhancing interaction between cancer cells and fibroblasts. Here, 
cancer cells were labelled with firefly luciferase reporter, whilst fibroblasts were labelled 
with renilla luciferase. Labelled cancer cells were seeded alone or co-cultured with 
labelled or unlabelled fibroblasts (wt or PKN2 deleted/depleted) in both 2D and 3D assays. 
At endpoint, the surviving cells can be quantified due to the differential expression of 
luciferase reporters between cancer cells and fibroblasts.  
Luciferase assays of 4T1 and MEF co-cultures show enhanced MEF proliferation in the 
presence of 4T1 cells, whilst the proliferation of 4T1 was unaffected by MEFs. MEF 
proliferation was lower in the presence of 4T1 cancer cells when PKN2 was deleted in the 
MEFs. This suggests that deleting PKN2 may be a way of limiting CAF proliferation in 
response to signals from cancer cells. Suppressing CAF proliferation may be desirable in 
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some breast cancer cell types where desmoplasia and fibrosis contributes to poor disease 
outcome. 
In contrast to the 4T1 cells, PyMT-BO1 assays show increased PyMT-BO1 proliferation in 
the presence of fibroblasts in 2D and 3D, which is unaffected by PKN2 loss on MEFs. This 
observation correlated with the mini-organotypic assays.  
Both MCF7 and MDAMB231 showed enhanced viability in the presence of MEFs 
(unaffected by loss of PKN2) and HMU19. The CAF cell lines, 1997 and 1939, promoted 
proliferation of MDAMB231 cells, whilst reducing MCF7 proliferation. This demonstrates 
overlap between fibroblasts from different origins and supports MEFs as a useful 
surrogate model. 
The use of siRNA to delete PKN2 in human fibroblasts cell line HMFU19 and particularly in 
primary CAF cells was challenging. As mentioned in chapter 3.1, we developed an 
inducible shRNA system to supress PKN2 expression in human breast cancer cell lines, 
which presented with technical difficulties. This system, once optimised, can be employed 
in human fibroblast models. Alternatively, CRISPR-Cas9 technology may provide a more 
robust and penetrant means of suppressing PKN2 expression. 
Optimising methods of PKN2 deletion in fibroblasts can add value to this luciferase co-
culture assay system, as the differential labelling of two cell types enables the study of 
cancer-fibroblast interaction with the ability to attribute any change to an individual cell 
type. This method can be employed on a large high-throughput screen, as cells can be co-
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cultured in multi-well plates (reducing number of cells and reagents required) and the 
output can be quantified in an automated manner.  
3.3.4.3 Interaction of MEFs (wt & PKN2 ko) with 4T1 and PyMT cells in vivo 
After investigating the effect of PKN2 in fibroblasts on their interaction with cancer cells in 
in-vitro cultures, the effect in-vivo was investigated. Tumours with PKN2 ko MEFs had 
reduced areas of Sirius red staining and reduced proportion of area stained with -SMA, 
compared to tumours with wt PKN2. These changes suggest reduced stromal activation in 
tumours where PKN2 was deleted in MEFs. This phenotype can influence tumour stiffness 
and sensitivity to chemotherapy, which are worth examining in future studies.  
During the completion of my thesis write up, Lorena Alba-Castellon quantified blood 
vessel density in the 4T1 mixed cell xenografts and found that vessel density was 
significantly enhanced by the addition of MEFs, and further that this enhancement was 
reversed upon PKN2 deletion. This implies that stromal modulation of PKN2 may be a 
useful method for modulating tumour vascularisation, which will be discussed in more 
detail in Chapter 3.4. 
Whilst mixed cell xenografts provide an opportunity to study the interaction between 
cancer cells and fibroblasts, interpretation was limited by recruitment of host stromal 
fibroblasts which will be wt for PKN2. Recruitment of endogenous fibroblasts may mask 
any effect of PKN2-deleted MEFs that are known to have lower survival that wt MEFs. 
Therefore, the effect of PKN2 deletion on tumour growth and pathology was investigated 
in the following chapter by targeting the entire stroma using a novel inducible conditional 
PKN2 knockout mouse. 
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3.4 Using a novel inducible PKN2 knockout mouse orthotopic model to explore 
stromal PKN2 function 
 
Using in vitro co-culture models, we demonstrated that fibroblasts could enhance the 
growth of breast cancer cells in a PKN2 dependent fashion. These results were not 
recapitulated conclusively in vivo using mixed cell xenograft models. These models 
however suffer from some significant drawbacks. Firstly, as the injected mice are wild-
type for PKN2, resident PKN2 expressing stromal cells, including fibroblasts, can be 
recruited to tumours. This was highlighted by the presence of large numbers of -SMA 
positive mesenchymal cells in 4T1 tumours, even in the absence of any co-injected 
fibroblasts. This is likely to confound the effects of co-injecting PKN2 deleted fibroblasts. 
Added to this, we were unable to positively identify co-injected fibroblasts robustly in 
tumours, leading to ambiguity about the PKN2 status of fibroblast-like cells in the 
tumours. Finally, subcutaneous tumours are a poor substitute for orthotopic tumours 
where cells would be exposed to the breast microenvironment. 
To overcome these limitations, we sought to develop a syngeneic orthotopic model using 
our inducible conditional PKN2 knockout mouse model (iPKN2: PKN2fl/fl; Rosa26-CreERT2). 
This would allow us to examine the effect of systemic PKN2 deletion on tumour pathology, 
with the added benefit of preserving an intact immune system. Orthotopic models are 
physiologically more relevant than subcutaneous models, particularly with regard to 
stromal responses (Fleming et al. 2010; Holen et al. 2017). Moreover, systemic deletion of 
PKN2 in this orthotopic model ensures that all resident and recruited fibroblasts should 
lack PKN2 expression. This will allow us to interpret any changes in fibroblast activation, 
due to PKN2 deletion, less ambiguously.  
4T1 cells could not be used for orthotopic injections in mice, as these cells were isolated 
from a spontaneous tumour formed into BALB/c mouse, while our iPKN2 mice are of a 
C57Bl6 background; implantation of 4T1 will result in immune rejection. We are thus 
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limited to syngeneic C57BL/6 derived model, and here selected the BO.1 cell line, derived 
from an MMTV-PyMT model on a C57BL/6 background. Tumours which develop 
spontaneously in the MMTV-PyMT model contain abundant CAFs and exhibit fibrosis, 
further supporting use of xenografts from this model (Holen et al. 2017) (Takai et al. 
2018). 
We hypothesised that growth and activation of host fibroblasts within the orthotopic 
tumour may also be affected by PKN2 deletion resulting in changes in tumour growth, 
pathology, fibrosis and angiogenesis. Further, we envisaged that deletion of PKN2 might 
recapitulate some of the tissue phenotypes observed when PKN2 is deleted during mouse 
embryogenesis; induced deletion of PKN2 in embryos resulted in collapse of the 
mesenchymal compartment, a reduction of mesenchymal cell growth and contractility, 
and disruption of the developing vasculature (Quétier et al. 2016) 
3.4.1 Experimental procedure of inducing PKN2 deletion and breast orthotopic 
injections in mice 
We bred our conditional PKN2 mice to obtain littermate females to form the cohort for 
our 3 experimental groups (Fig. 54). PKN2fl/fl; Rosa26-Cre/ERT2 mice were crossed with 
female PKN2fl/+; Rosa26-Cre/ERT2 mice to give a 50:50 mix of PKN2fl/fl; Rosa26-Cre/ERT2 
and PKN2fl/+; Rosa26-Cre/ERT2. These mice were divided into three experimental groups: 
(1) PKN2 Homo-KO: PKN2fl/fl; Rosa26-Cre/ERT2 + Tamoxifen; (2) PKN2 Het-KO: PKN2fl/+; 
Rosa26-CreERT2 + Tamoxifen; (3) PKN2 WT: Either genotype without Tamoxifen treatment 
(Vehicle). 
Tamoxifen was administered, at the dose of 3mg per 20g mouse weight (dissolved in 
sunflower oil via oral gavage), thrice within two weeks to induce PKN2 deletion. This 
schedule has been demonstrated to induce penetrant systemic deletion of PKN2 in adult 
mice. Meanwhile control mice were treated with vehicle (Fig. 54). During embryogenesis, 
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heterozygous expression of PKN2 was sufficient to maintain PKN2 function, and it was 
envisaged that the tamoxifen treated heterozygous cohort would also control for the non-
specific effects of tamoxifen administration. 
 
Figure 54. Breeding Schematic 
Conditional PKN2 mice, homozygous (blue) for floxed PKN2 alleles and heterozygous (green) for 
floxed PKN2 with homozygous allele for CRE/ERT2 were bred to give littermates with heterozygous 
alleles for Cre/ERT2. Mice with homozygous floxed PKN2 were treated with tamoxifen to induce 
PKN2 deletion in both alleles (PKN2 homo-KO; n=6) Mice heterozygous for PKN2 floxed gene were 
also treated with tamoxifen to induce PKN2 deletion in one allele (PKN2 Het; n=5).  Mice from both 
genotypes were untreated as control mice (WT; n=5). 
 
Mice were injected with 3x105 BO.1 cells in each (left and right) inguinal mammary fat 
pad. Cells were injected in 30uL Matrigel. The experiment was terminated two weeks post 
injection, when the mice were culled and the tumours were harvested.  PCR analysis of 
extracted tumour DNA indicated robust recombination of the floxed allele in tamoxifen 
treated mice. 
3.4.2 Systemic PKN2 deletion does not significantly affect breast orthotopic growth 
Excised tumours were weighed and recorded at endpoint. When harvesting tumours from 
the mice at endpoint, it was apparent that there was sometimes additional tumour 
growth between the two injected sites, along the line of tumour engraftment. In some 
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mice, this resulted in additional subcutaneous tumours. We thus separately examined the 
total tumour burden and the size of the individual orthotopic tumours, remaining within 
the mammary fat pad.  
There was a trend towards high total tumour burden when PKN2 was deleted, with no 
difference between het and homo PKN2 ko mice (Fig. 55). The orthotopic tumours were 
separated and weighed individually. There were no significant differences in the 
orthotopic tumour weights between the three groups (Fig. 56), indicating that loss of 
PKN2 in the surrounding tissue had no impact on net tumour growth within the mammary 
gland.  
 
Figure 55. Total tumour weight (g) per mouse 
A. Weights of tumours from left and right inguinal mammary fat pad sites as well as any additional 
subcutaneous tumours were added to give total tumour weights. B. Scatter plot representing 
weights per mouse in each experimental group – wt: n= 5; het: n=5, homo: n=6 mice). Data 
represents the raw values +/- SD of biological repeats. Statistical analysis was carried out using 
ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 56. Excised orthotopic tumours and weights 
A. Images of examples of tumours excised from i) wt, ii) het and iii) homo-KO mice at end-point. B. 
Plot of weights of excised tumours that could be separated as individual tumours from left and 
right inguinal mammary fat pads at endpoint in each cohort group of mice - wt: n= 10; het: n=4, 
homo: n=11 tumours). Data represents the raw values +/- SD of biological repeats. Statistical 
analysis was carried out using ANOVA followed by Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), 
P<0.001 (***). 
 
3.4.3 Systemic PKN2 deletion in mice reduces fibrosis in orthotopic tumours 
The potential role of PKN2 in the activation of fibroblasts was discussed in the previous 
chapter. Here, the effect of PKN2 ablation on activation of the tumour stroma was 
investigated in vivo using the orthotopic tumours. Tumours were fixed and embedded in 
paraffin. Sections were cut and mounted on slides to stain for α-SMA to give an indication 
of the activation state of mesenchymal cells within the tumour stroma (Fig. 57). Tumour 
sections were also stained for Sirius Red (Fig. 58), to give an indication of the collagen 
deposition from desmoplastic reaction within the tumour (Lattouf et al. 2014).  
The ratio of Sirius Red or α-SMA-positive pixels to total number of pixels (RPT) was 
calculated by the DensitoQuant tool in Pannoramic Viewer. The average RPT from multiple 
158 
 
fields of views within a tumour (covering most of the inner tumour and avoiding the very 
outer edge of the tumour, where there is commonly darker artificial staining) was used to 
analyse for differences upon PKN2 loss. There were no significant differences in the ratio 
of -SMA-positive pixels to total pixels in WT, het-KO or homo-KO groups (Fig. 57B). On 
the other hand, tumours from homozygous PKN2 KO mice had significantly lower RPT of 
Sirius Red than the WT and het group tumours (Fig. 58B). Whilst there were no differences 
in α-SMA positive pixel ratio upon PKN2 loss, reduced Sirius Red staining in PKN2-deleted 
tumours is an indication of reduced fibrosis and activated stromal activity. The lack of 
difference between WT and het mice suggests that one allele of PKN2 is sufficient to drive 
the fibrosis. Furthermore, the similarity between the tumours from WT and het PKN2-
deleted mice controls for any potential effects of the tamoxifen administration used to 
induce recombination.  
 
Figure 57. α-SMA staining of orthotopic breast tumours  
A. Brightfield images of α-SMA stained tumours from i) wt: n= 9, ii) het: n=6 and iii) homo mice: 
n=10 tumours. Scale bar represents 200µm. B. Ratio of positive to total pixels (RPT) of α-SMA. 
Average RPT per tumour from several fields of view is plotted. Data represents the mean values +/- 
SD of biological repeats. Statistical analysis was carried out using ANOVA followed by Bonferroni 
post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 58. Sirius Red staining of orthotopic breast tumours 
 A. Brightfield images of Sirius red stained tumours from i) wt: n= 7, ii) het: n=8 and iii) homo mice: 
n= 10 tumours. B. Ratio of positive to total pixels (RPT) of Sirius red staining. Average RPT per 
tumour from several fields of view is plotted. Data represents the mean values +/- SD of biological 
repeats. Statistical analysis was carried out using ANOVA followed by Bonferroni post-hoc test: 
P<0.05 (*), P<0.01 (**), P<0.001 (***). 
 
3.4.4 Systemic PKN2 deletion reduces blood vessel density in orthotopic tumours 
Systemic deletion of PKN2 in mouse embryos presented with abnormal vasculature and an 
absence of vitelline vessels in the yolk-sacs, seemingly contributing to lethality at E10 
(Quétier et al. 2016). Furthermore, the related PKN3 isoform has been shown to regulate 
tumour angiogenesis in a breast cancer model (Mukai et al. 2016). Therefore, tumours 
were stained for endomucin (Fig. 59A) to study differences in tumour vascularisation upon 
stromal PKN2 deletion (collaboration with postdoctoral colleague Dr Lorena Alba 
Castellon). The number of vessels were counted from several fields of view within the 
inner tumour, and the averages were compared.  There was a significant reduction in the 
number of blood vessels in tumours from the homo KO group compared to wt and het 
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group (Fig. 59B). Thus, further investigation of PKN2 as a potential target for regulating 
angiogenesis and fibrosis in tumours may reveal clinical relevance with respect to tumour 
growth and metastasis.  
 
 
3.4.5 Summary 
Here we used an orthotopic model to investigate the effect of deleting PKN2 throughout 
the tumour stroma, focusing on the fibrotic nature of the tumour and vascularisation. We 
acknowledge that this model does not delete PKN2 in fibroblasts alone, and phenotypes 
may therefore be attributed to loss from other stromal cells. As previously demonstrated 
in mouse embryos (Quétier et al. 2016), homozygous loss of PKN2 is required to see any 
overt phenotypic differences, whilst 50% PKN2 expression (heterozygous mice) is 
sufficient to mimic the WT mice. This behaviour appears to be the same for the fibrosis 
Figure 59. Endomucin staining of breast orthotopic tumours 
A. Brightfield images of endomucin-stained tumours from i) wt, ii) het and iii) homo mice. B. 
Number of blood vessels. Multiple sections per tumour section was counted. Data represents the 
mean number of blood vessels per field +/- SD of biological repeats (wt: n= 6; het: n=4; homo: n=8 
tumours). Statistical analysis was carried out using unpaired t-test to compare the differences 
between two cohort groups. 
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and vascular phenotypes in tumours. Overall, these data indicate a potentially important 
role for PKN2 in tumour fibrosis and vascularisation.  
Increased fibrosis and stromal activation has been associated with affecting drug entry 
(Orimo et al. 2005) and poor prognosis in breast cancer (Yazhou et al. 2004; Surowiak et 
al. 2006), and therefore further investigation of PKN2 in light of this phenotype can have 
important clinical relevance. In our study, tumours in mice with systemic PKN2 deletion in 
the surrounding stroma had reduced Sirius red staining. This suggests PKN2 as a potential 
target in stromal fibroblasts, as desmoplasia is a phenotype mediated by activated 
fibroblasts, which can affect disease prognosis and response to therapy (Pearce et al. 
2018b); (Lovitt, Shelper, and Avery 2018).  
Another factor related to stromal desmoplasia that can be examined in relation to PKN2 
expression is tumour stiffness. In breast cancer, tumour stiffness is associated with 
promotion of cancer cell invasion and metastasis (Cavo et al. 2016), where stromal cells 
secrete factors that contribute to ECM re-modelling (Kharaishvili et al. 2014; McLane and 
Ligon 2016). Since evidence in this chapter and chapter 3.2 suggest modulation of stromal 
activation by PKN2, assessing tumour stiffness may provide interesting results of clinical 
significance.  
Reduced numbers of endomucin stained vessels in tumours from PKN2 homo-KO mice has 
potential therapeutic implications. In mouse embryos, vascular defects were not caused 
by loss of PKN2 from endothelial cells; two independent endothelial specific PKN2 
knockout models indicated normal vascular development and no lethality or overt 
phenotype in adult mice (Quétier et al. 2016). Rather, vascular defects in the mouse were 
attributed to collapse of the underlying mesenchyme, with defects in the cell biology of 
mesenchymal fibroblasts observed both in vitro and in vivo (Quétier et al. 2016). It 
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remains to be determined whether similar mechanisms play a part in the reduced blood 
vessel density we see with stromal knockout of PKN2 in tumours. 
Tumour vasculature has many important roles, such as maintenance of tumour survival at 
the primary site as well as intravasation, dissemination and metastasis to secondary sites. 
Whilst anti-angiogenic therapies have positive effects on disease-free survival, no 
improvements in overall survival is observed (Bergers and Hanahan 2008). This failure has 
been attributed to acquired resistance as well as side effects, such as spontaneous 
internal bleeding (Elice and Rodeghiero 2012). Furthermore, reduced vascularisation 
causes increased intra-tumoural hypoxia, hindering delivery of chemotherapeutic drugs 
(Wong, Bodrug, and Hodivala-Dilke 2016) and potentially promoting metastatic spread. 
Therefore, in terms of therapy, vascular perfusion can have significant effects on drug 
delivery and it remains controversial whether reducing vasculature will be of benefit in 
tumour therapy.  
3.4.5.1 Concluding remarks 
Global deletion of PKN2 in mice resulted in tumours that are less fibrotic, with reduced 
vasculature. These characteristics have impacts on tumour stiffness, invasion, metastasis 
and chemosensitivity. Therefore, it will be valuable to examine these phenotypes and the 
relevance of PKN2 in future studies. Differences in other phenotypes, such as levels of 
immune cell infiltrates and degree of inflammation may provide insights into other 
functions related to PKN2.  Additionally, comparisons can be made between global PKN2 
deletion and stromal cell-specific PKN2 deletion, as well as exploiting genetic and 
pharmacological means of targeting PKN2.  
Further study in the role of PKN2 in the regulation of the tumour fibrosis and vasculature, 
particularly with regard to mechanism, is clearly warranted and may reveal important and 
therapeutically exploitable avenues.  
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4. Discussion 
 
PKN kinases are an enigmatic group of kinases that have received little attention to date, 
compared to their close PKC family relatives and the Rho effector kinases, ROCK1 and 
ROCK2. However, domain and sequence homology suggest that PKN kinases are the 
closest mammalian orthologues of yeast PKC (Mukai 2003; Roelants et al. 2017). The roles 
of yeast PKC include regulation of cell wall integrity, cytoskeletal dynamics and cell cycle 
progression downstream of yeast Rho1 (Heinisch et al. 1999) (Marini et al. 1996). In 
mammals, the PKC kinase family is broad and functionally diverged; the PKN kinases 
represent as a subgroup within this family which have retained the ability to regulate cell 
biology downstream of the Rho family (Amano et al. 1996). As downstream effectors of 
Rho, PKN kinases have demonstrated roles in regulating the cell cytoskeleton and motility 
(Vincent and Settleman 1997). Furthermore, studies using xenograft tumour models 
suggests similar functions to affect cancer invasion and metastasis (Mukai et al. 2016; 
Lachmann et al. 2011). Recent studies in genetically engineered mouse models, where 
PKN isoforms have been knocked out, have helped to delineate in vivo roles of PKN 
kinases in both normal physiology and in cancer (Quétier et al. 2016; Danno et al. 2017; 
Yang et al. 2017; Yasui et al. 2012; zur Nedden et al. 2018). 
4.1 Role of PKN2 in breast cancer survival 
 
Several studies suggested a role for PKN kinases in cell survival under normal physiological 
conditions and in cancer. Schmidt et al showed that PKN2-depleted HeLa cells showed 
delayed G2/M progression and increased apoptosis (Schmidt et al. 2007). Furthermore, 
the work in our lab on the role of PKN kinases in mouse embryonic development indicated 
selective dependency of mouse embryonic fibroblasts  (MEFs) on PKN2 for cell growth 
both in vitro and in vivo (Quétier et al. 2016). In prostate cancer cells, depletion of PKN1 
results in reduced hormone-induced proliferation (Metzger et al. 2008). Meanwhile, 
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depletion of PKN3, whose expression is driven by PI3K signalling, in prostate cancer causes 
reduced tumour cell proliferation (Leenders et al. 2004). Therefore, the project started 
with the aim to investigate the significance of PKN kinase expression on survival and 
proliferation of breast cancer cell models in vitro. 
Bioinformatic analysis of the TGCA dataset was conducted to study the expression of PKN 
kinases in normal tissue and breast cancer tissue of different subtypes. This analysis 
revealed no significant changes in expression between normal and breast cancer tissues or 
across the different breast cancer subtypes. This finding contrasts with data from a recent 
study by Lin et al, that suggested high expression of PKN1 and PKN2 selectively in TNBC, in 
comparison to non-TNBC (Lin et al. 2017). However, their study was limited to cell line 
data from the CCLE database and moreover, the differences observed were minimal. 
Therefore, the unclear biological relevance in a disease setting needs to be noted when 
considering this study. 
Perhaps more importantly, analysis of PKN kinase expression and relapse-free survival 
(RFS), using an online tool to generate Km plots (Györffy et al. 2010), indicated a 
correlation between low PKN2 expression and high RFS in patients with ER-negative and 
basal breast cancer. This pattern was not seen when considering TNBC patients overall, 
however improved RFS with low PKN2 expression was observed when refining the analysis 
to patients with basal-like and mesenchymal-like TNBC using the Pietenpol subtype 
classification (Lehmann, Bauer, Chen, Sanders, Chakravarthy, and JA 2011). These 
subtypes of TNBC are mesenchymal in phenotype, perhaps further supporting a cell 
differentiation state dependent reliance on the PKN2 pathway. The limitation of the data 
set is the comparatively small sample size representing TNBC subtypes available for 
analysis (e.g. Mesenchymal subtype with PKN2 data; 171 patients). 
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The dependency on PKN2 in mesenchymal-like TNBC for survival corroborated with a 
study by Brough et al, whereby PKN2 was identified as a candidate gene for cell viability 
dependence in an siRNA screen (Brough et al. 2011). Cell viability upon PKN2 depletion 
was markedly reduced in TNBC that are known to have a mesenchymal phenotype, such 
as MDAMB231 and CAL120.  
The dependency for PKN kinases in TNBC was investigated in vitro, comparing three TNBC 
and three non-TNBC cell lines. Moderate reduction in cell viability was observed upon 
siRNA-mediated PKN2 and PKN3 depletion in SUM159, MDAMB231 and MDAMB468, with 
no effect on non-TNBC cell lines. However, validating this effect with pharmacological 
agents was limited by non-specific PKN kinase-targeting inhibitors.   
Since I started my research, Mukai et al published their work on a study involving 
knockout of PKN3 in a mouse prostate tumour model, that demonstrated decreased 
tumour size and reduced metastasis (Mukai et al. 2016). Furthermore, Lin et al published 
their work demonstrating the selective dependency of TNBC for PKN2 in vitro and in vivo 
(Lin et al. 2017). In this study PKN2 knockdown resulted in reduced colony formation and 
xenograft tumour growth.  
Further investigation into the role of PKN kinases in TNBC was halted due to the relatively 
modest reduction in TNBC survival observed with PKN2/PKN3 depletion, the limited ability 
to target PKN2 pharmacologically and the publication of the aforementioned competing 
studies. However, the dependency on PKN2 for mesenchymal TNBC and in MEFs from our 
conditional PKN2 knockout model gave a new focus to the project, focusing on how PKN2 
regulates fibroblast cell biology.  Cancer-associated fibroblasts (CAFs), are important 
components of the tumour microenvironment, and PKN2 may this represent and 
interesting regulator of the tumour microenvironment, with implications on tumour 
progression and therapy response. 
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4.2 Role of PKN2 in stromal activation 
 
Fibroblasts within the tumour environment can promote tumour progression. This 
requires the differentiation of fibroblasts in myofibroblast-like cells, otherwise described 
as activation into cancer-associated fibroblasts. Work by Kojima et al demonstrates an 
autocrine loop, whereby fibroblast activation and tumour progression are mediated by 
secreted factors SDF-1 and TGFβ (Kojima et al. 2010). Furthermore, enriched expression of 
TGFβ1 is associated with highly fibrotic tissue and ECM secretion (Brenmoehl et al. 2009). 
Work by Desmoulière et al demonstrated that treatment of fibroblasts with TGFβ induced 
the expression of α-SMA fibres, a marker of cellular differentiation into myofibroblasts 
(Desmoulière et al. 1993), and also a key biomarker for labelling CAFs in tumours. 
 
Our work in mouse embryos indicated a potential requirement for PKN2 in the EMT of 
neural crest cells and mesenchymal contractility in vivo (Quétier et al. 2016); in the absence 
of PKN2, neural crest cells fail to migrate away from the neural tube and embryos fail to 
undergo axial turning, which is driven by coordinated contraction and elongation of 
mesenchymal cells within the mesoderm.  The effect of PKN2 deletion on MEF activation in 
response to TGFβ was therefore examined.  
A common characteristic of activated fibroblasts is their increased contractility within the 
ECM. Encouragingly, we showed that PKN2-deleted MEFs, treated with TGFβ, had reduced 
contractile ability in collagen gels. Based on this finding, the effect of PKN2 expression on 
the induction of α-SMA fibres in response to TGFβ, another marker of fibroblast activation, 
was tested. Overall, induction of α-SMA expression was reduced in both MEFs and primary 
breast cancer derived CAFs with loss of PKN2. This supports the idea that PKN2 has an effect 
on fibroblast activation and that this phenotype is conserved in both mouse and human 
fibroblast models. As CAF activation plays an important role in cancer progression and 
167 
 
metastasis, the mechanism behind the reduction in −SMA fibres upon PKN2 loss was 
investigated. 
The mechanism behind the reduced activation in PKN2-deleted fibroblasts will aid in 
targeting this pathway therapeutically. Therefore, the immediate signalling pathway 
downstream of TGFβ1 was tested in MEFs, HMFU19 normal breast fibroblasts and CAFs. 
This revealed no changes in the amplitude or time-course of SMAD2/3 phosphorylation 
when comparing wt and PKN2-deleted fibroblasts.  
Work is in progress to study other related signalling pathways that may be affected, such as 
the non-canonical TGF signalling, through mechanosensory pathways including YAP and 
MRTF. Quantitative mass spectrometry (MS) analysis and KSEA of serum-induced activation 
of MEFs revealed differences between wt and PKN2 ko MEFs in phosphorylation of proteins 
such as YAP, MRTF, MEK1, ERK1, Akt and p70SK. These proteins have been associated with 
signalling pathways downstream of TGFβ1 (Piersma, Bank, and Boersema 2015), (Stratton 
et al. 2002), (Deaton et al. 2005), (Liu et al. 2016) (Gao et al. 2013). Therefore, the 
phosphorylation of these proteins can be assessed in response to TGFβ1 or other fibroblast 
activating signals upon PKN2 loss.  
Additionally, it will be important to measure functional outputs of the TGFβ pathway, such 
as transcriptional activation. The ability of PKN2-deleted MEFs to mediate translocation of 
the SMAD2/3/4 complex to the nucleus can be assessed. SMAD reporter cell lines have been 
generated in the lab to investigate the potential of transcriptional regulation and activation 
by the SMAD2/3/4 complex, in PKN2-deleted cell models. Reporters for the 
mechanosensory regulated transcription factors YAP (TEAD-luciferase) and MRTF (SRF-
luciferase) are also being used to ask whether PKN2 regulates mechanotransduction, which 
is known to depend on Rho (Provenzano and Keely 2011; Dupont et al. 2011; Small 2012). 
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In summary, these studies have provided preliminary evidence that suggest the 
importance of PKN2 in TGFβ-mediated fibroblast activation. In order to understand this 
phenotype better and identify intermediate targets that regulate this phenotype, the 
mechanism needs to be defined. Subsequently, the significance of stromal PKN2 
expression on prognosis was investigated using data from patient’s tumour samples.  
 
4.2.1 Prognostic relevance of PKN2 expression and stromal activation 
 
Understanding the cell biology of the TME is of both therapeutic and prognostic interest. 
Activation of the stroma can be a predictor of patient outcome and modulating the stroma 
has been proposed as a therapeutic opportunity to block tumour progression or enhance 
response to established therapies. Therefore, the potential of PKN2 as a modulator of 
tumours via the TME was investigated.  
 
 
The prognostic relevance of PKN2-directed fibroblast activation in response to TGFβ was 
explored. As PKN2 is ubiquitously expressed, differences in expression of PKN alone 
cannot be solely considered when studying its function in normal and activated stroma. 
This was also supported by previous gene expression analysis that showed no difference in 
PKN2 expression between normal tissue and breast tumours or between different breast 
cancer types (3.1.1). Furthermore, protein lysates from a panel of CAF cells revealed no 
difference in PKN2 expression, when compared to the matched normal fibroblasts.  
 
Hence, we sought to define a signature for fibroblasts depleted for PKN2, to act as a 
surrogate readout for PKN2 suppression or loss. A panel of surrogate markers for PKN2 
was chosen from an experiment where wt and PKN2 ko MEFs were stimulated with TGFβ 
in collagen gels to measure changes in mRNA levels. Genes that were upregulated upon 
TGFβ stimulation in wt PKN2, but not in PKN2 ko MEFs were chosen as PKN2-related 
markers for stromal activation (Section 3.2, Table 10). The panel identified comprised the 
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following genes: IGF1, IGF2, CTGF, THBS2, COL1A1, CDH11, GLI1, POSTN, OGN, ITGA11, 
FAP and BAMBI. A similar study was conducted in breast cancer, using IGF-1 induced 
genes in primary breast fibroblasts, as the signature (Rajski et al. 2010).  Genes in this 
panel that are in common with our PKN2 stromal panel include THBS2, COL1A1, FAP, 
CDH11, ITGA11 and POSTN. 
 
Several other studies consider the gene expression profile of tumour stroma to identify 
prognostic markers. For example, a study identified 16 different stromal gene signatures, 
by comparing gene expression between cancer cells and stromal cells in TNBC tumours 
(Winslow et al. 2015). The set of genes in one of those signatures was ECM-related and 
was associated with increased risk of recurrence. This signature included genes in 
common with our signature: COL1A1, POSTN, THBS2 and CDH11. Heatmap clustering of 
TCGA data on the expression of this stromal gene signature shows clustering of basal 
breast cancer with low expression of signature 1, compared to all other subtypes and 
normal controls. 
 
Furthermore, a study in PDAC cancer generated two stromal signatures that distinguish 
between normal and activated stroma (Moffitt et al. 2015). The gene signature for 
activated stroma includes THBS2, COL1A1, FAP, CDH11, ITGA11 and POSTN that is in 
common with our signature, suggesting that a number of PKN2 upregulated genes may 
correlate with a poor prognostic signature in the tumour stroma.  
The clinical relevance of the TME has recently been explored in ovarian cancer by Pearce 
et al. Multiple genomic, proteomic, transcriptomic and functional analyses were 
conducted on ovarian cancer samples at various stages of the metastatic process (Pearce 
et al. 2018a). Profiling of genes and proteins in the ECM of TME identified a molecular 
signature that is predictive of outcome and tumour stiffness, not only in ovarian cancer 
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but also applicable in other cancer types (including TNBC). This paper essentially defined a 
common activated stromal signature, associated with poor outcome. 
 
4.2.2 Prognostic relevance of PKN2 surrogate markers in breast cancer 
 
Sources of stromal samples to investigate the clinical relevance of genes in the TME is 
often limited. Alternatively, whole tumour section scan be employed to conduct studies 
on changes in genes specific to the stroma, such as the study by Moffit et al. This study 
addressed the issue of bulk tumour analysis, which was overcome by using non-negative 
matrix factorization (NMF – a source separation technique) for microdissecting PDAC 
samples virtually, on the basis of tumour, stroma, and normal gene expression (Moffitt et 
al. 2015). A number of genes in our stromal signature are specifically increased in tumour-
associated stroma. Therefore, a similar approach can be used to dissect the role of PKN2-
regulated genes in activated stroma, using data from whole tumour samples, by focussing 
on those genes which are restricted in their expression to activated fibroblasts. 
Gene expression of whole tumour samples from the TCGA dataset was analysed, 
considering the expression of PKN2 surrogate markers. Amongst the different TNBC 
subtypes, BL2 and MSL tumours were associated with high expression of the surrogate 
markers. However, there were no difference in survival outcomes between patients with 
low or high PKN2 expression. The major limitation of this dataset, for the purpose of 
studying the prognostic relevance of PKN2 in the tumour microenvironment, is that the 
sample is not specifically stromal tissue but includes cancer cells.  
To address this limitation, the prognostic relevance of the twelve chosen surrogate 
markers of PKN2, associated with activated stroma, was interrogated in the stromal gene 
expression dataset from breast cancer patients from Finak et al (Finak et al. 2008). This 
data includes gene expression of stromal tissue from patients with breast cancer matched 
with normal surrounding stroma, dissected by laser capture microscopy. 10 (out of 12) 
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surrogate markers for PKN2 were differentially expressed between tumour-associated 
stroma, in comparison to matched normal stroma. This validated the specificity of most of 
the genes in our stromal signature to tumour-associated stromal tissue.  
Furthermore, clustering analysis on the expression of genes in our stromal signature and 
Finak et al data on patient stromal samples revealed two clusters. One of these clusters 
encompassed patients that presented with poor outcome. This data strongly supports the 
validity of our stromal gene signature to study its potential as a predictor of patient 
outcome. Patients with poor outcome had low expression of IGF1 and OGN, in contrast to 
high expression of BAMBI - considered to be a negative regulator of TGFβ signalling. 
4.3 Effect of PKN2 loss on the interaction between fibroblasts and cancer cells 
 
Cancer-associated fibroblasts (CAFs) are activated fibroblasts found within the tumour 
microenvironment and studies have begun to unpick the reciprocal signalling between 
fibroblasts and cancer cells. This has been extensively studied in other common solid 
cancers such as those of the lung (Eberlein et al. 2015) and pancreas (Tape et al. 2016). In 
vitro co-culture studies demonstrated TGFβ- and αvβ6-mediated fibroblast activation by 
non-small cell lung cancer cells (NSCLCs), identified by induction of α-SMA fibres (Eberlein 
et al. 2015). This led to upregulation of genes that mediate mesenchymal phenotypes and 
invasive behaviours.  Additionally, reduced sensitivity to anti-cancer agents was also 
observed in NSCLC in the presence of activated fibroblasts. Moreover, heterocellular 
multivariate phosphoproteomics using pancreatic ductal adenocarcinoma (PDA) and 
stromal cells, demonstrated that oncogenic signalling is also influenced by fibroblasts, 
which adds to the cell-autonomous oncogenic signalling in tumour cells ((Tape et al. 
2016)). Furthermore, studies on fibroblasts and their interaction with breast cancer cells 
revealed implications on growth, invasion and chemo-sensitivity of breast cancer cells 
(Tao et al. 2017).  
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4.3.1 In vitro studies investigating the role of stromal PKN2 expression in breast 
cancer cell survival 
 
In a related project in our lab on pancreatic cancer, deletion of PKN2 from either MEFs or 
pancreatic fibroblasts (pancreatic stellate cells), dramatically reduced their ability to 
support pancreatic cancer cell invasion in 3D collagen-matrigel gels. In my studies we 
sought to examine whether such interaction extended to breast cancer models.  
Fibroblasts that do or do not express PKN2 was investigated in in vitro and in vivo co-
cultures.  
 
Mini-organotypic assays were used as an in vitro model, where the 3D conditions and the 
Matrigel-collagen mix attempts to model the ECM that cancer and stromal cells reside in. 
Different mouse mammary cancer cell lines were cultured alone or co-cultured with wt or 
PKN2 ko MEFs. This demonstrated the dependence for stromal PKN2 in 4T1 cells for 
invasion. 
 
To generate a simple system for assessing the growth of two different cell types in co-
culture, cells were engineered for firefly (cancer cells) and renilla (fibroblasts) luciferase 
reporters were used. In general, increased cell viability of cancer cells was observed when 
in co-culture with fibroblasts. Co-cultures with MEFs resulted in increased proliferation of 
PMT.BO1, MDAMB231 and MCF7 cancer cells, which was unaffected by the expression 
level of PKN2 in MEFs. Similarly, MDAMB21 and MCF7 cell lines in co-culture with human 
mammary fibroblast cell line HMFU19, resulted in increased cancer cell proliferation. The 
CAF cell lines, 1997 and 1939, promoted proliferation of MDAMB231 cells, whilst reducing 
MCF7 proliferation. 
 
The inducible system of conditional PKN2 knockout in MEFs provided a robust means of 
studying the effect of PKN2 loss on the interaction with cancer cells. However, the use of 
siRNA to delete PKN2 in human fibroblasts cell line HMFU19 and particularly in primary 
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CAF cells was challenging. Therefore, the results regarding the effect of PKN2 loss in 
HMU19 and CAFs on cancer cell proliferation could not be conclusively interpreted. 
 
As well as affecting tumour growth, CAFs have also been demonstrated to mediate 
chemo-resistance. Tamoxifen resistance is an example that has been attributed to CAFs, 
mediated by upregulation of PI3K/AKT and MAPK/ERK pathways and phosphorylation of 
ER (Pontiggia et al. 2012). As part of the luciferase co-culture assays of human cancer cells 
and fibroblasts, the effect on drug sensitivity was also tested. Although the use of siRNA 
for PKN2 depletion caused experimental difficulties, preliminary results suggest that cell 
viability of MCF7 and MDAMB231 were largely unaffected when treated with doxorubicin 
or paclitaxel, in coculture with wild type CAFs. However, in order to assess the effect of 
PKN2 deletion in CAFs on cancer cell chemosensitivity better, more robust methods of 
depleting or deleting PKN2 are required, such as using shRNA or CRISPR/Cas9 system.  The 
apparently senescent nature of many of the primary CAF lines used in the study, in 
addition to unknown toxicity caused by siRNA transfection affected basal survival of these 
cells. 
  
4.3.2 In vivo studies investigating the effect of PKN2 deletion in the stroma on 
breast tumours 
 
The interaction between cancer cells and fibroblasts was also investigated in vivo, using 
mixed cell xenografts. The significance of PKN2 expression in MEFs on cancer cells in 
contact, was investigated by monitoring tumour volumes. Differences in the level of 
stromal activation and tumour fibrosis, factors that can affect tumour progression, were 
also determined by -SMA and Sirius Red staining. Two different syngeneic mixed-cell 
xenograft models were conducted tested with 4T1 and PyMT.BO1 cell lines. We used 
MEFs as a surrogate model for CAFs, as PKN2 deletion can be induced in these fibroblasts 
robustly.  
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4T1 tumour volumes and Sirius red staining were unaffected either by the presence of 
MEFs or their PKN2 status. On the other hand, co-injection of MEFs with PyMT.BO1 cells 
resulted in slightly larger tumours (statistically insignificant), although once again PKN2 
status had little effect. Intriguingly however, tumours with PKN2 ko MEFs had reduced 
areas of strong Sirius red staining and reduced proportion of area stained with -SMA, 
compared to tumours with wt PKN2. These results indicate that loss of PKN2 expression 
may result in reduced stromal activation in tumours.  
 
A major drawback with this experiment was the technical difficulty with identifying 
injected MEFs despite cells being engineered to express GFP. This was in part attributed to 
diminished GFP-expression in cultured cells but may also indicate that injected fibroblasts 
are lost from the tumour or die. Additionally, large numbers of α-SMA positive cells were 
recruited to tumours, even in the absence of co-injected MEFs, making definitive 
interpretation of results difficult. 
To address these limitations, the significance of stromal PKN2 expression on tumour 
pathology was investigated in a syngeneic orthotopic model using our inducible 
conditional PKN2 knockout mouse model (iPKN2: PKN2fl/fl; Rosa26Cre/ERT2). Hereby, tumour 
growth and biology can be studied in mice with systemic deletion of PKN2 and an intact 
immune system. Mice were injected with 3x105 BO.1 cells in each (left and right) inguinal 
mammary fat pad. The experiment was terminated two weeks post-injection, where 
tumours showed no differences in size, regardless of stromal PKN2 expression status. 
Despite no differences in immunohistochemical staining for α-SMA, tumours from PKN2-
deleted mice had dramatically reduced staining for Sirius Red, indicating reduced 
desmoplasia and suggesting reduced stromal activation.  Furthermore, there was a 
significantly reduced number of blood vessels detected by endomucin staining in tumours 
from PKN2-deleted mice.  
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Exploring the mechanism of reduced vasculature upon PKN2 loss will provide useful 
insights into potential targets for anti-angiogenic therapy in tumours. This phenotype was 
also observed in mouse embryos with global deletion of PKN2, which resulted in abnormal 
vasculature and a lack of angiogenic remodelling (Quétier et al. 2016).Endothelial-specific 
deletion of PKN2 in embryos did not however replicate this phenotype, indicating that the 
reduced expression of PKN2 in other cells mediates the effect of reduced blood vessels. 
Several studies indicate that CAFs in the TME play a major role in tumour angiogenesis 
(Bussard et al. 2016; Luo et al. 2015; Mao et al. 2013). One proposed mechanism is 
through the secretion of pro-angiogenic factors by CAFs themselves or by promoting 
secretion from cancer cells. In vivo studies by Hu et al in a DCIS mixed cell xenograft model 
showed increased expression of cyclooxygenase-2 (COX-2) in tumours that were co-
injected with CAFs, compared to those with no or normal fibroblast co-injections (Hu et al. 
2009). This was accompanied by increased expression of the pro-angiogenic factor VEGF. 
Orimo et al observed increased growth and tumour vascularisation when breast cancer 
cells were co-cultured with CAFs but not with normal fibroblasts (Orimo et al. 2005). These 
effects were demonstrated to be mediated by secretion of stromal cell-derived level 
factor 1 (SDF1) by CAFs.  
Sewell-Loftin et al describe changes in mechanical properties of CAFs to promote tumour 
vascularisation (Sewell-Loftin et al. 2017). Employing a 3D in vitro model of blood vessel 
formation, it was observed that co-culture of endothelial cells with CAFs from breast 
tumours, rather than normal mammary fibroblasts, resulted in establishment of vascular 
network. Partial disruption of the vascular network via VEGF receptor inhibition 
demonstrated that other signalling pathways are involved. Further investigation revealed 
mechanotransductive pathways to be involved, where inhibition of YAP, ROCK2 and SN1 in 
CAFs suppressed vascularisation.  
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Lack of ER, PR and HER expression limits treatment of TNBC to chemotherapy and 
therefore gene candidate for targeted therapy has significant value. The raised 
microvessel density (Mohammed et al. 2011), VEGF gene amplification (Andre et al. 2009) 
and overexpression (Linderholm et al. 2009) suggests that blood vessels play an important 
role in TNBC tumours. These characteristics therefore indicate that TNBC may be 
susceptible and benefit from anti-angiogenic therapy. For example, Di Mauro et al 
recently identified the hedgehog signalling pathway, particularly Gli1 protein, as a 
potential target for anti-angiogenic therapy for TNBC (Di Mauro et al. 2017). This gene is 
one of the 12 genes in our stromal signature, as it was downregulated upon PKN2 deletion 
in MEFs. Therefore, studying the hedgehog signalling pathway and the relevance of PKN2 
in tumours may provide mechanistic indications for the reduced blood vessels observed in 
our in vivo tumour model. 
 
4.4 Concluding remarks 
 
Data from this project strongly indicate a role for PKN2 in fibroblast activation. 
Investigating the molecular mechanism of this phenotype may provide therapeutic 
targets, as modulating fibroblast activation can have significant implications on tumour 
progression and disease outcome. Tumour models employing fibroblast-specific PKN2 
deletion will provide insights into the relevance of PKN2 expression in fibroblasts, which 
can be compared to the phenotypes observed with global PKN2 knockout. Furthermore, 
the reduced blood vessels in tumours upon PKN2 deletion is worth further exploration as 
tumour angiogenesis is also a very important characteristic of cancer that has implications 
on tumour growth, invasion and metastasis.  
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Appendix 
 
Figure 60. Fold change in gene transcript levels after 24h stimulation with TGFβ1 and BMP4 in 
MEFs 
Fold change, relative to wt MEFs treated with vehicle, of genes that were not selected as PKN2 
surrogate markers upon TGFβ1 and BMP4 stimulation. These genes along with the 12 genes chosen 
as PKN2 surrogate markers, were part of the custom Fluidigm expression assay panel in 
collaboration with Ivan Quétier and Claus Jorgensen (Manchester CRUK). Data represents the mean 
+/- SD for n=3 biological repeats. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 61. Fold change in gene transcript levels after 48h stimulation with TGFβ1 and BMP4 in 
MEFs 
Fold change, relative to wt MEFs treated with vehicle, of genes that were not selected as PKN2 
surrogate markers upon TGFβ1 and BMP4 stimulation. These genes along with the 12 genes chosen 
as PKN2 surrogate markers, were part of the custom Fluidigm expression assay panel in 
collaboration with Ivan Quétier and Claus Jorgensen (Manchester CRUK). Data represents the mean 
+/- SD for n=3 biological repeats. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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Figure 62. Fold change in gene transcript levels after 72h stimulation with TGFβ1 and BMP4 in 
MEFs 
Fold change, relative to wt MEFs treated with vehicle, of genes that were not selected as PKN2 
surrogate markers upon TGFβ1 and BMP4 stimulation. These genes along with the 12 genes chosen 
as PKN2 surrogate markers, were part of the custom Fluidigm expression assay panel in 
collaboration with Ivan Quétier and Claus Jorgensen (Manchester CRUK). Data represents the mean 
+/- SD for n=3 biological repeats. Statistical analysis was carried out using ANOVA followed by 
Bonferroni post-hoc test: P<0.05 (*), P<0.01 (**), P<0.001 (***). 
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